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The abnormal regulation of H+ ions, leading to a reversed pH gradient in cancer cells 
when compared to normal cells, is considered to be one of the most distinctive 
features of cancer. However, this characteristic has yet to be fully exploited as a 
therapeutic target in cancer. This project assessed whether targeting pH regulating 
proteins, which permit cancer cells to survive in the hostile hypoxic and acidic 
tumour microenvironment, could produce an effective therapeutic response in breast 
cancer. The pH regulating proteins carbonic anhydrase IX (CAIX), Na+/H+ 
exchanger 1 (NHE1) and vacuolar (H+)-ATPase (V-ATPase) were the focus of this 
thesis. Initial experiments were conducted in 2D tissue culture before progressing 
into 3D, using models that more faithfully re-create the in vivo tumour 
microenvironment.  
 
Expression analysis conducted with MCF-7, MDA-MB-231 and HBL-100 human 
breast cancer cell lines cultured in 2D, and in 3D as multicellular tumour spheroids, 
showed that protein and mRNA levels of CAIX were very responsive to lower O2 
concentrations. Both MDA-MB-231 and HBL-100 cells displayed large increases in 
CAIX expression levels in hypoxia, with the HBL-100 cell line exhibiting the largest 
change in CAIX mRNA (42-fold increase) and protein (78-fold increase) levels in 
0.5% O2 conditions. Hypoxia inducible factor 1-α (HIF-1α) controls the expression 
of CAIX, but the induction of CAIX in hypoxic MCF-7 cells was lower in 
comparison to the other cell lines, despite the presence of similar levels of HIF-1α. 
The differences in CAIX expression observed between the cell lines was consistent 
with a varying activity of factor inhibiting HIF-1 (FIH-1), an oxygen sensor that 
controls signalling through HIF-1α, as siRNA targeting FIH-1 led to increased levels 
of CAIX in hypoxic MCF-7 cells. While NHE1 protein levels did increase in 
hypoxic conditions in MCF-7 cells in 3D, overall, the expression levels of both 
NHE1 and V-ATPase were not as responsive to changes in O2 concentrations when 
compared to CAIX across differing O2 conditions in each of the cell lines.  
 
Inhibitors targeting CAIX, NHE1 and V-ATPase were all shown to reduce cancer 
cell number in 2D culture conditions. Differing O2 conditions changed the sensitivity 
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of these cell lines to CAIX inhibition. Cells cultured in 20% O2 conditions were 
responsive to CAIX inhibition, while acute hypoxic cells cultured in 0.5% O2 
displayed an increased resistance to drug treatment. Chronically hypoxic cells, which 
had spent over 10 weeks in 0.5% O2 before treatment, exhibited a re-sensitisation to 
CAIX inhibition.  
 
3D invasion assays demonstrated that CAIX inhibition significantly reduced the 
invasion of cells from MDA-MB-231 spheroids into collagen type 1 in both 20% O2 
and 0.5% O2 conditions, while drugs targeting either NHE1 or V-ATPase had no 
such inhibitory effects. Preliminary clonogenic assays, used to assess radiation 
sensitivity and performed with MDA-MB-231 spheroids, indicated that inhibitors 
targeting CAIX and NHE1 led to a significant decrease in colony formation when 
combined with irradiation, compared to either drug treatment or irradiation alone.  
 
Further invasion assays, carried out with primary tissue derived from human patients, 
showed that drugs targeting CAIX retained their inhibitory effects when tested on 
heterogeneous cancer material of varying tumour subtypes. CAIX inhibition also 
exhibited anti-cancer effects in vivo on mouse MDA-MB-231 xenografts, 
significantly reducing the proliferation and growth of tumours within mice.  
 
Together, this work demonstrates that inhibitors targeting the pH regulation 
mechanisms of cancer cells have potential in the treatment of breast cancer, 
highlighted by their capacity to affect cancer cell number, cancer cell invasion, and 
their ability to combine with irradiation. Of the 3 pH regulatory molecules studied, 











Hydrogen ions (H+ ions) are one of the most important and reactive ions present in a 
cell. Alterations in the concentrations of H+ ions, measured as changes in pH, can 
affect many processes that occur within a cell. Because of the importance of pH to 
cellular function, cells have developed the ability to control the amount of H+ ions 
within them through the expression of pH regulating proteins.  
 
The regulation of H+ ions in cancer cells is different to the regulation of H+ ions in 
normal cells in the body. In fact, the abnormal regulation of pH within cancer cells is 
thought of as one of the most distinctive features of cancer. However, this 
characteristic has yet to be fully exploited in the treatment of cancer. The aim of this 
project therefore was to assess the effects of drugs targeting pH regulatory proteins 
that have been linked with cancer, evaluating whether inhibiting these proteins could 
produce an effective therapeutic response in breast cancer. The pH regulating 
proteins carbonic anhydrase IX (CAIX), Na+/H+ exchanger 1 (NHE1) and vacuolar 
(H+)-ATPase (V-ATPase) were the focus of this thesis. 
 
The uncontrolled proliferation of cancer cells within the tumour leads to some cells 
being pushed further and further away from blood vessels, inhibiting the delivery of 
O2 and the removal of wastes, leading to hypoxia (a lack of O2) and the formation of 
an acidic environment. Hypoxia has been shown to induce the expression of pH 
regulating proteins that enable the survival of cancer cells within this hostile 
environment. Initial experiments assessed the expression of CAIX, NHE1 and V-
ATPase in hypoxic conditions. Breast cancer cell lines were used in these 
experiments. The results showed that CAIX expression levels were very responsive 
to changes in O2 concentrations, with large increases in the amount of this target 
observed in hypoxic conditions. However, the extent of CAIX expression differed 
between the cell lines studied. The expression of CAIX is controlled by an oxygen 
sensor within the cell called hypoxia inducible factor 1-α (HIF-1α), and despite the 
presence of similar levels of this protein in each of the cell lines, the levels of CAIX 
were still reduced in one of the cell lines. Further work showed that the differences in 
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CAIX expression seen between the cell lines were consistent with the varying 
activity of another oxygen sensor present in the cell called factor inhibiting HIF-1 
(FIH-1), as reductions in the levels of FIH-1 led to increases in the amount of CAIX. 
While NHE1 protein levels did increase in hypoxic conditions in one of the cell 
lines, overall, the hypoxic expression levels of both NHE1 and V-ATPase were much 
more consistent when compared to CAIX. 
 
The anti-cancer effects of drugs targeting the 3 pH regulation proteins were also 
assessed. Inhibitors targeting CAIX, NHE1 and V-ATPase were shown to reduce 
cancer cell number. However, the sensitivity of the cells to CAIX inhibition varied 
with the oxygenation of the cells. Aerobic (well-oxygenated) cells were responsive to 
CAIX inhibition, while cells present in hypoxic conditions for up to 5 days showed 
an increased resistance to drug treatment. However, the presence of cells for 20 
weeks in hypoxic conditions led to a re-sensitisation to CAIX inhibition. 
 
The invasion and migration of cancer cells from the breast to other parts of the body 
is the main cause of breast cancer mortality. pH regulating proteins have been linked 
to this process. Invasion assays, conducted to assess the effects of drugs targeting pH 
regulation molecules on the invasion of cancer cell lines, showed that inhibiting 
CAIX reduced the amount of invasion in both aerobic and hypoxic conditions. 
However, no such inhibitory effects were seen with drugs targeting either NHE1 or 
V-ATPase. Further invasion assays carried out with tissue derived from human 
breast cancer patients showed that CAIX inhibitors retained their effects in this more 
complex cancer model. The abnormal pH of cancer cells has also been linked with a 
resistance to radiotherapy. Preliminary experiments indicated that drugs targeting 
both CAIX and NHE1 were able to improve the effects of irradiation. Finally, in vivo 
experiments showed that CAIX inhibitors reduced the proliferation and growth of 
tumours in mice. 
 
Together, this work demonstrates that inhibitors targeting the pH regulation 
mechanisms of cancer cells have potential in the treatment of breast cancer. Of the 3 
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ALDOA   Aldolase A 
ANOVA  Analysis of variance 
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ATP    Adenosine-5’-triphosphate 
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ENO1    Enolase 1 
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GLUT   Glucose transporter 
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IGMM   Institute of Genetics and Molecular Medicine 
IGRT   Image guided radiotherapy 
IHC   Immunohistochemistry 
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IORT   Intra-operative radiotherapy 
LDHA    Lactate dehydrogenase A 
LFQ   Label-free quantitation 
MCT   Monocarboxylate transporter 
MEGM   Mammary epithelial cell growth media 
min   Minute 
MMP   Matrix metalloproteinase 
MRI   Magnetic resonance imaging 
mRNA   Messenger RNA 
mTOR   Mammalian target of rapamycin 
NADH   Nicotinamide adenine dinucleotide 
NADPH   Nicotinamide adenine dinucleotide phosphate 
NEAA    Non-essential amino acid 
NHE   Na+-H+ exchanger 
NMR   Nuclear magnetic resonance 
N-TAD   N-terminal transactivation domain 
OD   Optical density 
ODDD   O2-dependent degradation domain 
OH-   Hydroxide 
OXPHOS  Oxidative phosphorylation 
PARP   Poly (ADP-ribose) polymerase 
PBS   Phosphate buffered saline 
PDH   Pyruvate dehydrogenase 
PEP    Phosphoenolpyruvate 
PFK-1   Phosphofructokinase 1 
PGI   Phosphoglucose isomerase 
PGK1    Phosphoglycerate kinase 
PGM    Phosphoglycerate mutase 
PHD   Prolyl hydroxylase domain 
PI3K   Phosphoinositide 3-kinase 
PKM   Pyruvate kinase M 
PKM2    Pyruvate kinase M2 
PPI   Proton pump inhibitor 
PPP   Pentose phosphate pathway 
PR   Progesterone receptor 
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1  Chapter 1: Introduction 
 
1.1  Breast cancer incidence and survival 
	
Breast cancer is the most common cancer to occur in women. GLOBOCAN statistics 
show that approximately 1,670,000 women were diagnosed with breast cancer 
worldwide in 2012, with 522,000 breast-cancer related deaths occurring in that same 
year [1]. In the UK, over 53,000 cases of breast cancer were reported in 2013, with 
breast cancer being responsible for over 11,000 deaths in 2014 alone [2]. It is thought 
that the incidence of breast cancer in women around the world will rise to 
approximately 3,200,000 cases per year by 2050 [3]. These figures reveal the scale of 
breast cancer incidence and the effect it has on societies around the world, along with 
the need for more effective methods of detection and treatment [4]. 
 
1.2 Hallmarks of cancer 
 
In 2000, Hanahan and Weinberg published a paper proposing that cancer cells have 
unique capabilities that enable them to survive, proliferate and metastasise [5]. 
Altogether, six different abilities were proposed: (i) sustaining proliferative 
signalling, (ii) evading growth suppressors, (iii) activating invasion and metastasis, 
(iv) enabling replicative immortality, (v) inducing angiogenesis and (vi) resisting cell 
death. Research conducted in the decade following this paper led to the authors 
modifying the original 6 core hallmarks, adding two emerging hallmarks along with 
two enabling characteristics [6]. The two emerging hallmarks added to the original 6 
were (i) deregulating cellular energetics and (ii) avoiding immune destruction. The 
enabling characteristics, which the authors say make it possible for cancer cells to 
acquire the differing hallmarks, were (i) genomic instability and mutation and (ii) 
tumour-promoting inflammation (figure 1). Hanahan and Weinberg propose that 
these hallmarks, in combination with the enabling characteristics, are a foundation 





Figure 1. The hallmarks of cancer. 
The acquired abilities of cancer cells that allow them to survive, proliferate and metastasise 
are shown. Genome instability and mutation, in addition to tumour-promoting inflammation, 
are characteristics that enable cancer cells to acquire these abilities or hallmarks. Figure 
adapted from [6]. 
 
1.3 Anatomy and physiology of the breast 
	
The breast is composed of both adipose and glandular tissue supported by a fibrous 
connective tissue called Cooper’s ligaments. The glandular tissue is organised into 
lobes, with each lobe consisting of numerous lobules. The lobules themselves are 
made up of alveoli, the glandular physiological units of the breast. While not active 
in non-pregnant females, these structures change during lactation and acquire 
secretory features, discharging milk into the lumen of ducts, which store and 
transport milk to the nipples during lactation. The ducts are lined by cells that can 
contract, opening the ducts and assisting in the flow of milk (figure 2)[7]. The breast 
is well supplied by both blood vessels and the lymphatic system, enabling the 




Figure 2: Anatomy of a normal mammary gland.  
The connective tissue supports the glandular tissue of the breast, which is made up of lobes, 
with each lobe organised into lobules. The lobules themselves are made up of lobular cells, 
also known as alveoli. The milk secreted from the alveoli is transported to the nipple via the 
ducts. Figure adapted from [9]. 
 
1.4 Histological subtypes, staging and molecular classification 
 
Cancer can be classified according to the tissue or cell type it is derived from. 
Carcinomas (arise from the epithelial cells of the body), sarcomas (develop from the 
connective tissue or muscles), leukaemias (cancer arising from blood cells), 
lymphomas and myelomas (begin in the immune system), and cancers of the central 
nervous system are the main types of cancer that occur. Breast cancer develops from 
cells present in the tissue of the breast, with the majority of breast tumours 
characterised as carcinomas [10]. 
 
1.4.1 Histological subtypes 
 
Breast cancers can be classified based on the invasion of tumour cells into the 
surrounding tissue. Tumours that have not invaded are labelled as in situ breast 
cancers, while tumours that have invaded are categorised as invasive or infiltrating. 
In situ breast tumours are further divided into either ductal or lobular depending on 
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both the cytological features and growth patterns of the cells of the cancer [11]. 
Invasive carcinomas can also be sub-classified into different histological subtypes. 
The main invasive cancer subtypes include invasive ductal, invasive lobular, mixed 
(has features of both invasive ductal and invasive lobular), medullary, tubular, 
mucinous and papillary carcinomas [11]. The invasive ductal subtype is the most 
common of all of the invasive cancers that occur [12]. 
 
1.4.2  Staging, grading, NPI and prognosis 
 
The stage of a cancer assesses the tumour size and whether it has spread. Breast 
cancers are staged according to the TNM (tumour, node, metastasis) system. Briefly, 
this system of staging is based on the size of the cancer, whether it has spread to 
lymph nodes, and whether the tumour has metastasised to other parts of the body 
[13]. In addition to breast cancer staging, the degree of differentiation of the cells of 
the tumour is also analysed in a process called grading. The grading system 
developed by Bloom and Richardson [14], and modified by Elston and Ellis [15], 
gives scores dependent on the proportion of glandular/tubule formation, the degree of 
nuclear polymorphism and the proportion of mitotic nuclei. Breast cancers with a 
low grade usually have a good clinical outcome, while breast cancers with a high 
grade score are more aggressive and have a greater likelihood of recurring after 
treatment (reviewed in [16]). The Nottingham Prognostic Index (NPI) is another 
method which has been developed to help predict patient outcome, and is based on a 
combination of the tumour size in cm (S), lymph-node stage (N) and grade (G) 
assembled into a prognostic index formula (NPI = [0.2 x S] + N + G) [17]. As the 
NPI numerical value rises, the prognosis worsens, with patients stratified into NPI 
groups ranging from ‘good’ to ‘very poor’ based on the overall value obtained [18]. 
Breast cancer staging, grading and the NPI are extremely helpful tools for both 
patients and doctors, enabling patients to understand their conditions better, while 





1.4.3 Molecular subtypes of breast cancer 
 
The analysis of gene expression patterns of breast cancer has led to the identification 
of distinct molecular subtypes of cancer. These subtypes have been classified as: (i) 
normal breast like (genetic signature similar to adipose tissue), (ii) luminal A (ER+ 
[oestrogen-receptor positive], PR+ [progesterone-receptor positive], HER2- [human 
epidermal growth factor negative]), luminal B (ERlow, HER2low, PR+/-), (iii) HER2+ 
(ER-, PR-, HER2+), (iv) basal-like (ER-, HER2-, PR-; with expression of cytokeratin 
5 and 14), (v) triple negative (ER-, PR-, HER2-) and apocrine (ER-, PR-, HER2+/-) 
[19-21]. While both breast cancer staging and grading do have some prognostic 
value, they do not take into account these molecular markers that can predict 
response to the identified targeted therapies (see section 1.5.3). 
 
The use of some of these molecular markers to further classify carcinomas has been 
accepted in breast cancer diagnosis. Analysis of PR, ER and HER2 levels through 
immunohistochemistry (IHC) is used to guide treatment, determining which patients 
are most likely to respond to therapies targeting these molecules [22, 23]. ER and PR 
expression staining is currently measured using the Allred score, which ranges from 
0 to 8 depending on the proportion and intensity of staining [24]. A scoring system 
ranging from 0 to 3+ is used to measure HER2 over-expression, with 0 and 1+ values 
considered negative for over-expression, while a value of 2+ is considered weakly 
positive and 3+ is strongly positive [25]. The HER2 IHC staining results can be 
verified by identifying the number of HER2 gene copies through fluorescent in situ 
hybridization (FISH) [25].  
 
While the traditional tissue-based testing mentioned above uses a single marker 
approach, other panel-based molecular tests have recently been developed to classify 
clinical cases of breast cancer into the different subtypes. The PAM-50 Breast 
Cancer Institute Classifier assay is one such assay that uses the mRNA levels of 50 
genes to categorise breast cancer tissue into the different molecular subtypes, with 




1.5 Treatment of breast cancer 
 
Treatment for breast cancer can be classified into either systemic or local therapy.  
Chemotherapy, hormone therapy and targeted therapies are examples of systemic 
therapies, which are given either by mouth or intravenously, and reach cancer cells 
throughout the body.  Surgery and radiotherapy are examples of local therapy. 
Overall, there are 3 different types of breast cancer that clinicians treat: (i) non-
invasive breast cancer; (ii) breast cancer that has invaded locally into the surrounding 
tissue or regional lymph nodes ; (iii) breast cancer that has metastasised to other parts 
of the body. The type of treatment, and the combinations of treatments, that the 
patient receives depends on which of the above cancers the patient is diagnosed with, 
in addition to the subtype, stage and molecular classification of the tumour (see 




Chemotherapy is a form of treatment that involves the administration of cytotoxic 
drugs that damage targets such as DNA and tubulin in replicating cells, thereby 
leading to cell death. Paul Ehrlich, a German scientist whose interests included the 
use of drugs to treat cancer, coined the term chemotherapy in the early 1900s, 
defining it as the use of chemicals to treat infectious diseases (reviewed in [26]). The 
start of the modern era of chemotherapy can be traced to the 1940s, with the 
discovery that nitrogen mustard induced tumour regression in a patient with non-
Hodgkin’s lymphoma (reviewed in [26, 27]).  
 
Many different chemotherapy drugs are available for the treatment of breast cancer, 
with different combinations used for breast cancer treatment. These are outlined in 
table 1. While these drugs target highly proliferative cancer cells in the tumour, there 
are also non-malignant cells in the body with high proliferation rates that are 
similarly affected. This can lead to many adverse side effects, including nausea and 
vomiting, weight loss, hair loss, fatigue, and a compromised immune system [28].  
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As a result of these wide-ranging side effects, treatments are usually given in cycles, 
with drugs given for periods ranging between 1 and 5 days, followed by a break of 
up to 4 weeks. Drug treatment, followed by a break, makes up one cycle. Up to 8 
treatment cycles may be given to patients suffering from breast cancer, depending on 
the drugs used and the stage of the cancer [29]. In addition to variations in the 
number of cycles received, the timing of chemotherapy treatment can also differ 
between patients. Treatment given before surgery, with the purpose of shrinking the 
tumour before the surgical procedure, thus reducing the extent of surgery required, is 
known as neoadjuvant chemotherapy. This approach is used for the treatment of 
primary non-operable breast cancer, locally advanced operable breast cancer, and 
inflammatory breast cancer [30]. Treatment provided after surgery, in an attempt to 
prevent metastasis or cancer recurrence, is termed adjuvant chemotherapy, and has 
been shown to improve overall patient survival by approximately 10% [31].  
 
 






1.5.2 Hormone therapy 
	
Oestrogen and progesterone are hormones that control the growth and activity of 
normal cells, but which can also affect cancer cells if they express the appropriate 
receptors. These hormones are synthesised by the ovaries in pre-menopausal women 
[32, 33], with oestrogen also produced in the body fat in post-menopausal women 
[32]. Around 80% of breast cancers diagnosed are either oestrogen receptor (ER) or 
progesterone receptor (PR) positive [34], with the presence of ER or PR frequently 
driving tumour growth and progression [35, 36]. Hormone therapy removes or 
blocks the actions of hormones on these receptors.  
 
Different types of hormone treatment are used to treat breast cancer depending on 
whether or not the patient has gone through menopause. Selective oestrogen receptor 
modulators (SERMs), such as tamoxifen, are an example of one form of hormone 
therapy used mostly in pre-menopausal women [37]. SERMs work by blocking the 
ER on breast cancer cells, thereby removing the growth-promoting effects of 
oestrogen on the tumour. Fulvestrant (Faslodex) is an example of a selective 
oestrogen receptor down regulator (SERD) that not only inhibits ER, but also 
accelerates ER degradation [38].  
 
Suppressing the production of oestrogen from the ovary, and thereby lowering the 
amount of oestrogen available to the tumour, is another form of hormone therapy 
used to treat pre-menopausal patients. Blocking the production of luteinising 
hormone, which usually acts to stimulate the production of oestrogen from the 
ovaries, is one form of treatment used. Goserelin (Zoladex) is an example of a 
luteinising hormone blocker employed in the clinic [39]. Surgery to remove the 
ovaries themselves is another method used to reduce the production of oestrogen in 
the body [39].  
 
Oestrogen can also be synthesised from androgens in the tissues of the body in post-
menopausal women, a reaction catalysed by aromatase [40]. Letrozole (Femara), 
anastrozole (Arimidex) and exemestane (Aromasin) are examples of aromatase 
inhibitors used in these patients that work either through competing with substrates 
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binding to aromatase, or by mimicking the substrates of aromatase and inactivating 
the enzyme, thereby reducing the amount of oestrogen produced [40].  
 
As in chemotherapy, hormone therapy can be given in a neoadjuvant or an adjuvant 
setting. Hormone therapy can also be employed as a primary treatment in those 
patients with ER positive breast cancer who are unsuitable for general anaesthetic 
and cannot undergo surgery [41]. Hormone therapy used in this context is known as 
primary endocrine therapy.  
 
1.5.3 Targeted therapy 
 
Targeted therapies have been developed to disrupt molecules and pathways that are 
over-expressed or deregulated in cancers. However, even though the agents used in 
targeted therapy are directed specifically at cancer cells, adverse side effects can still 
occur with these treatments (reviewed in [42]).  
 
HER2 is an example of a molecule, over-expressed in around 20% of breast cancers 
[43], which can be targeted in breast cancer patients. Activation of the HER2 
receptor leads to the stimulation of a number of signalling pathways associated with 
cell growth and proliferation [44]. Trastuzumab (Herceptin), an antibody targeting 
HER2, is a targeted therapy currently used in the clinic. It functions by binding to 
HER2 and blocking the cellular signalling pathways initiated by the receptor, thereby 
inhibiting the growth and survival of HER2-dependant tumours [45]. Trastuzumab 
can be given in neoadjuvant, adjuvant and metastatic settings, and has been shown to 
improve the overall survival rates of breast cancer patients with over-expressed 
levels of this receptor [46].  
 
Pertuzumab is another monoclonal antibody used as a targeted therapy that operates 
by binding the HER2 receptor at a different site from trastuzumab, inhibiting ligand-
dependent signalling between HER2 and HER3. These 2 monoclonal antibodies have 
complementary mechanisms of action as a result of their different binding sites 
(reviewed in [47]), and clinical trials have shown the benefits and tolerability of 
combined treatment [48, 49].   
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Lapatinib, a dual tyrosine kinase inhibitor of HER2 and epidermal growth factor 
receptor (EGFR or HER1), is another example of targeted therapy in clinical use 
[50]. Both Trastuzumab and lapatinib have been combined with chemotherapy [51, 
52] and hormone therapy [51, 53], leading to improved patient outcomes compared 
to single agent treatment. Further studies have also shown the benefits of combining 
trastuzumab and lapatinib together in breast cancer treatment [54, 55].   
 
Other forms of targeted therapy involving trastuzumab include trastuzumab 
emtansine (Kadcyla), which consists of a monoclonal antibody combined to a 
chemotherapy drug. With this treatment, trastuzumab directs the conjugate to the 
HER2 over-expressing breast cancer cells, inhibiting HER2 signalling, while the 
emtansine causes cancer cell death through impeding microtubule assembly [56].  
Another instance of a targeted therapy in clinical use is everolimus. This drug 
inhibits the mammalian target of rapamycin (mTOR) pathway, which is an 
intracellular signalling pathway involved in the regulation of the cell cycle, thereby 




Breast cancer treatment generally involves the surgical removal of tumour tissue. 
There are various types of surgery [58], with the surgical procedure carried out 
dependent on both the size of the tumour and whether or not it has metastasised. 
Lumpectomies are carried out on small tumours, and involve the removal of only the 
breast lump and a small area of the surrounding normal tissue, which is then checked 
for the presence of any cancer cells. Quadrantectomies involve the removal of about 
a quarter of the breast tissue, with further surgery required if cancer cells are 
discovered at the edges of the removed tissue. These procedures are often termed 
breast-conserving surgery [58].  
 
Women who have larger tumours, who have a tumour present in the middle of the 
breast, or who have cancerous tissue present in more than one area of the breast, 
require more extensive surgery. These procedures are termed mastectomies, and 
 11 
involve the removal of the central part of the breast close to the nipple. There are a 
variety of mastectomy procedures carried out [58]. A simple mastectomy involves 
the removal of the entire breast, leaving the lymph nodes and tissue below the breast. 
A modified radical mastectomy is the same as a simple mastectomy, with the 
underarm lymph nodes removed as well. A radical mastectomy is the most extensive 
operation, in which the entire breast, lymph nodes and chest wall muscles under the 
breast are removed.  
 
For many years radical mastectomies were the main surgery implemented for breast 
cancer of any size. However, randomised studies showed that removal of the whole 
breast was not always necessary, as patients who underwent breast-conserving 
surgery followed by radiotherapy had a similar survival rate to patients who had 
mastectomies [59-61]. Breast reconstruction surgery is usually carried out following 
the surgical removal of cancer tissue. This procedure can be performed at the same 
time as the breast cancer surgery (immediate reconstruction), or at a later date 




Radiotherapy, first used in the treatment of cancer in the 1890s (reviewed in [62]), 
still plays a major role in the management of breast cancer today, despite the 
multitude of advances made in both systemic therapy and surgery since that time. 
Radiotherapy involves the use of ionizing radiation to kill cancer cells. 
Brachytherapy is one form of radiotherapy, comprising the placing of radioactive 
material beside breast tumours inside the body [63]; however, external radiotherapy 
is another form of radiotherapy that is much more commonly performed.  
 
Radiotherapy is traditionally performed post-surgery, after breast conserving surgery 
and sometimes after mastectomies, and functions to eradicate any residual tumour 
cells left behind post-surgery [64]. The considerable benefit of adjuvant radiotherapy 
to patients suffering from breast cancer is well recognised, with studies showing a 
significant reduction in breast cancer recurrence and mortality in patients that have 
received radiotherapy [65-68]. In addition to treatment after surgery, radiotherapy 
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also has a role in the management of advanced breast cancer subsequent to systemic 
therapy, when inflammatory changes preclude surgical intervention [64]. The effect 
of neo-adjuvant radiotherapy, in combination with chemotherapy, has recently been 
assessed in phase 1 clinical trials [69].  
 
Adjuvant radiotherapy is broken up into fractions, which involves giving patients 
repeated smaller doses of radiation within a course of treatment. Radiation treatment 
can last from 3 to 5 weeks, with fractions given once a day every weekday [70]. The 
aim of these treatments is to distribute an effective dose of radiation to the tumour 
tissue whilst minimising damage to the surrounding healthy tissue. The favourable 
effects of adjuvant radiotherapy on long-term survival can be counterbalanced by an 
increase in the percentage of non-breast cancer related deaths, including vascular 
mortality [68]. A linear relationship has been found between the dose of radiation the 
heart receives and the rate of major coronary events [71]. There have been numerous 
studies investigating mechanisms to reduce the dose the heart receives during breast 
cancer radiotherapy. Strategies such as prone patient positioning and patient 
breathing techniques have been shown to be effective in reducing the irradiation dose 
received by the heart [72]. Recent developments in the field of radiotherapy involve 
the application of intensity-modulated radiotherapy (IMRT) and image guided 
radiotherapy (IGRT), which have led to the improved accuracy in radiation treatment 
[72, 73]. Intra-operative radiotherapy (IORT) is another method of radiotherapy that 
has been developed [74] that is currently undergoing clinical trials (HTA - 
10/104/07). Instead of giving a course of irradiation treatment post-surgery, this 
technique sees patients receiving a single dose during surgery, with the aim of 
avoiding the irradiation of normal tissues surrounding the tumour.  
 
1.6 Physiology of breast cancers 
 
Blood capillaries are present in close proximity to metabolically active tissues within 
the body, enabling the effective exchange of nutrients and metabolites between the 
blood and cells of the tissue [75]. The breast is well vascularised [8], ensuring that 
normal cells within the breast are provided with sufficient O2 and nutrients, enabling 
them to perform their functions. Tumour cells also require O2 and nutrients to 
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survive, along with the ability to remove metabolic wastes. As tumours grow and 
develop, some cells within the tumour can be pushed further and further away from 
the blood vessels, preventing their access to metabolites and O2 [76, 77]. The ability 
of tumour cells to induce the formation of new blood vessels from existing blood 
vessels, through the process known as angiogenesis, is one of the hallmarks of cancer 
fundamental to tumour biology [6].  
 
While angiogenesis only occurs in particular physiological conditions in healthy 
adults, it is much more persistent within tumours [78]. However, studies show that 
these newly made blood vessels within tumours have many structural abnormalities 
compared to the normal vasculature (figure 3) [79, 80]. These defects lead to blood 
flow that can vary considerably between differing breast tumours [79]. The 
characteristics of newly formed blood vessels lead to areas within tumours where the 
O2 concentrations are low. Cells within these areas are described as being hypoxic. 
 
 
Figure 3: Differences in the vasculature of normal and cancerous tissue.  
The blood vessels of normal tissue are well-organised and lead to the oxygenation of all 
areas of the tissue. Tumour vasculature, however, have incomplete vessel walls along with 
sluggish and irregular blood flow, leading to areas of tissue that are not adequately supplied 








Hypoxia is defined as a state of reduced O2 availability. The O2 concentration in air 
is 21%, however, most tissues in mammals function in O2 concentrations ranging 
from 2-9% O2. Tissues with O2 concentrations ≤ 2% O2 are usually defined as 
hypoxic, with tissues in ≤ 0.02% O2 conditions defined as severely hypoxic [82].  
 
1.7.1 Mechanisms leading to hypoxia 
 
There are two main mechanisms that lead to the formation of hypoxia in tumours. 
Gray and Thomlinson discerned the first in 1955 (figure 4). They identified a 
connection between the necrotic areas that formed in tumour tissues and distance 
from blood vessels, with this distance being consistent with the diffusion properties 
of O2 [77]. This type of hypoxia is known as diffusion limited hypoxia, or steady 
state hypoxia. In 1968 a study was published which provided an example of diffusion 
limited hypoxia that is more typical in solid tumours, with tumour tissue observed 
surrounding blood vessels, and necrosis evident in areas of the tumour further away 
from the blood vessels [76]. Diffusion limited hypoxia occurs as a result of cells 
closest to the blood vessel consuming much of the available O2. The O2 
concentration decreases as distance from the blood vessel increases, leading to the 
development of hypoxic cells [83]. The distance from the blood vessel at which this 
form of hypoxia develops is variable, as the diffusion distance of O2 depends on how 
much of the O2 is used by the cells closest to the blood vessel, in addition to how 
much O2 is being carried in the blood [84]. This type of hypoxia is also known as 
chronic hypoxia, as cells can be exposed to low levels of O2 through this mechanism 





Figure 4: Visualisation of hypoxia in tumours.  
Figure adapted from a paper by Gray and Thomlinson [77], which was the first to visualise 
the presence of hypoxia in tumours. Their paper describes the presence of tumour regions 
enclosed by vascular stroma, with necrotic areas present in the centre of many of the pieces 
of tumour tissue. The size of the region of viable tumour cells between the stromal tissue and 
necrotic tumour tissue was in a similar range to their calculated diffusion distance of O2. 
They therefore suggested that O2 was being consumed by the tumour cells as it diffused in 
from the stroma, leading to the formation of necrotic areas in the centre of the tumour, with 
hypoxic cancer cells adjacent to these necrotic areas. 
 
For many years it was thought that diffusion-limited hypoxia was the only form of 
hypoxia to exist in tumours. However, late in the 1970s it was suggested that hypoxia 
could develop in tumours through a differing mechanism termed perfusion-limited 
hypoxia, or cycling hypoxia, which can lead to the re-oxygenation of previously 
hypoxic cancer cells [85]. The development of hypoxia through this process was 
confirmed in the 1980s [86]. This form of hypoxia arises from disturbances in the 
blood flow through the tumour vasculature, thereby preventing the delivery of O2 
from red blood cells. Blockage of the vasculature by circulating tumour cells, or the 
collapse of abnormal blood vessels, are possible causes for the cessation of blood 
flow (reviewed in [87]). This type of hypoxia is also known as acute hypoxia, as it 
can be transient in nature.  
 
This classification of hypoxia into two groups, which many refer to as acute 
(perfusion limited) and chronic (diffusion limited) hypoxia, is perhaps an 
oversimplification. These two groups can be further broken down into subgroups. 
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Acute hypoxia can been subdivided into ischemic hypoxia (no blood flow at all due 
to complete blockage, leading to no O2 delivery) and hypoxemic hypoxia (still a 
small amount of blood flow with abnormally low levels of O2). Chronic hypoxia can 
be further divided into diffusion-limited hypoxia, hypoxemic hypoxia (reduced O2 
content in the blood for long periods of time), and IHT (interstitial hypertension)-
induced hypoxia (lack of flow due to compromised perfusion) [84].  
 
More recently, a third form of tumour hypoxia, termed macroscopic regional 
hypoxia, has also been identified [88, 89]. In tumours, blood vessels and their 
branches can continue for many millimetres through the tumour tissue. At the arterial 
end of the blood vessel there is the highest concentration of O2. However, towards 
the venous end the concentration of O2 decreases as the cells present nearer the 
arterial end consume O2. This produces a gradient in O2 concentration within the 
blood vessel, and can lead to cancer cells at the distal parts of the vessel being 
hypoxic, despite being in close proximity to the vasculature. 
 
1.7.2 Hypoxic levels within normal and breast cancer tissue 
 
Because of a lack of suitable methods for the measurement of O2 tensions within 
human tissues, it was challenging for clinicians and scientists to assess tumour 
hypoxia within patients for many years after its initial observation in the 1950s [90]. 
While there are a number of methods in development for analysing the oxygenation 
levels of tissues in the body (reviewed in [91, 92]), a non-invasive technique that 
accurately measures O2 levels within tissues still does not exist. The Eppendorf pO2 
histograph is one technique that has been used to analyse the oxygenation of tissues 
in the human body [93-96]. This method consists of using an O2 electrode that is 
placed into the tissue and provides histograms of O2 partial pressures. Studies carried 
out assessing the O2 concentrations in both normal and cancerous breast tissue 
showed that the O2 concentration of breast tumours was distinctly lower than that of 
normal tissue [93]. The median O2 concentration measured in normal breast tissue 
was found to be around 8.5% O2, while the median O2 concentration in locally 
advanced breast cancer tissue was 3.9% O2. Severe hypoxia was prevalent in many 
of the breast tumours analysed, with nearly 60% of cancers having areas of tissue 
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with O2 tensions of under 0.33% O2. This contrasted greatly with normal breast 
tissues, in which O2 concentrations below 1.6% O2 were not found [93]. Another 
study assessing the oxygenation status of breast cancers using the same method also 
showed the extensive presence of hypoxia in breast tumour tissue [95].  
1.7.3 Hypoxia and treatment resistance 
 
The abnormal structure of the tumour blood supply, leading to hypoxia, has many 
consequences for cancer and its treatment. In fact, hypoxia was one of the first 
modifiers of treatment outcome recognised for cancer, and remains one of the most 
important influences of responsiveness today [97]. The efficacy of systemic therapy 
is adversely affected, as the irregular vasculature hinders the delivery of blood-borne 
drugs to many of the cancer cells in the tumour. This leads to a heterogeneous 
distribution of drugs within cancers, compromising chemotherapy, hormone therapy 
and targeted therapy (reviewed in [98]). The hypoxia created by the inefficient 
delivery of O2 also has an effect on systemic therapy, as the hypoxic conditions lead 
to a decrease in the proliferation rate of cancer cells [99-101]. Since many of the 
cytotoxic agents used in cancer treatment function by targeting rapidly dividing cells, 
the effects of these cytotoxic agents can also be reduced [100].  
 
From 1909 onwards, many different studies indicated that O2 levels could influence 
the radio-sensitivity of cells (reviewed in [82]). Research conducted in the early 
1950s by Gray et al confirmed this effect, when they demonstrated that cells which 
were anoxic at the time of irradiation were more resistant to treatment than cells 
which were well oxygenated [102]. At a given dose of irradiation, hypoxic cancer 
cells tolerate a dose 2-3 times higher than aerobic cells, recognised as the O2 
enhancement effect. Radiotherapy can lead to the generation of free radicles within 
the cell that may react with DNA. The presence of even low concentrations of O2 can 
‘fix’ (make permanent) any radiation-induced DNA damage before this damage can 
be repaired by radical scavengers in the cell. This is known as the oxygen fixation 
hypothesis (reviewed in [82] and [103]). This process leads to a molecular change in 
the DNA that is not repairable, and can lead to reproductive cell death if the cell tries 
to divide [104].  
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1.8 Cancer cell metabolism and HIF 
 
The reprogramming of energy metabolism to support the growth and proliferation of 
cancer cells (reviewed in [105, 106]) is recognised as an attribute that is extremely 
important in the development and progression of cancer. This characteristic is now 
considered an emerging hallmark of cancer [6].  
 
1.8.1 Glycolysis, the citric acid cycle, and oxidative phosphorylation 
 
The breakdown of glucose is the dominant form of energy production in most animal 
cells. There are 2 main parts in the production of energy from glucose. Part 1 
(reviewed in [107, 108]) occurs in the cytosol of the cells, and involves the 
breakdown of glucose to pyruvate, which is accompanied by the production of small 
amounts of NADH (nicotinamide adenine dinucleotide, reduced) and ATP 
(adenosine triphosphate) (figure 5A). This process is known as glycolysis, and does 
not require O2. Part 2 (reviewed in [107, 109, 110]) comprises the citric acid cycle 
and oxidative phosphorylation (figure 5B). The citric acid cycle involves converting 
pyruvate into acetyl-CoA, followed by the consumption of acetyl-CoA molecules, 
leading to the production of NADH, FADH2 (flavin adenine dinucleotide, reduced) 
and ATP. In a process termed oxidative phosphorylation (OXPHOS), the NADH and 
FADH2 produced in the cell pass their electrons down the electron transport chain, 
leading to the generation of large amounts of ATP. Part 2 occurs in the mitochondria 
and requires O2. While most aerobic cells in the body derive their energy from 
glycolysis followed by OXPHOS, low O2 conditions lead to a reduction in 
mitochondrial respiration within cells [111]. One of the ways through which hypoxic 
cancer cells adapt their metabolism to low O2 conditions is through the hypoxia 
inducible factors (HIFs). 
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Figure 5: Simplified diagram of cellular metabolism.  











































































(A) Glycolysis. Glycolysis is a sequence of reactions that can be thought of as comprising three main stages. (i) The conversion of glucose into 
fructose 1,6-bisphosphate, which traps glucose in the cell. (ii) Cleavage of the fructose 1,6-bisphosphate into two three-carbon fragments that are inter-
convertible. (iii) The transfer of energy to NADH and ATP when the three-carbon fragments are oxidized to pyruvate. Glycolysis does not require O2 to 
function. Despite the production of some ATP during glycolysis, pyruvate still contains most of the energy that was present in glucose. (B) 
Mitochondrial respiration. Vast amounts of energy can be produced through the citric acid cycle and oxidative phosphorylation in the presence of 
O2. Firstly, pyruvate is shuttled into the mitochondrion of the cells and is converted into an acetyl group, which is attached to coenzyme A, leading to 
the formation of acetyl CoA. Acetyl CoA combines with another molecule to form citrate. Citrate enters a sequence of reactions called the citric acid 
cycle, which produces ATP and CO2 along with large amounts of the electron carriers NADH and FADH2. The electrons from NADH and FADH2 are 
subsequently passed along the electron transport chain present in the mitochondria, leading to the production of large amounts of ATP and the 
consumption of O2 through oxidative phosphorylation. (C) Lactic acid fermentation. Hypoxic cancer cells, along with many normoxic cancer cells, 
rely on glycolysis for the production of energy. However, an energy-producing pathway that ceases at pyruvate is unable to continue for long as NAD+ 
is consumed in this pathway, and there is only a limited amount of NAD+ present in a cell. Lactic acid fermentation, a process in which pyruvate is 
converted into lactic acid, leads to the regeneration of NAD+, thus enabling the continuation of glycolysis.  (D) Pentose phosphate pathway (PPP). 
The PPP is mainly an anabolic pathway that consists of 2 parts; the oxidative branch and the non-oxidative branch. The oxidative branch, using 
glucose-6-phosphate (G6P) as the substrate, consists of 3 reactions and leads to the generation of NADPH. The non-oxidative branch of the PPP 
primarily functions to generate ribose-5-phosphate (R5P). Other reactions of the non-oxidative branch convert 5-carbon sugars into 6 (fructose 6-
phosphate) and 3 (glyceraldehyde-3-phosphate) carbon sugars, which can be used by the glycolytic pathway. (E) Glutamine metabolism. ASCT2 
mediates the uptake of glutamine into the cell. The imported glutamine is then converted into glutamate either in the cytosol by GLS1, or by GLS2 in the 
mitochondria. The glutamate present in the cytosol is a source of non-essential amino acids (NEAAs), and is also a precursor of glutathione. The 
glutamate present in the mitochondria can enter the citric acid cycle.  
GLUT glucose transporter; HK hexokinase; G6P glucose-6-phosphate; PGI phosphoglucose isomerase; F6P fructose- 6-phosphate; PFK-1 
phosphofructokinase 1; F1,6BP fructose-1,6-bisphosphate; ALDOA aldolase A; DHAP dihydroxyacetone phosphate; G3P glyceraldehyde 3-phosphate; 
TPI triose-phosphate isomerase; GAPDH glyceraldehyde 3-phosphate dehydrogenase;  1,3-BPG 1,3-bis-phosphoglycerate; PGK1 phosphoglycerate 
kinase 1; 3-PG 3-phosphoglycerate; PGM phosphoglycerate mutase; 2-PG 2-phosphoglycerate; ENO1 enolase 1; PEP phosphoenolpyruvate; PKM2 
pyruvate kinase M2; ATP adenosine-5’-triphosphate; PDH pyruvate dehydrogenase; PDK1 pyruvate dehydrogenase kinase; LDHA lactate 
dehydrogenase A; NADH nicotinamide adenine dinucleotide; PO43- phosphate; G6PDH glucose 6-phosphate dehydrogenase;  6PGδL; 6-
phosphogluconolactone; 6PGL 6-phosphogluconolactonase; 6PG 6-phosphogluconate; NADPH nicotinamide adenine dinucleotide phosphate; CO2 
carbon dioxide; 6PGDH 6-phosphogluconate dehydrogenase; Ru5P ribulose 5-phosphate; RPI ribose 5-phosphate isomerase; RPE ribulose 5-
phosphate epimerase; R5P ribose 5-phosphate ; Xu5P xylulose 5-phosphate; TKT transketolase; S7P sedoheptulose 7-phosphate; TAL transaldolase ; 





Activation of the hypoxia inducible factor (HIF) pathway is one of the main 
mechanisms that enable hypoxic cancer cells to survive in their low O2 environment. 
HIFs are O2-responsive transcription factors, and are master regulators of genes 
involved in the control of many different processes, including metabolism, 
proliferation, angiogenesis and migration (reviewed in [112]).  
 
HIFs consist of both an α and a β subunit. There are 3 different isoforms of the alpha 
subunit (HIF-1α, HIF-2α and HIF-3α) and only 1 beta subunit (HIF-1β) (reviewed in 
[82]). In contrast to HIF-1β, the HIFα proteins are sensitive to changes in the levels 
of O2 (figure 6). HIFα protein stability is controlled through a region called the O2-
dependent degradation domain (ODDD) [113]. Under high O2 concentrations, HIF-
specific prolyl hydroxylase domain (PHDs) proteins, which require O2 for activity, 
hydroxylate the proline residues present within the ODDD [114-116]. Hydroxylation 
within the ODDD of the α subunit leads to its recognition by the von Hippel-Lindeau 
(VHL) tumour suppressor protein, which catalyses the transfer of ubiquitin onto the 
HIFα protein [113, 117, 118]. HIFα hydroxylation, and the subsequent poly-
ubiquitination, leads to the proteasomal degradation of the protein [113, 119]. PHD 
proteins are inhibited in lower O2 conditions [114], leading to the accumulation of 
the HIFα subunits and translocation to the nucleus. When present in the nucleus, the 
HIFα subunit dimerizes with HIF-1β [120], and the HIFα-HIFβ heterodimer binds to 
hypoxic response elements (HREs) present in target genes [121].  
 
HIF-1α and HIF-2α, the 2 principle mediators of the cellular response to hypoxia, 
have distinct roles within cells. This is reflected in their stabilisation at different O2 
tensions, their differing temporal response, and their selectivity with regard to 
transcriptional targets (reviewed in [122]). In contrast to the HIF-1α and HIF-2α 
subunits, HIF-3α is thought to have a dominant negative function, reducing the gene 
expression induced by the other subunits [123].  
 
In addition to the ODDD, which regulates HIFα stability, HIFα subunits contain two 
transactivation domains termed N-TAD (N-terminal transactivation domain) and C-
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TAD (C-terminal transactivation domain) [124, 125], which are areas where co-
regulatory proteins can bind and control gene expression [126-128]. While the PHD 
proteins control the levels of HIFα in differing O2 conditions, the extent of 
expression through stabilised HIF is controlled by another protein, factor inhibiting 
HIF-1 (FIH-1). FIH-1 is an additional O2 sensor present in cells that has been 
described as a negative regulator of HIF transcriptional response [129, 130]. While 
the PHD proteins are inactivated in low O2 conditions, FIH-1 has been shown to 
retain its activity in hypoxia [131, 132], catalysing the hydroxylation of an 
asparaginyl residue in the C-TAD of HIFα. This hydroxylation impairs the 
interaction between C-TAD and the transcriptional co-activator p300/CREB binding 
protein (CBP) [130, 133], thus impairing the expression of C-TAD sensitive genes 
(figure 6).  
 
Since HIF-1α was originally recognized due to its response to hypoxic conditions, it 
has become apparent that HIF signalling can be influenced by O2-independent 
factors. Increased HIF signalling can be induced in normoxic conditions by various 
genetic alterations that lead to the activation of oncogenes (ERBB2 and SRC) and 
the inactivation of tumour suppressor genes (VHL, PTEN and CDKN2A)[134, 135]. 
Most of these genetic alterations can lead to HIF signalling in aerobic conditions 
through either increasing the synthesis or decreasing the ubiquitination of HIF-1α. 
Other O2-independent factors have also been linked to HIF-1α signalling in normoxic 
conditions, including signalling through growth factors [136, 137] and lactate or 




Figure 6: Regulation of HIF signalling.  
PHDs (prolyl hydroxylase domain) are Fe2+-dependent proteins that control the levels of 
HIF-1α in the cell. In oxygenated conditions, these proteins hydroxylate the proline residues 
within the ODDD (oxygen-dependent degradation domain) of HIF-1α. This leads to the 
binding of the VHL (von Hippel-Lindau) protein to HIF-1α, resulting in the ubiquitination 
and subsequent proteasomal degradation of HIF-1α. When O2 levels drop, the PHDs are 
inactivated, leading to the accumulation of HIF-1α in the cell. The stabilised HIF-1α 
translocates to the nucleus and dimerises with HIF-1β, which is facilitated by the bHLH 
(basic helix loop helix) and the PAS (Per/ARNT/Sim) domains present in both proteins. The 
heterodimer then binds to hypoxic response elements (HREs) within the regulatory regions 
of target genes, leading to the expression of genes involved in hypoxic response through 
RNA polymerase II. Factor inhibiting HIF-1 (FIH-1) is another oxygen sensor present in the 
cells that controls the extent of signalling through stabilised HIF-1α. FIH-1 hydroxylates the 
asparaginyl residue within the C-terminal transactivation domain (C-TAD) of HIF-1α, 
preventing the binding of the transcriptional co-activator p300/CREB binding protein (CBP) 
to HIF-1α, leading to only partial HIF signalling through stabilised HIF-1α. More severe 
hypoxic conditions inhibit FIH-1, enabling the binding of co-activators to HIF-1α, leading to 
full HIF signalling. Image adapted from [140].  
 
1.8.3 HIF and glycolysis 
 
Oxygen is vital for cell survival as it is necessary for the production of large amounts 
of energy through OXPHOS (reviewed in [107, 109]). However, as already 
mentioned (see section 1.8.1), hypoxic cancer cells are unable to rely on this process 
for energy production due to their low O2 levels. The HIF pathway helps cancer cells 
survive in reduced O2 concentrations by causing two alterations in the metabolism of 




Although HIF-1α and HIF-2α control the expression of overlapping sets of genes, the 
effects of HIF-1α on metabolism have been more thoroughly investigated. HIF-1α 
increases the expression of many of the enzymes involved in the glycolytic pathway, 
including hexokinase 2 (HK2), aldolase A (ALDA), phosphoglycerate kinase 1 
(PGK1), enolase 1 (ENO1), and pyruvate kinase M (PKM) [141-143]. To ensure that 
there is sufficient glucose to support the amplified rate of glycolysis, HIF-1α also 
induces the expression of the plasma membrane glucose transporters GLUT1 and 
GLUT3 [144-146].  
 
In addition to instigating increased rates of glycolysis, HIF-1α also affects 
mitochondrial respiration through blocking the citric acid cycle and oxidative 
phosphorylation (reviewed in [147]). Under sufficient O2 conditions, the pyruvate 
derived from glucose is usually converted into acetyl-CoA by pyruvate 
dehydrogenase (PDH), which then enters the citric acid cycle [110]. HIF-1α inhibits 
mitochondrial respiration through inducing the expression of pyruvate 
dehydrogenase kinase 1 (PDK1) [148-151], which inactivates PDH (reviewed in 
[152, 153]), thus depriving the citric acid cycle of citrate. HIF-1α also reduces 
mitochondrial respiration through the down-regulation, inhibition and degradation of 
proteins involved in oxidative phosphorylation, such as mitochondrial complex 1 
[154] and cytochrome C oxidase subunit 4 (COX4) [155]. In addition to blocking the 
citric acid cycle and OXPHOS, HIF-1α also leads to reduced mitochondrial 
biogenesis [156] and an induction of mitochondrial degradation [157]. Overall, these 
changes help hypoxic cancer cells adapt their metabolism to the low O2 environment 
through the induction of a highly glycolytic phenotype.  
 
1.8.4 The Warburg Effect 
 
While hypoxic cancer cells adapt to their low O2 environment by inducing 
glycolysis, there are also cancer cells in the body present in normoxic conditions that 
also exhibit a highly glycolytic phenotype. This observation was first made in the 
1920s by Otto Warburg [158], and was later termed the Warburg Effect [159]. 
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Warburg originally suggested that an ‘irreversible injuring of respiration’ was the 
cause of the aerobic glycolysis [160], with normoxic cancer cells increasing their rate 
of glycolysis to deal with the lack of ATP generation through dysfunctional 
mitochondrial [160]. However, research performed in the decades following 
Warburg’s paper indicated that defects in the mitochondria were a rare occurrence, 
and therefore could not explain the aerobic glycolysis seen in cancer cells [161]. 
More recent work showing that cancer cells maintain the ability to produce ATP via 
OXPHOS indicate that the mitochondria within cancer cells are not dysfunctional 
[162, 163].  
 
The causes of the Warburg effect are still unknown today, nearly a century after it 
was first observed. One suggestion put forward involves hypoxia, with some 
proposing that the low O2 conditions present in tumours leads to cancer cells 
adapting their metabolism through increasing their rate of glycolysis. This adaptation 
enables these cancer cells to survive in the hypoxic environment, and leads to a 
dependence on glycolysis in these cells that persists even in aerobic conditions [164]. 
Conversely, studies have shown that the induction of aerobic glycolysis is an early 
event in cancer development, emerging from oncogenic mutations in the early stages 
of cancer [165]. Therefore, even though hypoxia has an important role in the 
metabolic reprogramming of cancer cells in low O2 environments, it has been 
suggested that hypoxia is a delayed event and is not the reason behind the Warburg 
effect [166]. However, while hypoxia may not play a role in the genesis of the 
Warburg effect, the HIF pathway may still have a part to play, as the loss of tumour 
suppressors (such as PTEN, VHL and p53) or the activation of oncogenes (including 
SRC, Ras and PI3K), along with other O2 independent factors, can lead to HIF-1α 
stabilisation in normoxic conditions (see section 1.8.2), thus inducing aerobic 
glycolysis. 
 
It is thought that the Warburg Effect benefits cancer cells and encourages cancer cell 
proliferation [166]. However, exactly how the Warburg Effect is advantageous for 
cancer cells is still debated, because although the rate of ATP production is increased 
in these cells, aerobic glycolysis is an inefficient way of producing ATP compared to 
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mitochondrial respiration (reviewed in [167]). Some believe that cells with a higher 
rate but lower yield of ATP production may have an advantage when competing for 
shared energy resource such as glucose [168], of which there is only a limited 
amount in the tumour microenvironment [169-171]. There are those that disagree 
with the reasoning that the increased rate of ATP production through aerobic 
glycolysis aids in proliferation. Studies conducted in the late 1960s showed that 
energy consumption not associated with proliferation in mammalian cells is very 
high [172], leading to the belief that cells actually require more ATP for normal 
cellular maintenance than they do for proliferation [167]. This means that ATP levels 
in proliferating cancer cells may never be a limiting factor [167].  
 
Anabolic or biosynthetic pathways are a vital part of cancer cell metabolism, as they 
enable the production of the macromolecules required for cell division and cancer 
growth (reviewed in [105]). Another hypothesis put forward to explain the existence 
of the Warburg Effect is that it increases the availability of precursors for these 
anabolic pathways, with the production of ATP not representing a major component 
of this phenotype [105]. Studies presenting evidence that functional mitochondrial 
are required for tumourigenesis [173-175], in addition to other work showing that 
limiting ATP production through the inhibition of glycolysis does not prevent 
oncogenesis [176], leads some to believe that aerobic cancer cells rely on 
mitochondrial respiration for the production of energy [105].   
 
Several papers explain the Warburg Effect as a ‘switch’ from OXPHOS to glycolysis 
[164, 166]. However, more recent work has provided evidence against the idea of a 
‘switch’ occurring, with studies showing that cancer cells exhibit the ability to 
enhance both lactate production and the citric acid cycle in parallel [177-179]. One 
possible way through which this might be achieved in cancer cells is through 
enhanced enzyme expression and substrate delivery [105].  
 
1.8.5 Lactic acid fermentation 
 
Within the glycolytic pathway, conversion of glyceraldehyde 3-phosphate (G3P) to 
1,3-bis-phosphoglycerate (1,3-BPG), catalysed by glyceraldehyde 3-phosphate 
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dehydrogenase (GAPDH), leads to the reduction of NAD+ to NADH. As there is 
only a limited amount of NAD+ in a cell, this molecule must be regenerated for 
glycolysis to continue (reviewed in [107, 108]).  
 
In cells undergoing low levels of glycolysis, mitochondrial shuttles (the most 
commonly known is the malate-aspartate shuttle) restore NAD+ levels in the cytosol, 
with the concomitant generation of NADH in the mitochondria. The NADH 
generated in the mitochondria passes its electrons down the electron transport chain, 
and the NAD+ produced in the cytosol enables the continuation of glycolysis 
(reviewed in [167]). During glycolysis in normal cells, these shuttles are able to 
regenerate sufficient NAD+ for glycolysis to persist. However, the rate of NAD+ 
consumption is vastly increased in both hypoxic and aerobic cancer cells as a result 
of their highly glycolytic phenotype, which results in the mitochondrial shuttles 
being unable to regenerate NAD+ at a fast enough rate (reviewed in [167]). Cancer 
cells therefore require other methods to maintain NAD+ levels.  
 
The major mechanism through which highly glycolytic cells restore their NAD+ 
levels is through lactic acid fermentation (reviewed in [107, 108]) (figure 5C). In this 
process, NADH transfers its electrons to pyruvate, leading to the production of lactic 
acid and the regeneration of NAD+, thus enabling glycolysis to continue in these 
cells. Normoxic and hypoxic cancer cells, through both oncogenic transformation 
and HIF-1α stabilisation, are adapted to increase the rate of lactic acid fermentation. 
Hypoxia and HIF-1α stabilisation induce the expression of pyruvate dehydrogenase 
kinase 1 (PDK1) (see section 1.8.3) and lactate dehydrogenase (LDHA) [151, 180]. 
PDK1 inactivates pyruvate dehydrogenase (PDH) (see section 1.8.3), inhibiting the 
conversion of pyruvate to acetyl CoA, thereby impeding mitochondrial respiration 
and increasing the amount of pyruvate present in the cells. The amplified levels of 
LDHA, which catalyses lactic acid fermentation, leads to an increase in the 
conversion rate of this pyruvate to lactate [151]. In this way, cancer cells are adapted 




1.8.6 The pentose phosphate pathway 
 
Instead of using glycolysis, followed by either oxidative phosphorylation or lactic 
acid fermentation, glucose can take an alternative pathway termed the pentose 
phosphate pathway (PPP) (reviewed in [181, 182]) (figure 5D). The PPP is 
principally an anabolic pathway that supports the synthesis of macromolecules 
through the production of NADPH (nicotinamide adenine dinucleotide phosphate, 
the majority of which is used in reductive biosynthesis reactions in the cell [183, 
184]), and ribose [185] (required for nucleotide biosynthesis). The contributions of 
the PPP are very important in the production of the raw materials required for cell 
proliferation [185]. The PPP is a crucial pathway in cancer cells as a result of their 
high proliferative rate.  
 
Apart from contributing to the production of raw materials required for cell 
proliferation, the PPP also has a part to play in controlling the levels of reactive 
oxygen species (ROS) produced in cells due to metabolism. Electrons transported 
through the electron transport chain (ECT) during OXPHOS can react with O2, 
leading to the formation of ROS [186]. It has been estimated that between 0.2-2% of 
the O2 consumed by the mitochondria is released as ROS (reviewed in [187]). A 
build up of ROS within the cells can cause damage to cellular components and 
induce cell death [188]. Antioxidants reduce the effects of these ROS, with 
glutathione being one of the most important anti-oxidants present in the cell [189]. 
However, GSH cannot be produced in the mitochondria, and must instead be 
imported from the cytosol [189]. The production of GSH requires the presence of 
NADPH; the PPP, through the production of NADPH, has a role to play in the 
generation of GSH in cells (reviewed in [181, 182]). This aspect of the PPP is 
especially important in cancer cells as a result of their increased rates of metabolism 
and ROS generation [190].  
 
Studies have indicated that rapidly dividing cancer cells can modulate the PPP, 
leading to increased levels of nucleic acids and NADPH, thereby enabling increased 
proliferation and leading to greater control over oxidative stress levels [182]. For 
example, hyperactivation of a number of pro-oncogenic signalling pathways, such as 
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the PI3K/Akt, Ras and Src pathways, are thought to promote the post-translational 
modification and activation of glucose 6-phosphate dehydrogenase (G6PDH) [182], 
an enzyme which catalyses the first committed step of the PPP. The expression levels 
of transaldolase (TAL), another enzyme involved in the PPP, have also been shown 
to be up-regulated in cancer cells [191].  
 
1.8.7 Glutamine metabolism 
 
There are energy sources other than glucose available to cells. Glutamine is an 
example of one such source (figure 5E). The essential requirement of glutamine for 
cells in culture was first observed in 1948 by Albert Fischer [192], and later by Harry 
Eagle in 1956 [193]. Later experiments provided evidence that glutamine was being 
used to produce energy in cells [194]. These observations led to the concept that 
glutamine metabolism was a major component of the metabolic phenotype of cancer 
cells [195].  
 
Glutamine is a non-essential amino acid that can be synthesised within cells. 
However, during periods of stress or rapid growth, the demand for this amino acid 
can outstrip the supply, causing glutamine to become conditionally essential [196]. 
Some cells are unable to survive in environments lacking glutamine, exhibiting a 
phenotype known as ‘glutamine addiction’ [197]. Metabolism of glutamine in the 
citric acid cycle produces reducing equivalents for oxidative phosphorylation, 
thereby functioning as a source of energy [198], while also replenishing the citric 
acid cycle intermediates that have been extracted for biosynthesis [199]. Even though 
OXPHOS is inhibited in low O2 conditions [111], mitochondrial respiration can still 
occur in hypoxia [200]. Studies have shown that glutamine can also be used as a fuel 
for OXPHOS in hypoxic cancer cells [201], while other work has highlighted the 
vital role glutamine metabolism has for cancer cell survival in conditions of either 
hypoxia or glucose deficiency [202]. The dependence of breast tumours on glutamine 
seems to differ with the tumour subtype, as basal-type breast cancers have been 
shown to have an increased dependence on glutamine compared to luminal breast 
cancers [203, 204].  
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Proliferating cells are required to synthesise a number of different nitrogen-
containing molecules, including nonessential amino acids and nucleotides. In 
addition to its other roles in metabolism, glutamine (containing 2 atoms of reduced 
nitrogen) acts as a major structural building block for the synthesis of many different 
nitrogen-containing compounds (reviewed in [106]).  
 
1.8.8 Metabolic co-operation 
 
Tumours are heterogeneous environments, containing regions under the influence of 
different O2 conditions, along with various cell types, producing many opportunities 
for metabolic co-operation [205]. Monocarboxylate transporters (MCTs) function in 
the bidirectional transport of lactate across the plasma membranes of cells, with 
MCT1 and MCT4 representing the isoforms most extensively expressed in cancer 
cells (reviewed in [206]). For many years, the lactate produced by hypoxic cancer 
cells was considered as a waste product. However, recent work has shown that 
aerobic cancer cells can use this lactate for the production of energy [207, 208]. This 
work led to the conception of the metabolic symbiont model, wherein the lactate 
produced by hypoxic cancer cells is exported by MCT4, and taken up through MCT1 
into the normoxic cancer cells, where it fuels metabolism. This spares glucose for the 
highly glycolytic hypoxic cancer cells within the tumour, helping them survive 
within their hostile microenvironment [207]. Further evidence that lactate can be 
used as a fuel for mitochondrial respiration has recently been published [178].  
 
Metabolic co-operation between cancer and stromal cells has also been proposed. In 
one model, termed the Reverse Warburg Effect, cancer cells induce aerobic 
glycolysis in the neighbouring stromal fibroblasts, with the tumour cells taking up 
the metabolites released from the stromal cells and using them for energy production 
[209]. Breast cancer cells are thought to induce the Reverse Warburg Effect in 
stromal cells through initiating the down-regulation of caveolin-1 (Cav-1) [210], a 
transformation suppressor protein present in fibroblasts [211]. Other evidence of 
metabolic co-operation between cancer cells and stromal cells has been found in 
studies on ovarian cancer, with ovarian cancer cells using fatty acids produced in 
adipocytes to fuel mitochondrial respiration [212].  
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1.9 Metabolism and pH 
 
Hydrogen (H+) ions, or protons, are one of the most important and reactive ions 
present in a cell. Changes in the concentration of H+ ions leads to changes in pH of 
the cell (reviewed in [213]). Proteins act as pH buffers in the cell, with H+ ions 
usually present at low concentrations in biological solutions as they are generally 
bound to proteins. The binding or release of protons to and from proteins can change 
the ionization state of a protein, thereby changing protein function [214]. Therefore 
changes in the concentration of H+ ions within the cell, or changes in intracellular pH 
(pHi), can affect many different cellular processes (reviewed in [215]). This 
highlights the importance of regulating pH in cells, controlling H+ ion concentration 
to suit protein function.  
 
Numerous processes contribute to the production of acids in cells, and the production 
of energy from glucose is one such process (reviewed in [213]). Under well-
oxygenated conditions in normal cells, the respiration of glucose to CO2 leads to the 
production of ATP, a process that consumes an H+ ion (ADP3- + HPO42- è ATP4- + 
OH-). This disturbance in the acid-base equilibrium is later cancelled out by the 
breakdown of ATP. The main source of acidity from cells undergoing mitochondrial 
respiration is therefore the CO2 that is produced, which can react with water (H2O + 
CO2 ↔ HCO3- + H+), leading to the formation of H+ ions. In hypoxia, ATP 
production through glycolysis is linked to lactic acid fermentation (glucose + 
2xADP3- + 2xHPO42- è 2xATP4- + 2xlactate-). This process does not lead to the 
generation or consumption of H+ ions. However, the subsequent breakdown of ATP 
does lead to the release of protons, thus explaining how anaerobic metabolism 
produces acid [213, 216].  
 
Normal cells in the body possess mechanisms to counter the effects of the acid 
produced by metabolism. The CO2 produced from respiration can passively diffuse 
across the plasma membrane, with some studies indicating the presence of 
specialised gas channels in cells that increase membrane permeability to CO2 [217]. 
However, others believe that the contribution of these channels to the movement of 
CO2 out of the cell is not significant [218]. The H+-lactate produced from anaerobic 
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metabolism has a much lower lipid:water partition coefficient than CO2, and is 
unable to pass freely through the plasma membrane (reviewed in [213]). Cells must 
therefore possess other extrusion methods to remove these products of metabolism to 
help keep the pHi at an optimum level.   
 
Cells express many pH-regulating proteins whose primary function is to control pHi. 
MCTs, already introduced in section 1.8.8, are one such group of proteins. These 
transporters translocate the H+-lactate across the plasma membranes of cells, thus 
reducing the acid load produced from metabolism [219]. The rate of diffusion of 
metabolic products, such as CO2 and H+-lactate, is dependent on the concentration 
gradients of these products across the plasma membrane. In normal tissue with a 
structured and well-developed vasculature, the efficient blood perfusion leads to 
favourable diffusion gradients and efficient solute flux (reviewed in [213]). Both 
normoxic and hypoxic cancer cells are more reliant on glycolysis for energy 
production than normal cells in the body (see sections 1.8.3 and 1.8.4). This 
increased dependence on glycolysis in cancer cells leads to the production of 
increased amounts of acids within these cells in comparison to normal cells. The 
chaotic tumour vasculature results in inadequate perfusion within cancer tissues and 
the build-up of CO2 and H+-lactate in the extracellular environment, impairing the 
outward diffusion of these metabolic products (reviewed in [213]). The increased 
acid production through glycolysis, combined with impaired diffusion, would lead to 
an acidic pHi and probable cell death if additional compensatory mechanisms did not 
exist. As such, an adaptive feature of cancer cells is the over-expression or elevated 
activity of a number of pH regulating proteins.  
 
Some of the main proteins involved in the regulation of cancer cell pH include the 
anion exchangers (AE1, AE2, and AE3) (reviewed in [220]), the Na+/HCO3- co-
transporters (NBCs) (reviewed in [220]) and the monocarboxylate transporters 
(MCT1, MCT2, MCT3 and MCT4) (reviewed in [206]). The carbonic anhydrases, 
the Na+/H+ exchangers, and the vacuolar (H+)-ATPases are 3 other groups of proteins 
that have also been linked with the control of pH within tumours (figure 7). These 3 
proteins are the focus of this thesis. 
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Figure 7: Cancer cell metabolism, HIF and pH. 
 See next page for description
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Figure 7: Cancer cell metabolism, HIF and pH. As cancer cells are pushed further 
away from blood vessels, the level of O2 and nutrients available to the cells decreases. 
Normoxic cells can produce energy either through oxidative phosphorylation (OXPHOS) or 
through aerobic glycolysis (Warburg Effect). Hypoxic cancer cells, however, are unable to 
acquire energy through OXPHOS due to low O2 levels. Activation of the hypoxia inducible 
factor (HIF) family of transcription factors is one of the principle oxygen-responsive 
signalling pathways that allows the adaptation of hypoxic cancer cells to this hostile 
microenvironment. HIF signalling shifts energy production from OXPHOS in the 
mitochondria towards glycolysis, allowing hypoxic cancer cells to continue to produce 
energy despite the low O2 levels. This shift towards glycolysis may also occur in normoxic 
cancer cells as a result of genetic alterations leading to increased HIF signalling in well-
oxygenated conditions. The increased dependency on glycolysis leads to the production of 
increased amounts of H+ ions, which can lead to changes in the pHi of cancer cells if not 
dealt with. To help cope with the excess H+ ions being produced, cancer cells up-
regulate/activate a number of pH regulating proteins; these proteins include CAIX, NHE1 
and V-ATPase. 
 
1.10 Carbonic anhydrases 
 
Carbonic anhydrases (CAs) are metalloenzymes that have a bound zinc atom in the 
active site of the protein that is essential for enzymatic activity. Sixteen carbonic 
anhydrase isoforms have been identified in primates, with 15 of these present in 
humans (reviewed in [221]). These isoforms differ in their catalytic activity, 
subcellular localization, and their sensitivity to inhibitors. There are secreted 
(CAVI), cytosolic (CAI, CAII, CAIII, CAVII and CAXIII), mitochondrial (CAVA 
and CAVB), and membrane-bound (CAIX, CAXII, CAXIV and CAXV) forms of 
the protein. Three inactive isoforms (CAVIII, CAX and CAXI), which lack catalytic 
function, have also been identified (reviewed in [221]). The carbonic anhydrase 
family of proteins are involved in many different physiological functions. These 
include ion transport, bone resorption, the secretion of gastric and pancreatic juices, 
and pH regulation [222].  
 
As already discussed (see section 1.9), membrane-permeant CO2 is a form in which 
much acid is removed from cells. This CO2 is generated either from oxidative 
phosphorylation or from the reaction of metabolic acids with HCO3-. The poor 
perfusion of tumour tissues inhibits the diffusion of CO2 out of cancer cells (see 
section 1.9). The spontaneous hydration reaction involving CO2 (CO2 + H2O ↔ 
HCO3- + H+) reduces the concentration of CO2 outside of the cells, increasing the 
diffusion rate of CO2 across the plasma membrane (reviewed in [223]). However, 
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this reaction is very slow. Carbonic anhydrases facilitate CO2 diffusion from cancer 
cells by catalysing the extracellular hydration of CO2, leading to the generation of H+ 
and HCO3-, thereby maintaining a steeper efflux gradient for CO2 [223, 224]. Some 
of the membrane-bound carbonic anhydrase proteins are thought to interact with 
HCO3- transporters, forming a transport metabolon. In this complex, the carbonic 
anhydrase proteins supply the membrane-impermeant HCO3-, which is then 




Carbonic anhydrase IX (CAIX) (figure 8A) is one member of the carbonic anhydrase 
family that is associated with cancer, with higher levels of this protein connected to 
increased tumour aggressiveness and progression, resulting in a poor prognosis in a 
number of different cancers [226]. CAIX expression is rarely seen in most postnatal 
tissues, with CAIX only observed in cells of the stomach and intestine [227]. 
However, ectopic expression of CAIX can also occur in tumours. The stabilization of 
HIF-1α in the hypoxic areas of tumours leads to high levels of CAIX expression in 
these regions [228-230].  
 
This link between hypoxia, HIF and CAIX has led to interest in the use of CAIX as a 
biomarker to distinguish the presence of hypoxia in cancer [231]. However, the use 
of CAIX as a biomarker for hypoxia has been hampered by the results of several 
studies conducted on cervical cancer, where tumour oxygen tension levels and HIF 
staining did not always correlate with CAIX expression [232-234]. These 
discrepancies may be explained by 3 observations: (i) it can take several hours after 
initial HIF-1α stabilization for CAIX expression to be seen, which could explain the 
absence of CAIX in cells that have only recently become hypoxic and have stained 
positive for HIF-1α [235]. (ii) HIF-1α is an extremely labile protein that degrades 
rapidly in well-oxygenated conditions. Re-oxygenation of previously hypoxic areas 
may therefore be leading to an absence of HIF-1α and the retention of CAIX [235]. 
(iii) While hypoxia is the major inducer of CAIX expression in cancers, stabilisation 
of HIF-1α through oncogenic mutations, or through other O2-independent 
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mechanisms (see section 1.8.2), could also lead to increased CAIX levels in 
normoxic conditions. 
 
Figure 8: Protein structures.  
(A) CAIX consists of a large extracellular domain, a single-pass transmembrane region, 
and a short intracellular tail. The extracellular portion contains a well-conserved CA 
domain that binds zinc and hydrates CO2 extracellularly, along with a proteoglycan-like 
region that is thought to mediate CAIX function, in addition to having a role in cell 
adhesion. The cytoplasmic tail present intracellularly contains 3 putative phosphorylation 
sites that may have a part to play in the regulation of the protein. CAIX proteins are believed 
to assemble as either dimers or trimers on the plasma membranes of cells, stabilised by the 
formation of disulfide bonds (reviewed in [236, 237]. Image adapted from ref [236]). (B) 
The V-ATPase complex consists of 2 domains, the peripheral V1 domain and the integral V0 
domain, each of which is composed of many different subunits. ATP hydrolysis results in the 
rotation of a central motor consisting of D, F, d and proteolipid (c, c’, and c’’) subunits. 
This leads to the uptake of H+ ions by glutamic acid residues through hemichannels present 
in the protein, and the transport of these H+ ions through to the other side of the membrane 
(reviewed in [238, 239]. Image adapted from [238]). (C) The NHE1 protein consists of a 
short N-terminal intracellular region, a membrane-spanning region consisting of 12 
transmembrane domains, and a large intracellular C-terminal tail. The membrane domain of 
NHE1 functions in the transport of ions, extruding one Na+ ion in exchange for one Na+ ion, 
while the cytoplasmic domain of NHE1 functions in the regulation of activity of the protein. 
NHE1 can also regulate cytoskeleton organisation through its C-terminal domain (reviewed 








CAXII is another protein that has been linked with cancer [242-244]. However, this 
link is not as well evidenced as that observed for CAIX, with fewer studies carried 
out to date on CAXII. Therefore, less is known about the role of this carbonic 
anhydrase isoform. CAXII is also a transmembrane protein that catalyses the 
extracellular hydration reaction of CO2, thus aiding in the cellular control of pH 
[245]. In contrast to CAIX, which is only rarely expressed in normal tissues within 
the body, CAXII expression is much more widespread (reviewed in [236, 246]). In a 
study comparing CAXII and CAIX levels in normal adult tissues, there was largely 
no overlap in CAXII and CAIX expression, with the CAXII isoform detected at high 
levels in the colon, kidney, oesophagus, pancreas, rectum and brain [243]. However, 
the overexpression of CAXII has been found in numerous types of cancer, including 
breast cancer [243, 244]. Like CAIX, CAXII levels are also increased in hypoxia 
[242, 243]. However, the molecular mechanism through which CAXII expression is 
induced in low O2 conditions is not currently known, as the presence of a functional 
HRE that could bind HIF has yet to be identified in the CAXII promoter region 




The Na+-H+ exchanger 1 (NHE1) is a pH regulating protein that removes an H+ ion 
from the cytoplasm in exchange for the influx of a Na+ ion in a 1:1 ratio (figure 8C) 
(reviewed in [241]). Ten isoforms of the Na+-H+ exchanger have been identified so 
far (NHE1-NHE10), of which NHE1 is the best characterised. As a result of its 
presence in nearly all cell types, NHE1 expression is widespread in the human body, 
with NHE1 detected in the heart, the vasculature, the kidney, different parts of the 
gastrointestinal tract and the central nervous system, along with many other organs in 
the body (reviewed in [241]). This protein has been shown to have roles in numerous 
processes within cells in addition to its central role in pH regulation, including 
migration, proliferation, vesicle trafficking and cell signalling  (reviewed in [241]). 
Structurally, the NHE1 protein consists of a large cytoplasmic domain at the C-
terminal end of the protein, followed by a transmembrane domain consisting of 12 
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membrane-spanning regions, and a short N-terminal cytoplasmic domain (reviewed 
in [241]).  
 
In normal cells above a set pHi value the NHE1 protein remains inactive. Allosteric 
H+ binding sites present on NHE1 make this protein very sensitive to changes in the 
pHi [247]. When the pH drops below a certain level in the cell, H+ ions bind to these 
allosteric binding sites, activating NHE1 and leading to the extrusion of a proton in 
exchange for the influx of a Na+ ion, thereby alkalinizing the pHi. The allosteric H+ 
binding sites allow NHE1 to vary its activity in response to small changes in the 
concentrations of intracellular H+ ions [247], enabling these proteins to maintain pHi 
within a limited range. Studies support the idea that NHE1 may actually function as a 
dimer [248], and that this dimeric interaction may control the pH-dependent 
regulation of NHE1 [249].  
 
Considerable work has been carried out assessing the post-translational regulation of 
NHE1. Secreted stimuli including hormones, cytokines, growth factors, and physical 
stimuli including shear stress, integrin-mediated adhesion and osmotic cell 
shrinkage, can all regulate the activity of NHE1 (reviewed in [241]). The binding of 
proteins and lipids, along with phosphorylation of the C-terminal tail of NHE1, are 
other forms of post-translational modification identified that affect NHE1 activity 
(reviewed in [241]). Translocation of the NHE1 protein to or from the plasma 
membrane is another way in which protein activity can be controlled [250].  
 
Aside from NHE1 activity, NHE1 expression levels are regulated by a multitude of 
different influences. Growth factors [251] and reactive oxygen species [252] have 
been shown to lead to increased NHE1 expression levels. NHE1 expression levels 
are higher in some cancers, with amplified levels of NHE1 observed in 
hepatocellular carcinoma tissue compared to normal liver tissue [253]. The 
relationship between hypoxia and NHE1 expression in cancer is not as evident as 
that seen with hypoxia and CAIX. However, certain studies indicate that hypoxia 
may influence NHE1 expression in some cell types, with reports of NHE1 regulation 




The vacuolar (H+)-ATPases (V-ATPases) are ATP-dependent proton pumps made up 
of 2 domains connected by multiple stalks. The peripheral domain (V1) consists of 8 
subunits (A-H) and functions to hydrolyse ATP. The second domain (V0) is made up 
of 6 proteolipid subunits arranged in a ring, and functions in the translocation of H+ 
ions across the membrane (figure 8B) (reviewed in [238, 239]). V-ATPase proteins 
act by a rotary mechanism, wherein the hydrolysis of ATP at the V1 domain drives 
rotation of the central stalk and the attached proteolipid subunits of the V0 domain. 
The subunits of the V0 domain contain acidic residues that are capable of undergoing 
reversible protonation. These subunits pick up H+ ions as they are rotated and 
transport the H+ ions across the membrane (reviewed in [238, 239]).  
 
V-ATPases have a role to play in the acidification of intracellular compartments, 
contributing to processes such as receptor-mediated endocytosis and the digestion of 
internalized macromolecules in lysosomes (reviewed in [238, 239]). Besides their 
presence on the membranes of intracellular organelles, V-ATPase complexes have 
also been shown to be present on the plasma membranes of specialized cells, where 
they act to pump H+ ions out of the cell. This function of V-ATPases has connected 
them to normal physiological processes such as such as bone resorption, sperm 
maturation and renal acidification (reviewed in [238, 239]).  
 
Since V-ATPase proteins function in numerous cellular compartments, mechanisms 
are required to target the complexes to differing cellular sites. There are varying V-
ATPase subunit isoforms produced for each subunit (reviewed in [238]). Studies 
have shown that V-ATPase complexes may selectively form to contain specific 
combinations of subunit isoforms in different tissues [257], and some believe that 
these unique combinations of subunit isoforms may drive the localization of the V-
ATPase complex [239]. In addition to the possibility that the whole V-ATPase 
complex subunit signature may play a part in localization, other studies have shown 
that the information needed for V-ATPase targeting may be present within subunit a 
of the V0 domain. Altogether there are 4 isoforms of the a subunit (a1-a4) (reviewed 
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in [238]), with V-ATPase complexes with the a3 isoform shown to targeted to the 
plasma membranes of mouse osteoclast cells [258].  
 
In addition to the presence of V-ATPase on the surfaces of specialized cells in the 
body, studies have also reported the existence of the V-ATPase complex on the 
plasma membranes of cancer cells [259, 260], where they are thought to play a role 
in pH control. In fact, some hypothesize that cancer cells primarily control pH 
through the V-ATPase complex, rather than through other pH regulating proteins 
such as NHE1 or bicarbonate transporters [261].  
 
Regulation of V-ATPase activity in cells is mainly accomplished through 3 
mechanisms: (i) reversible dissociation of the V1/V0 complex, (ii) changes in 
complex density at the plasma membrane through the reversible fusion of V-ATPase 
carrying vesicles, and (iii) alterations in the efficiency of coupling of H+ movement 
with ATP hydrolysis (reviewed in [238, 239, 262]). While regulation of gene 
expression is a common method for cells to control the activity of many proteins, the 
combined gene regulation of a multi-subunit complex such as V-ATPase, which is 
made up of at least 13 different polypeptides, is cumbersome [262]. Therefore most 
cells in the body are thought to regulate V-ATPase activity through the above 3 
mechanisms. However, examples of the overexpression of certain subunits of the V-
ATPase complex have been found in oral squamous carcinoma cells [263, 264]. V-
ATPase subunit expression levels are also increased after treatment with cisplatin 
[265, 266]. While these studies show some evidence of V-ATPase expression 
differences in cancer cells compared to normal cells, little has been published to date 
connecting hypoxia/HIF to V-ATPase expression.  
 
1.13 pH and cancer 
 
The activation and/or up-regulation of pH regulating proteins on the plasma 
membranes of cancer cells leads to the alkalinisation of the pHi and the acidification 
of the extracellular pH (pHe) of tumour cells, resulting in pHi and pHe values in 
these cells that differ greatly from those in normal cells. Studies conducted using 
microelectrodes to measure the pH values of cancerous tissue and normal tissue, 
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which were later confirmed with NMR and MRI techniques, have shown that the 
pHe of cancer cells is regularly lower than the pHe of normal tissue, whereas the pHi 
values of cancer cells is more alkaline compared to normal cells (reviewed in [267, 
268]). The abnormal regulation of H+ ions in cancer cells, leading to the formation of 
this reversed pH gradient in cancer cells and tissues when compared to normal cells 
and tissues within the body, is a phenomenon that is increasingly being considered as 
one of the most differential characteristics of cancer [269]. This reversed pH gradient 
has a large effect on both cancer cell biology and the treatment of cancer.  
 
1.13.1 pH and invasion/migration 
	
The invasion and metastasis of tumour cells to other parts of the body is the main 
cause of cancer mortality, with 90% of deaths from solid tumours resulting from 
metastasis [270]. Many of the different processes underlying cell invasion/migration 
are dependent on pH. The assembly of actin filaments drives the formation of 
lamellipodium and invadopodia, membrane structures that protrude into the 
extracellular matrix (ECM) and enable cell migration. At pHi values of greater than 
7.2, the assembly of actin filaments increases as a result of the increased activity of 
actin-binding proteins, thereby increasing cell motility (reviewed in [215, 271]). In 
addition to the assembly of actin filaments, cell migration requires the remodelling of 
focal adhesion contacts (cell-substrate interactions that enable the migrating cell to 
transmit force) to either surrounding cells or the ECM, a process aided by reversed 
pH gradient of cancer cells [272, 273].  
 
The migration and invasion of cells into tissue is also dependent on the degradation 
of the ECM. This degradation is mediated by the secretion of proteinases and the 
activity of matrix metalloproteinases (MMPs) (reviewed in [274]). Acidic pHe 
values lead to the increased secretion of proteinases and MMPs, thereby further 
aiding invasion and migration [275]. The acid-mediated invasion hypothesis is one of 
the mechanisms through which cancer cells are thought to invade (reviewed in 
[225]). In this model, acidosis of the tumour microenvironment causes the 
breakdown of normal tissue surrounding the tumour. The tumour itself, however, is 
able to cope with the low pHe values as a result of the expression and/or activation of 
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pH regulating proteins, with the cells of the tumour undergoing greater levels of 
migration on exposure to the acidic microenvironment.  
 
1.13.2 pH and proliferation/apoptosis 
 
Proliferating cells go through the cell cycle, which is made up of the Gap 1 phase 
(G1 phase; cells increase in size and prepare to duplicate DNA), the Synthesis phase 
(S phase; DNA replication occurs), the Gap 2 phase (G2; any repair needed is carried 
out and the cell prepares for mitosis), and mitosis (M phase; the cell divides into 2 
daughter cells) (reviewed in ref [276]). Entry into each of the phases is regulated by 
cell-cycle checkpoints, controlled by the cyclin-dependent kinase (Cdk) proteins 
bound to proteins called cyclins (reviewed in [277]). More alkaline pHi values have 
been demonstrated to contribute to an increase in the rate of cell proliferation 
through increasing the proportion of cells entering the S phase [278] and G2/M 
phases of the cell cycle [279], with more acidic pHi values delaying entry into the 
G2/M phase [279]. While intracellular alkalinisation seems to be a common feature 
in proliferative processes, the role of pH in cell death is not as clear. Cytosolic 
acidification seems to be a common feature of apoptosis, indicating that acidic pHi 
may have a permissive role in the apoptotic cascade [280]. For example, the 
cytochrome C-mediated activation of caspases (proteins that have an essential role to 
play in apoptosis) is much more efficient in acidic pH compared to neutral cytosolic 
pH conditions [281].  
 
1.13.3 pH and irradiation 
 
pH can affect the responsiveness of cells to irradiation. Investigations carried out in 
the 1980s showed that cells cultured in acidic media were more resistant to the 
effects of irradiation [282-284], with other work showing that acidic pHe values 
reduce the fixation of radiation damage [285]. Studies have shown that acidic pHe 
values can lead to the inhibition of radiation-induced apoptosis in cells, with an 
increase in radiation-induced apoptosis observed in cells exposed to a more alkaline 
pH [286, 287]. Altered cell cycle progression in acidic environments is also thought 
to contribute to resistance to irradiation. The G2 checkpoint before entry into the M 
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phase, or the G2/M phase arrest, enables cells to repair any DNA damage before 
mitosis (reviewed in [288]). One study showed that radiation-induced G2/M-phase 
arrest was delayed in colorectal cancer cells cultured in medium with a pH of 6.6, 
compared to cells cultured in pH 7.5 medium [289]. This elongation of the G2 phase 
after irradiation in cells present in acidic conditions allows a greater amount of time 
for the DNA damage repair, thereby decreasing the proportion of cells that undergo 
mitotic death, and thus increasing radiation-resistance [289].  
 
1.13.4 pH and drug treatment 
 
In addition to affecting radiotherapy responses, the reversed pH gradient of cancer 
cells also has an influence on the effectiveness of chemotherapeutics (reviewed in 
[215, 290]). Drugs display acidic, basic and neutral properties. For pharmacological 
agents that are either weak acids or weak bases, the amount of ionization is 
dependent on pH (reviewed in [290]). Some of the drugs used in chemotherapy are 
weak bases (examples include Doxorubicin [Adriamycin] and Daunorubicin 
[Cerubidin]) [291], which are protonated in the acidic extracellular environments of 
cancer cells, changing them from a neutral to a charged species. The differing ratios 
of charged and neutral species can influence drug distribution both intracellularly 
and extracellularly, and also within different subcellular compartments with varying 
pH values, with charged agents having lower rates of diffusion through cell 
membranes (reviewed in [215, 290]). Because chemotherapeutics such as 
doxorubicin have intracellular targets [292], this inhibits some drugs from reaching 
their targets, thereby leading to increased resistance to chemotherapy treatment.  
 
Conversely, the more alkaline pHi of cancer cells leads to a large proportion of weak 
base chemotherapeutics being present in a neutral form intracellularly, which can 
lead to increased diffusion of drug out of the cell. The increased concentration of 
basic drugs in the acidic organelles of cancer cells, which also inhibits drugs from 
reaching their target, is another mechanism of chemotherapy resistance [293]. The 
opposite situation is the case in normal cells, where pH gradients lead to higher 
concentrations of the anti-cancer agents being found intracellularly, increasing the 
likelihood of toxic effects (reviewed in [215]). Several studies conducted in vitro 
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[293-295] and in vivo [295, 296] have shown that these pH effects do occur and that 
drug efficacy is affected as a result. In addition to affecting drug distribution through 
changing the passive diffusion of drugs, the reversed pH of cancer cells may also 
influence drug effectivity through modifying the active efflux of drugs. It is thought 
that the acidic pHe of cancers may lead to the activation of multidrug transporters 
such as P-glycoprotein [297, 298], and the breast cancer resistant protein ABCG2 
[299], which may contribute to multidrug resistance in some cancers.  
 
1.14 Targeting the pH regulation of cancer cells 
 
Given the influence of the reversed pH gradient on cancer cell biology (see sections 
1.13.1 and 1.13.2) and resistance to therapy (see sections 1.13.3 and 1.13.4), 
interference with the pH regulation mechanisms of cancer cells is one possible 
approach to improve patient outcomes. Targeting the proteins responsible for the 
control of pH in cancer cells is a mechanism that is not exploited by any of the 
traditional anti-cancer drugs.  
 
1.14.1 CAIX inhibition 
 
The role of CAIX in cancer progression is well recognised (reviewed in [237, 300, 
301]), and it is an established marker of poor prognosis across a wide variety of 
cancers [302-305], including breast cancer [306, 307]. However, CAIX has great 
potential as a target for cancer therapies as a result of its limited expression in normal 
tissues within the body (see section 1.10.1), suggesting that limited drug toxicity 
should be expected when targeting this molecule. Evidence of this comes from 
mouse studies where knockout of CAIX led to little abnormality, other than gastric 
hyperplasia [308]. The majority of cancer deaths result from metastasis (see section 
1.13.1). The recognition of CAIX as a target for metastatic disease [309, 310], in 
addition to the extracellular catalytic domain of CAIX facilitating access to drug 
treatment [311], has led to considerable interest in CAIX as a target for cancer 
therapy.  
 
There has been much work conducted on the development of inhibitors targeting 
tumour-associated carbonic anhydrases (reviewed in [222, 311-313]), with 2 main 
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approaches used to target CAIX in particular. One such approach is the use of CAIX-
specific monoclonal antibodies, which can exhibit anti-cancer effects through the 
induction of antibody-mediated cellular cytotoxicity [314]. Some of these agents 
have already been tested in humans. Phase I and phase II clinical trials with the 
CAIX-specific antibody Girentuximab (cG250) demonstrated that this antibody led 
to disease stabilisation either alone or in combination with IL-2 treatment, and was 
well tolerated in patients with advanced renal cell carcinoma [315, 316]. However, a 
phase III trial conducted in patients suffering from non-metastatic renal cell 
carcinoma did not show any improvement in disease-free survival with this antibody 
(NCT00087022). 
 
Monoclonal antibodies can also be used to target the delivery of therapeutic 
compounds. cG250 labelled with Lutetium 177, a β-emitting radionucleotide, is an 
example of one such compound that has been tested in humans. Phase I clinical trials 
carried out using cG250 labelled with Lutetium 177 showed this compound to be 
safe and well-tolerated [317]. A phase II study demonstrated that 177Lu-cG250 led to 
disease stabilisation in patients with advanced renal cell carcinoma [318]. However, 
other studies using monoclonal antibodies targeting CAIX have not produced such 
positive results, with a phase I clinical trial involving the use of a novel CAIX 
monoclonal antibody conjugated to the microtubule inhibitor MMAE (monomethyl 
auristatin E) terminated due to patient safety [311].  
 
The development of small molecule inhibitors of carbonic anhydrases represents 
another approach to target CAIX in cancer therapy [311]. The sulphamates are one 
class of small molecule inhibitors that have been established (figure 9A and B) [222, 
312]. These carbonic anhydrase inhibitors (CAIs) act by binding to the catalytic Zn2+ 
ion present in the active site of the protein [222, 312], blocking its function and 
inhibiting the carbonic anhydrase enzymes from catalysing the extracellular 
hydration reaction of CO2. Many of these pharmacological agents were specifically 
designed to inhibit the tumour-associated isoforms of the carbonic anhydrase 
proteins, with some dually inhibiting both CAIX and CAXII (reviewed in [319]). 
Nitroimidazole-based CAIX inhibitors, such as DTP348, have also been developed 
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for use in combination with radiotherapy [320] (figure 9C). The sulphamide 
component of these molecules inhibits CAIX, while the 5-nitroimidazole moiety acts 
as a radio-sensitizer through mimicking O2. The purpose of these compounds is to 
selectively target hypoxic cancer cells, thus improving the effects of radiotherapy. A 
selection of these small molecule inhibitors have also been tested in clinical trials. 
SLC-0111 is one such compound for which phase I clinical trials are currently 
underway (NCT02215850), with DTP-348 due to enter Phase I trials 
(NCT02216669) after beneficial effects seen in combination with irradiation [320] 
and doxorubicin [321] in vivo. 
 
Figure 9: Drug structures.  
Structures of the sulphamate CAIX inhibitors S4 (A) and FC9403A (B), the nitroimidazole 
based sulphamide CAIX inhibitor DTP348 (C), the NHE1 inhibitor DMA (D), and the V-
ATPase inhibitor bafilomycin A1 (E), are shown.  
 
1.14.2 NHE1 inhibition 
 
Despite the ubiquitous expression of NHE1 in cells all around the body, this protein 
has been firmly connected to the malignant transformation of cells and cancer 
progression [225, 322, 323], with many studies observing increased 
activity/expression of this protein in cancer cells compared to normal cells in the 





























































As a result of the importance of NHE1 in many different physiological processes, 
numerous inhibitors of NHE1 have been developed (reviewed in [241, 322, 324]). 
Many of these compounds are modifications of amiloride, the original drug shown to 
inhibit NHE1 activity. However, while NHE1 was the isoform most sensitive to 
amiloride, this drug also affected NHE2 [325] and NHE5 [326] isoforms as well. 
Using the basic structure of amiloride, inhibitors with increased specificity for 
NHE1, such as Dimethylamiloride (DMA) (figure 9D), were designed. Studies 
conducted into the mechanism of inhibition have shown that amiloride-type 
compounds are partly competitive with the binding of Na+, suggesting that drug 
binding involves the Na+ binding site, or an area nearby [241].  
 
In vivo studies exhibit the potential of NHE1 inhibitors in the treatment of cancer, 
with compounds of the amiloride series shown to inhibit the development of 
mutagen-induced lesions in animals, reducing the size of xenografts and suppressing 
metastases (reviewed in [327]). While there are clinical trials assessing the effects of 
the NHE1 inhibitor cariporide in a cardiological setting (reviewed in [328]), the anti-
cancer effects of NHE1 inhibition have not been assessed in humans. Because of the 
widespread expression of NHE1 in multiple cell types throughout the body, the 
selective targeting of the NHE1 protein present on cancer cells represents more of a 
challenge than that of CAIX. However, it has been hypothesised that the increased 
basal activity of NHE1 proteins in tumours compared to the NHE1 present in normal 
tissues should facilitate the use of future NHE1 inhibitors in human trials to assess 
their anti-tumour effects [323]. One possible approach that may decrease the toxicity 
of NHE1 inhibitors is the conjugation of either peptides or amino acids to NHE1 
inhibitors, producing a prodrug that could be activated by proteases present in the 
tumour microenvironment [329, 330].  
 
1.14.3 V-ATPase inhibition 
 
As with NHE1, V-ATPase has also been associated with cancer despite its 
widespread expression in normal tissues of the body [225, 331-333], with studies 
connecting V-ATPase to multidrug resistant mechanisms [266, 334] and cancer cell 
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invasion [260, 335, 336]. The first inhibitor specific for V-ATPase identified was 
bafilomycin A1 (figure 9E). This compound was originally isolated from species of 
the Streptomyces bacteria in the 1980s [337], and was synthesised for the first time 
in 1997 [338]. This compound inhibits V-ATPase by binding to both subunits a and c 
of the V0 domain of the V-ATPase complex [339-342], impeding the helical 
swivelling of the protein, and thereby blocking proton transport (reviewed in [239]). 
In addition to preventing proton transport through V-ATPase, bafilomycin A1 has 
also been shown to have ionophoric properties, leading to the transport of potassium 
across the inner mitochondrial membrane, causing mitochondrial damage [343].  
 
Similar to NHE1, the targeting of V-ATPase within humans represents more of a 
challenge than the pharmacological inhibition of the tumour-associated carbonic 
anhydrases due to the multitude of roles V-ATPase has within normal cells (see 
section 1.12).  Proton pump inhibitors (PPIs) such as esomeprazole and omeprazole, 
in addition to the targeting of H+/K+ ATPases, can inhibit V-ATPase activity, thereby 
giving them potential use in the treatment of cancer [344, 345]. These compounds 
are prodrugs that are activated in acidic conditions, and may provide less toxicity by 
targeting the acidic microenvironment of tumours [222]. Proton pump inhibitors such 
as these have been used in humans for acid related diseases with negligible side 
effects (reviewed in [346]).  
 
Various clinical trials have been carried out assessing the effects of PPIs on the 
treatment of cancer.  Proton pump inhibitors have been reported to reduce the risk of 
neoplastic progression in patients with Barrett’s oesophagus [347]. A number of 
studies have assessed the combination of PPIs with other treatment modalities. A 
Phase II trial showed that esomeprazole increased the sensitivity of osteosarcoma to 
neo-adjuvant chemotherapy, as identified through the visualisation of increased 
tumour necrosis, without any significant increase in toxicity [348]. A veterinary 
Phase I/II trial in canines and felines with tumours exhibiting resistance to 
chemotherapy showed the benefits of combining high doses of PPIs with 
chemotherapy for tumour treatment [349]. A pilot clinical trial investigating the 
effects of combining either docetaxel or cisplatin with esomeprazole in metastatic 
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breast cancer has reported the improved effects of chemotherapy with no escalation 
of toxicity [350].  
 
1.15 Cancer cell models 
 
Many different models are used in cancer research to analyse the expression of 
cancer-related proteins or the therapeutic effects of newly developed drugs. Cancer 
cell lines are intrinsic to many of the 2D and 3D cancer models used (reviewed in 
[351-353]). In terms of breast cancer, a cell line panel can represent the major breast 
cancer subtypes, while 3D modelling can examine compounds in a system that 
includes both O2 and pH gradients. The testing of pharmacological compounds on 
fresh untreated patient tissue derived from biopsies allows for the effect of the 
heterogeneity of tumour tissue and the presence of stromal cells in the experimental 
set up [354, 355]. In vivo studies can also be pursued by using cancer cell lines 
transplanted into mice (reviewed in [352, 356]). However, because all models of 
human breast cancer developed to date are imperfect, with both advantages and 
disadvantages to each model system, the soundest experimental approach is to use 
multiple systems for the initial phase of drug testing [356].  
 
1.15.1 2D cell culture 
 
The use of cell lines cultured in 2D is the most practical approach for assessing target 
protein expression or measuring the therapeutic effects of anti-cancer compounds. 
However, 2D cell culture represents a very simple model system that does not reflect 
the in vivo tumour environment, as cancer cells cultured in 2D exhibit extensive 
variation in morphology, proliferation, signalling and gene expression when 
compared to cells cultured in 3D (reviewed in [357]). Also, many experiments 
investigating breast cancer culture cells at 20% O2, while studies have shown that the 
O2 tensions of cells in both normal breast tissue and cancerous tissue are actually 
much lower (see section 1.7.2). Discrepancies in O2 conditions between 2D cell 
culture and O2 tensions in vivo can be partially resolved through using cell culture 
incubators that have the capacity to produce O2 concentrations that are more 
representative of physiological levels. However, while these systems enable the 
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analysis of gene/protein expression or drug response at a particular O2 tension, they 
do not enable simultaneous analysis across the range of O2 tensions that occur in 
tumours in vivo. In 2010 it was estimated that more than 70% of cancer researchers 
relied on 2D cell culture experiments to produce results [358]. Some believe that an 
over-reliance on 2D cell culture alone for the testing of new anti-cancer compounds 
may affect the choice of lead compounds for later in vivo studies, which could 
contribute to failure at the later stages of drug development [357, 359]. These 
failures are damaging to pharmaceutical companies, and ultimately affect patient 
treatment. The use of cancer cell models that simulate the in vivo tumour 
microenvironment in pre-clinical tests has the potential to help researchers identify 
compounds that are more likely to pass clinical trials [357, 359].  
 
1.15.2 3D models 
 
The value of 3D cultures in experimental research is obvious as experiments with 
these models show better correlation with results from in vivo studies (reviewed in 
[357]). To reproduce the in vivo situation more accurately, numerous 3D culture 
systems have been developed [360]. The multicellular tumour spheroid model is one 
that is extensively used. There are many different ways to produce spheroids for use 
in 3D assays [360-363], one of which is the spinner flask method. This involves 
placing a suspension of cells in media into a flask that is constantly stirred. As a 
result of the constant motion, the cells do not adhere to the surfaces of the flask, but 
instead aggregate together to form spheroids. The spinner flask method of spheroid 
formation leads to the production of a large number of spheroids in a short time 
frame [360-363]. These spheroids exhibit 3D cell-cell interactions and, if of a large 
enough size, develop gradients of O2, nutrients and catabolites (reviewed in [364]). 
Cells located in the outer rim of the spheroid have an ample supply of O2 and 
nutrients, mimicking the proliferative cancer cells present next to capillaries in the 
body. The levels of both O2 and nutrients are limited in cells further away from the 
outer rim of the spheroid. These cells mirror hypoxic cancer cells in vivo that are 
distant from the vasculature, with apoptotic/necrotic areas evident in the centre of the 




Figure 10: Multicellular tumour spheroid characteristics.  
Spheroids re-create many different aspects of the in vivo tumour microenvironment, 
including hypoxia and acidosis, which leads to the creation of necrotic, peri-necrotic and 
hypoxic areas within the spheroid. The proliferative and metabolic gradients found within 
cancers are also present in spheroids. The spheroid model enables the analysis of the effects 
of a drug in the context of diffusion gradients and adhesion and tight junction barriers. 
Heterogeneous cancer cell populations are present within the spheroids, with some cells in 
the normoxic layer undergoing proliferation, while at the core of the spheroid there are non-
cycling/dead cells, with hypoxic cells present in between these two layers. This image is 
taken from [364], and is a combination of spheroid sections analysed by the tunnel assay, 
autoradiography, probing with oxygen microelectordes, and bioluminescence imaging.  
 
1.15.3 3D invasion models 
 
The invasion and migration of cancer cells from the primary tumour to other parts of 
the body (metastasis) is the main cause of patient mortality [270]. As a result, studies 
assessing the anti-metastatic ability of potential cancer drugs are of the upmost 
importance. There are many different methods for analysing the effects of 
pharmacological inhibitors on cancer cell invasion and migration [365]. The use of 
spheroids embedded into a 3D extracellular matrix (ECM, a collection of 
extracellular molecules secreted by cells that provides structural and biochemical 
support) is one such method used. This experimental set-up closely mimics that 
which occurs in vivo, with invasion occurring from clusters of cells with established 
cell-cell interactions into the ECM [365]. A range of different ECM gels can be used 
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in these experiments. For studies conducted in breast cancer, the use of collagen type 
I further re-creates the in vivo conditions as there is a high proportion of this protein 
present within breast cancer stroma in the body [366].  
 
1.15.4 Patient-derived material 
 
The reconstruction of the 3D tumour environment of cancers through the use of 
models such as spheroids goes some way to reproducing the pathobiology of cancer. 
However, as with any cancer cell model, there are problems with the spheroid model 
described. One disadvantage encountered with spheroid invasion assays concerns the 
cancer cell lines used in these experiments. Many researchers use cell lines that 
represent certain sub-types of cancer. However, studies have shown that cancer cell 
lines cultured for extended periods in vitro can lose some of the biological traits of 
the cancer from which they derived, meaning that they may no longer represent the 
primary cancer from which they originated [367, 368]. 3D invasion assays conducted 
with primary tissue derived from human patients, cultured in a similar manner to that 
of spheroids in 3D [354, 355], do not encounter this problem. The analysis of the 
effects of pharmacological inhibitors on human tumour explants, which contain cells 
usually found within the cancer stroma in addition to the tumour cells [369], 
represent an improvement over the spheroid invasion assays, allowing the analysis of 
anti-cancer agents on heterogeneous cancer material and varying tumour sub-types. 
However, the cell culture environment is unable to totally re-create the complex 
multicellular and cell-extracellular matrix interactions that occur in vivo that 
contribute to the major aspects of breast cancer biology [352].  
 
1.15.5 In vivo systems 
 
The growth of human breast cancer cell lines in immunocompromised mice as 
xenografts allows the investigation of the effects of anti-cancer agents in an in vivo 
environment. Xenografts represent a model that is frequently used in breast cancer 
research (reviewed in [352, 356]). There are many advantages in the use of mice in 
cancer research, as they enable the testing of anti-cancer compounds in a model that 
re-creates some features of the human tumour micro-environment, including stromal 
and vasculature elements, along with relative ease of measurements of the effects of 
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drug treatment in this environment (reviewed in [356]). However, these strengths are 
counterbalanced by various limitations. The deficiencies associated with human 
cancer cell lines represents one such drawback (already discussed in section 1.15.4). 
The immune system is thought to play a key role in cancer progression [370, 371], 
and the use of immunodeficient mice therefore makes it impossible to precisely 
model tumourigenesis. Therefore, as with all of the models discussed so far, 




The abnormal regulation of H+ ions in both normoxic and hypoxic cancer cells, 
leading to a reversed pH gradient in these cells when compared to normal cells, is a 
phenomenon that is considered to be one of the most distinctive characteristics of 
cancer [269]. This feature of tumour cells, however, has only undergone limited 
exploitation in the treatment of cancer to date. The targeting of pH regulating 
proteins, implicated in the initiation and/or regulation of the reversed pH gradient in 
cancer cells, could result in more effective therapies that target tumour cells more 
selectively, causing less toxicity, leading to an overall improvement in cancer 
treatment.  
 
Low O2 conditions have been shown to lead to the increased expression of both the 
tumour-associated carbonic anhydrases (section 1.10) and NHE1 (section 1.11). 
While little has been published relating hypoxia/HIF to V-ATPase expression 
(section 1.12), some hypothesise that, due to its importance in pH regulation, 
hypoxia may have some part to play in the regulation of V-ATPase [261]. Studies 
also indicate that the activity of both CAIX and NHE1 is similarly affected by 
changes in O2 concentration, with increased levels of activity recorded in hypoxic 
conditions [254, 256, 372-374]. With these studies in mind, we hypothesised that 
inhibitors targeting the tumour-associated carbonic anhydrases, NHE1 and V-
ATPase would be more effective under hypoxic conditions. Based on this hypothesis 
and rationale, the aim of this project was to assess the therapeutic effects of 
inhibitors targeting these pH regulating proteins on cancer cell proliferation and 
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invasion, comparing their effects on cancer cells present in both aerobic and hypoxic 
conditions.  
 
While prior studies have exhibited the inhibitory effects of targeting these pH 
regulating proteins separately, a comparison of the effects of targeting these proteins 
within one study in differing O2 conditions has not previously been performed. Initial 
experiments were conducted in 2D, before moving into 3D, using models that more 
realistically re-create the in vivo tumour microenvironment (figure 11).  
 
For the initial stage of the project, we sought to investigate the expression levels of 
the tumour-associated carbonic anhydrases, NHE1 and V-ATPase in different breast 
cancer cell lines, in order to assess the expression of these target proteins in various 
O2 conditions in the 2D and 3D cancer cell models employed in this project. 
Experiments comparing the effects of inhibitors targeting each of the pH regulating 
proteins on both cancer cell number in 2D, and cancer cell invasion in 3D using 
multicellular tumour spheroids, were also carried out in both aerobic and hypoxic 
conditions to evaluate the effects of oxygenation on the response of the cells to 
treatment, while also enabling a direct comparison of the anti-cancer effects of these 
inhibitors to each other. pH has been shown to have a role in cancer cell radio-
resistance (section 1.13.3); experiments comparing the effects of combining drugs 
targeting the 3 pH regulating proteins with irradiation were also carried out. Further 
work was then performed with the agents identified as having the most promise. 
Additional invasion assays were conducted with explant tissue derived from human 
patients, a model that more realistically re-creates the in vivo tumour 
microenvironment (section 1.15.4). Lastly, the effects of inhibitors targeting the pH 
regulating mechanisms of cancer cells were assessed using in vivo mouse breast 








Figure 11. Project outline.  
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2  Chapter 2: Materials and Methods 
 
2.1  Cell Culture 
 
The breast cancer cell lines MCF-7, MDA-MB-231 and HBL-100 were chosen for 
this study due to their ability to form compact spheroids for 3D cell culture studies, 
in addition to their differing molecular classification and traits (see table 2). These 
breast cancer cells were acquired from either American Type Culture Collection 
(ATCC) or Public Health England (PHE, Salisbury, UK). The stocks of cells were 
authenticated by short tandem repeat (STR) profiling, undertaken by PHE in 
December 2014. Mycoplasma testing was performed within the lab by Helen 
Caldwell, with samples also sent to the IGMM for analysis at routine intervals.  
 
All cells were incubated at 37°C in a humidified atmosphere containing 5% CO2. 
Cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM, Gibco) 
supplemented with 10% heat-inactivated fetal calf serum (PAA) and 50 U ml-1 
penicillin and 50 mg ml-1 streptomycin. Cells were grown to confluence with 
intermittent medium changes and harvested by incubation with trypsin/EDTA 
(ethylene-diamine-tetra-acetic acid) solution. New stocks of cells were obtained after 
30 passages from STR authenticated stocks.  
 
Cell line Origin Classification Description 
MCF-7 Pleural effusion of 
patient with 
adenocarcinoma 
Luminal A ER+/PR+/HER2- 
MDA-MB-231 Pleural effusion of 
patient with 
adenocarcinoma 
Basal B ER-/PR-/HER2- 
HBL-100 Milk from healthy 
nursing mother 
Basal B ER-/PR-/HER2- 
Harbours SV40 
genome 
Table 2. Breast cancer cell lines studied.  
The effect of targeting the tumour associated carbonic anhydrases IX and XII, NHE1 and V-
ATPase, in addition to the expression levels of target proteins and mRNA, was assessed in 3 




Aerobic cells were cultured in atmospheric oxygen conditions (20% O2) in an 
incubator. Cells were cultured in lower oxygen concentrations using a hypoxic 
chamber (Whitley H35 hypoxystation); these cells were maintained at 0.5%, 2% or 
7% O2 and 5% CO2, balanced with N2, for up to 72h.  Cells were also cultured in the 
hypoxic chamber for over 10 weeks at 0.5% O2. The pre-gassing of media, PBS and 
tissue culture plastics was performed for the experiments conducted on the hypoxic 
cells, with these materials placed into the hypoxystation 24h before use to allow the 
O2 levels to equilibrate. 
 
2.2 Pharmacological inhibitors 
 
The NHE1 inhibitor DMA (5-(N,N-Dimethyl)amiloride hydrochloride) was 
purchased from Sigma. The CAIX inhibitors were gifted from Claudiu Supuran of 
the University of Florence. The V-ATPase inhibitor bafilomycin A1 was purchased 
from Wako Pure Chemical Industries, Ltd. DMA was re-suspended in sterile water, 
while both the CAIX and V-ATPase inhibitors were dissolved in DMSO. 
 
2.3 Sulforhodamine B (SRB) assays 
 
The Sulforhodamine B (SRB) assay was established in 1990 as a new approach for 
anticancer drug screening [377]. This method relies on the capacity of the SRB 
protein dye to bind to the basic amino acids of fixed proteins electrostatically in a 
pH-dependent manner [377-379]. Because this is a rapid and inexpensive method to 
use, SRB assays are frequently used to assess the effects of drugs on cancer cell 
number, and have previously been used to test compounds that are chemically 
similar to one another in pre-clinical drug development studies [380]. This method 
was used to assess and compare the effects of drugs targeting CAIX, NHE1 and V-
ATPase on cancer cell number in differing O2 conditions. 
 
Cells were fixed post-treatment with 50 µl/well of 25% TCA (trichloroacetic acid, 
Sigma) for 1h at 4°C, and washed with H20 (10x washes). The fixed cells were 
stained with 50 µl/well of SRB dye solution (Sigma) for 30 minutes, and the SRB 
washed off with 1% glacial acetic acid (VWR) (4x washes). The protein-bound SRB 
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was solubilised using 150 µl of Tris buffer solution (Sigma). Optical density (OD) 
was measured at 540 nM on a plate reader (BP 800 Biohit), and IC50 values were 
calculated on Excel using the Excel package Fit Designer. 
 
Due to the differential effects of O2 concentration on the growth rate of cells, 
differing numbers of cells were seeded depending on the culturing conditions. 500 
cells were seeded per well for the MCF-7 and HBL-100 cell lines, while 700 cells 
were seeded per well for the MDA-MB-231 cells cultured in 20% O2. 2000 and 4000 
cells were seeded for the acute and chronic hypoxic cells respectively. If the optical 
density (OD) values measured are below 3.0, the relationship between OD and cell 
number is linear. However, if the OD values are greater than 3.0, then there is a risk 
that saturation may be occurring. Each of these seeding densities led to OD values 
below 3 by the end of the 120h drug treatment in the differing O2 conditions (Figure 
12).  
 
Figure 12. Optical density (OD) values from the 3 cell lines cultured in differing 
O2 conditions indicate the cell seeding numbers used led to a linear relationship 
between cell number and the OD values obtained. 
Readings from control cells 120h after initial drug treatment. In 20% O2 conditions, 500 
MCF-7/HBL-100 and 700 MDA-MB-231 cells were seeded per well. 2000 cells were 
seeded per well for the acute hypoxic cells cultured in 0.5% O2, while 4000 cells 
were seeded per well for the chronic hypoxic cells cultured in 0.5% O2 conditions.  
 
2.4 Knockdown of FIH-1 in MCF-7 cells using siRNA 
 
There are different methods available to researchers to silence genes in order to study 
gene or protein function. RNA interference is a natural mechanism present within the 
cell that suppresses gene expression, and can be exploited to specifically inhibit the 
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function of target genes [381]. To investigate the effects of FIH-1 on CAIX 
expression in MCF-7 cells, short interfering RNA (siRNA) was used to reduce factor 
inhibiting HIF-1 (FIH-1) protein expression levels. 
 
Solutions of 4 siRNAs targeting FIH-1 (Dharmacon, L-004073-03), individual 
siRNAs targeting FIH-1 (Dharmacon, L-004073-19, L-004073-20, L-004073-20, L-
004073-22) and scrambled siRNA (Dharmacon, [D-01810-01-20]) were prepared 
using the protocols outlined [382], and siRNA transfection was carried out using the 
recommended protocols [383]. Briefly, 150,000 MCF-7 cells were seeded into the 
wells of a 6-well plate for the low O2 experiments, and 50,000 MCF-7 cells seeded 
per well for the cobalt chloride (CoCl2) experiments. Transfection was performed 
24h after seeding using 50 nM concentrations of siRNA with Dharmafect 
transfection reagent 1 (Dharmacon, T-2001-03). The cells were incubated for 48h, 
before the transfection/siRNA + DMEM solution was removed from each well and 
replaced with DMEM containing FCS. These cells were cultured for a further 72h 
before lysate acquisition. In the aerobic MCF-7 CoCl2 experiments, 400 µM CoCl2 
was added at 24h intervals after the removal of the transfection/siRNA + DMEM 
solution, with lysates acquired every 24h up to 72h after the initial CoCl2 treatment. 
 
2.5 Protein detection in cell lines 
 
Western blotting is a technique widely used by researchers to detect and quantify the 
levels of specific proteins from a complex mixture of proteins isolated from cells 
[384]. This method was used to detect and quantify the levels of proteins acquired 
from both whole-cell and nuclear/cytoplasmic lysates obtained from the 3 breast 
cancer cell lines. 
 
2.5.1 Whole cell lysate acquisition 
 
At the time of lysate acquisition, the cells were washed with ice-cold PBS and 
incubated for 10 mins on ice with 400 µl of lysis buffer [5 mM EGTA (Sigma) pH 
8.5, 50 mM Tris (Sigma) pH 7.5 and 150 mM NaCl (Sigma)] containing 100 µl 
phosphatase inhibitor cocktail 2 (Sigma), 100 µl phospahatase inhibitor cocktail 3 
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(Sigma), one complete protease inhibitor tablet (Roche), 50 µl aprotinin (Sigma) and 
1% Triton X-100 (Sigma). Samples were spun at 13,000 g at 4°C for 6 mins. The 
supernatant was isolated and stored at -80°C.  
	
2.5.2 Nuclear/cytoplasmic lysate acquisition 
 
At the time of lysate acquisition the cells were washed with ice-cold PBS, 1 ml of 
PBS was added, and the cells released from the plate using a cell scraper. The 
PBS/cell solution was spun at 4°C at 13,000 rpm for 1 min, the supernatant was 
discarded and the pellet was re-suspended in 0.4 ml of lysis buffer [10 mM HEPES 
pH 7.8 (Sigma), 10 mM KCl (Sigma), 2 mM MgCl2 (Sigma), 0.1 mM EDTA 
(Sigma)]. The lysates were left on ice for 15 mins, after which 15 µl of IGEPAL CA-
630 (Sigma) solution was added. The samples were mixed by vortexing and were 
then spun at 13,000 rpm for 1 min. The resulting supernatant was the cytoplasmic 
fraction. 50 µl of a solution made up of 50 mM HEPES pH 7.8, 50 mM KCl, 300 
mM NaCl (Sigma), 0.1 mM EDTA and 10% sterile glycerol (VWR) was then added, 
and the samples were  placed into a rotating table and slowly spun at 4°C. After 20 
mins, the samples were spun at 13,000 rpm for 5 mins at 4°C. The supernatant was 
the nucleic fraction. The samples were stored at -80°C.  
 
2.5.3 Bicinchoninic acid (BCA) protein assay 
 
BCA assays were carried out to determine the protein concentrations of the lysates 
obtained. An 8-point standard curve was created using a 1 mg/ml protein standard 
(Sigma, P0914). A 1:50 dilution of copper (II) sulphate (Sigma, C2284) in BCA 
solution (Sigma, B9643) was made up as the assay reagent. 5 µl of the lysate samples 
were diluted 1:10 in distilled water in separate 12 x 75mm borosilicate glass tubes 
(Fisherbrand, 14-961-26), and 1 ml of the assay reagent was added to each of these. 
All the samples were vortexed and incubated at 60°C for 15 mins. 200 µl of the 
standards and samples were pipetted into the wells of a 96-well plate in duplicate, 




2.5.4 SDS polyacrylamide gel electrophoresis 
 
Cell lysates (40 µg for whole cell samples, 10 µg for nuclear/cytoplasmic samples) 
prepared in 4x Laemmli sample buffer (Bio Rad) were denatured by placing into a 
heating block at 60°C for 60 mins. Samples were electrochemically separated by 
sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) with 
either the vertical electrophoresis systems Bio-Rad Mini-PROTEAN ® 3 or the Bio-
Rad Protean II xi cell, using a resolving gel made up of acrylamide, 1M Tris pH 8.85 
(Sigma), 10% SDS (Sigma), and dH2O. The stacking gel consisted of 3.6% 
acrylamide (Severn Biotech Ltd), 0.375M Tris pH 6.8, 10% SDS and dH2O. 
Polymerization was initiated by adding TEMED (Bio Rad) and 10% APS 
(ammonium persulphate) (GE Healthcare Life Sciences). Samples were loaded into 
the wells alongside a pre-stained protein marker broad range (Cell Signaling), and 
electrochemically resolved in running buffer (192 mM Glycine (Sigma), 25 mM 
Tris, 0.1% (w/v) SDS) at 100V for the stacking gel and 180V for the resolving gel.  
 
2.5.5 Western blotting 
 
The resolved proteins were electrophoretically transferred onto an Immobilon-P 
transfer membrane (Millipore) at 100V for 90 mins at 4°C (for the whole cell lysates 
protein transfer was performed at 30V overnight). The membranes were blocked for 
1 hour at 4°C with blocking buffer solution (PBS and Li-Cor Odyssey Blocking 
Buffer) and probed overnight with primary antibody (dilutions are listed in tables 3 
and 4). The membranes were washed twice with PBS-Tween20 (a 1:1000 solution of 
Tween20 (Sigma) and PBS), and incubated with fluorescently labelled secondary 
antibodies [IRDye 800CW (Li-Cor, 926-32210), IRDye 680LT (Li-Cor, 926-68021), 
1:10,000 dilution] for 45 mins. The membranes were washed and placed on filter 
paper to dry before scanning using a Li-Cor odyssey scanner. The expression levels 
of the proteins were analysed using Image Studio Lite (Li-Cor), with the signal of the 













Purified mouse anti 
NHE1 
1:1,000 Mouse BD/611774 
Purified mouse anti-
human HIF-1α 
1:250 Mouse BD/610958 




IX antibody, clone 
m75 
1:6,000 Mouse Bioscience Slovakia 
FIH-1/HIF-1AN 
antibody 





1:4,000 Rabbit Abcam/ab51074 
Cleaved PARP (Asp 
214)(19F4) 
1:8,000 Mouse Cell signaling/9546 




Primary antibody Working dilution Source Supplier/Cat No. 
Anti-β actin antibody 1:8,000 Rabbit Abcam/ab8227 








1:2,500 Mouse Abcam/ab51841 
Table 4. Primary antibodies used in western blots to detect proteins used as 
loading controls.  
 
2.6 RNA processing, microarray analysis and data analysis 
 
Both the RNA extraction and RNA amplification were carried out in collaboration 
with Arran Turnbull, Ed Jarman, Chrysi Xintaropoulou and Carlos Martinez.  
 
RNA extraction was carried out using the RNeasy Mini Kit from Qiagen as per the 
manufacturers instructions [385]. RNA was reverse transcribed, amplified and 
labelled using the Illumina ® TotalPrep™ RNA Amplification Kit (Ambion)[386]. 
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Samples were sent to Hologic Ltd (Manchester, UK), where the RNA was hybridized 
to whole genome HumanHT-12 v4 Illumina BeadChips, and the arrays were scanned 
with an Illumina iScan. Hologic Ltd provided the raw microarray scan result files. 
These raw gene expression files were filtered with Illumina probe detection P-value, 
and were log2-transformed and quantile-normalised with lumi Bioconductor.  
 
2.7 Multicellular Tumour Spheroids 
 
2.7.1 Multicellular tumour spheroid formation 
 
Different cancer cell models have been developed to replicate the in vivo tumour 
microenvironment, with multicellular tumour spheroids representing one such model 
that is extensively used [360]. To produce these spheroids, single cell suspensions 
obtained from cancer cell lines grown in flasks as 2D monolayer cultures were 
transferred into a sterile spinner flask (VWR) containing a magnetic stirrer rod. The 
spinner flask was placed onto a Cellspin stirrer (Integra Biosciences), which was 
present inside a humidified incubator set at 5% CO2 at 37°C.  
 
2.7.2 Hypoxyprobe labelling and fixing of spheroids 
 
Hypoxyprobe-1, a compound which has previously been used for the detection of 
hypoxic areas within different cancer models [387-390], was used to identify 
hypoxic regions within spheroids. The spheroids were transferred into 60 mm petri 




The fixed spheroids were embedded, cut and mounted on glass slides. Sections were 
de-waxed in xylene and rehydrated in alcohol and water before antigen retrieval 
using a NaCitrate solution [0.1M citric acid (Sigma), 0.1M NaCitrate (Sigma)]. 
Slides were washed with PBS/Tween20, incubated in 3% H2O2 solution (Dako) and 
washed again before the addition of Total Protein Block (Dako). The sections were 
incubated for 1h with primary antibody diluted in antibody diluent (Dako, see table 5 
for dilutions), followed with 30 mins in Envision Labelled Polymer (Dako) and 10 
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mins with DAB and substrate buffer (Dako, 1:50 dilution), with washes performed in 
between each step using PBS/Tween20. The sections were counterstained in 
hematoxylin for 1 min and brought through graded alcohols to xylene, and were then 
mounted in DPX mountant. Images of the sections were taken using Nanozoomer 
(Hamamatsu). 
 
Primary antibody Working dilution Supplier/Cat No. 
Hypoxyprobe antibody 1:500 – 1:8,000 Hypoxyprobe/HP1-100 
Carbonic anhydrase IX 
antibody clone m75 
1:1,000 Bioscience Slovakia 
Human carbonic anhydrase 
XII/CA12 antibody 
1:50 R and D systems/MAB2190 
Purified mouse anti-NHE1 1:400 BD Biosciences/611774 
FIH-1/HIF-AN antibody 1:1000 Novus Biologicals/NB100-
428 
Anti-MMP14 antibody 1:250 Abcam/ab51074 
Human carbonic anhydrase 
XII/CA12 antibody 




Anti-human Ki67 antigen, 
clone MIB-1 
1:300 Dako/M7240 
Cleaved caspase-3 1:300 Cell signaling/9661S 
Table 5. Antibodies used in immunohistochemistry.  
 
2.7.4 Analysis of spheroid immunohistochemical staining 
 
Developments in image acquisition technology and image analysis software have led 
to the increased use of computer-assisted image analysis of IHC staining [391]. The 
image analysis software Definiens has been shown to be a powerful tool for the 
analysis of protein expression levels in IHC-stained tissue [392]. Definiens Architect 
XD 64 Tissue Studio 4.1 was used to analyse target protein expression within the 
normoxic and hypoxic areas of spheroids.  
 
The image analysis was conducted using the different ‘cellular analysis actions’ 
available in this software. The cellular analysis action performed was dependent on 
the location of staining (either nuclear, plasma membrane or intracellular). For each 
of the analyses conducted, the hypoxyprobe stained spheroids acted as a guide to 
determine the normoxic and hypoxic regions within each spheroid. Overall, 4 
different methods of analysis were carried out.  
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The cellular analysis action ‘marker area detection’ was used to give the % area of 
caspase 3 staining. The first step in this analysis was to select the normoxic (blue 
region) and hypoxic (orange region) areas of the spheroids, using the hypoxyprobe-
stained spheroid images as a guide (figure 13A, number 1). The analysis was then 
performed using the settings indicated in figure 13. The marker threshold value 
(represents the threshold of the IHC stain, with any objects above this threshold 
labelled as positive brown staining) was set to 0.2. The threshold hematoxylin stain 
is used to detect nuclei, with any objects above the threshold hematoxylin value 
classified as nuclei. Since caspase 3 staining was the only staining of interest here, 
this was set to the maximum value, preventing the detection of any nuclei. The 
minimum area was set to 1, to try and ensure that all areas of positive caspase 3 
staining were detected. Yellow areas represent regions with caspase 3 positive 
staining detected (figure 13A).  
 
Using the settings indicated in figure 13B, the cellular analysis action ‘nucleus 
detection’ (distinguishes and classifies IHC-stained nuclei and nuclei stained with 
hematoxylin, giving the overall % of nuclei present with brown staining) was used to 





Figure 13. Caspase 3 and Ki67 Definiens analysis.  
The settings used to determine the % area of caspase 3 staining (A) and the % of Ki67-positive nuclei (B) are shown, in addition to screen shots taken 
during the analysis
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A number of different cellular analysis actions were combined to analyse the proteins 
that were present on the plasma membranes of cells. For CAIX, CAXII, NHE1 and 
MMP14 (all of which exhibited plasma membrane staining in spheroids of some of 
the cell lines), the same set of cellular analysis actions were used.  
 
Using CAIX staining within HBL-100 spheroids as an example (figure 14A), the 
following analysis was carried out. Firstly, regions encompassing the normoxic and 
hypoxic areas were selected using the hypoxyprobe stained spheroids as a guide 
(figure 14A, number 1), followed by the nucleus detection action to detect the nuclei 
(figure 14A, number 2). The ‘membranes and cells’ cellular analysis action was then 
used (figure 14A, number 3), which simulates a cell body using the presence of the 
nuclei and the presence of plasma membrane staining. The same settings were used 
for this analysis for all of the different plasma membrane proteins analysed (figure 
16A). The IHC threshold was set to 0 to include all areas for membrane detection, 
enabling regions without plasma membrane staining to be included in the analysis 
(figure 16A). Finally, the ‘cell classification’ cellular analysis action was carried out 
(figure 14A, number 4). This analysis sub-classified each cell based on plasma 
membrane marker intensity (white, no plasma membrane staining; yellow, low 
intensity plasma membrane staining; orange, medium intensity plasma membrane 
staining; red, high intensity of plasma membrane staining), giving the % of cells that 
had been identified within each subgroup.  
 
This same set of cellular analysis actions was carried out for CAXII (figure 14B), 
NHE1 (figure 15A) and MMP14 (figure 15B) plasma membrane staining analysis. 
While the membranes and cells settings remained the same for each analysis (figure 
16A), the settings used for the cell classification analysis varied with the target 
protein analysed (figure 16B). 
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Figure 14. Plasma membrane CAIX and CAXII staining analysis.  
Screenshots taken during plasma membrane CAIX (A) and CAXII (B) staining analysis, showing the region of interest selection (1), nucleus detection 
cellular analysis (2), membranes and cells cellular analysis (3), and cell classification cellular analysis (4). The screenshots showing the CAIX analysis 
have been rotated.  
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Figure 15. Plasma membrane NHE1 and MMP14 staining analysis.  
Screenshots taken during plasma membrane NHE1 (A) and MMP14 (B) staining analysis, showing the region of interest selection (1), nucleus detection 
cellular analysis (2), membranes and cells cellular analysis (3), and cell classification cellular analysis (4). The screenshots showing the MMP14 





Figure 16. Settings used for the analysis of plasma membrane protein staining. 
The membranes and cells cellular analysis settings (A) shown were used for each of the 
different plasma membrane proteins analysed. The cell classification settings employed 











Intracellular localisation of proteins was also evident with some of the staining 
performed. A number of different cellular analysis actions were combined to 
measure intracellular protein expression levels. Using MMP14 staining in MCF-7 
spheroids as an example (figure 18A), the following analysis was performed. 
Regions encompassing the normoxic and hypoxic regions of the spheroids were 
selected, and the nucleus detection cellular analysis action was carried out to detect 
the presence of nuclei (figure 18A, number 2). The ‘cell simulation’ cellular analysis 
action, which simulates a cell based on the presence of nuclei, was then performed 
(figure 18A, number 3). The simulation mode ‘grow from nuclei’ was chosen, in 
which cells grow from the nuclei to a maximum distance set by the user. The cell 
classification cellular analysis action was performed after this (figure 18A, number 
4), which sub-classified each cell based on the intracellular staining intensity (white, 
no intracellular staining; yellow, low intensity intracellular staining; orange, medium 
intensity intracellular staining; red, high intensity intracellular staining).  
 
This same set of analyses was carried out for CAXII staining analysis in MDA-MB-
231 and HBL-100 spheroids (figure 18B, showing the analysis within HBL-100 
spheroids), which exhibited intracellular staining of CAXII. The same cell 




Figure 17. Settings used for the analysis of intracellular protein staining. 
The cell simulation settings (A) and cell classification (B) settings were the same for the 
analysis of intracellular MMP14 and CAXII staining.  
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Figure 18. Intracellular MMP14 and CAXII staining analysis.  
Screenshots taken during intracellular MMP14 (A) and CAXII (B) staining analysis, showing the region of interest selection (1), nucleus detection 
cellular analysis (2), membranes and cells cellular analysis (3), and cell classification cellular analysis.
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2.8 3D invasion assays 
 
2.8.1 Multicellular tumour spheroid invasion assays 
 
The effect of inhibiting the pH regulating proteins of cancer cells on invasion was 
analysed through 3D invasion assays, using spheroids produced from each of the 
cancer cell lines. This assay is advantageous because the movement of cells through 
a 3D matrix closely mimics invasion in vivo, with invasion occurring from clusters of 
cells with established cell-cell interactions [365].  
 
A collagen gel was created on ice by mixing 1:1000 filtered acetic acid, cell matrix 
type 1-A (pH 3.0, 3 mg/ml, Alphalabs), 0.22 M NaOH (Sigma), FCS, and 10x 
DMEM (Sigma) at concentrations of 45%, 25%, 10%, 10%, and 10% respectively. 
The CAIX, NHE1 and V-ATPase inhibitors were added to the collagen mix at the 
desired concentrations. Spheroids were taken up into the collagen, and the spheroid + 
collagen mix was pipetted into the wells of a 24-well plate, with the plate placed into 
the incubator for 1h to allow collagen polymerisation. A p200 pipette tip was used to 
release the collagen gel, and DMEM +/- drug added to each well. Images of the 
spheroids were taken by phase contrast microscopy (Axiovert S100, x2.5 objective).  
 
MDA-MB-231 invasion was measured using a macro developed by Matthew 
Pearson, the Light Microscopy Application Specialist from the IGMM imaging 
facility (figure 19). This macro firstly processes the image to find the edges and 
highlights the cells using morphological filters, which improves the identification of 
cells by intensity thresholding. This thresholding can be altered if the auto step is not 
accurate. There are 3 readings given after the analysis; the total area, the spheroid 
area, and the invasive area alone. However, since the spheroid and invasion area 
alone measurements were not always accurate, the total area was the only 
measurement used for each spheroid (figure 19). While this macro worked well for 
the analysis of the MDA-MB-231 spheroids, it had trouble accurately measuring the 
HBL-100 spheroid areas at 72h. As a result, the HBL-100 spheroid areas were 
measured manually using the freehand selection tool in Fiji (figure 19). 
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Figure 19. Spheroid invasion measurement.  
The effect of drugs targeting pH regulators on MDA-MB-231 (A) and HBL-100 (B) spheroid invasion was measured using FIJI. Images show 1uM S4-
treated MDA-MB-231 and control HBL-100 spheroids cultured in 20% O2. MDA-MB-231 spheroid invasion was measured using a macro developed by 
Matthew Pearson, while HBL-100 invasion was measured manually using the freehand selection tool in FIJI. 
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2.9 3D invasion assays with explant tissue derived from human 
patients 
 
These experiments were carried out in collaboration with Carol Ward. The collection 
of breast cancer biopsy material was given local ethical approval from the Lothian 
Tissue Governance Committee (10/S1402/33). Informed consent for the collection of 
tissue and its use was acquired from patient’s prior to use. The breast tumour biopsy 
tissue was cut into 1 mm3 pieces using a sterile scalpel on a sterilised surface. The 
method used is the same as outlined in section 2.8.5, however MEGM complete 
media (Lonza, Switzerland) was used instead of DMEM culture media in these 
experiments. Images were acquired and the media replaced every 5 days for 15 days 
overall. For the reversal of invasion experiments the explants were left to invade for 
15 days before the first drug treatment, after which they were left to invade for 10 
further days. % invasion was quantified in collaboration with Carol Ward using the 
freehand selection tool in Image J.  
 
2.10 3D clonogenic assays 
 
The Faxitron RX-650 was used to irradiate MDA-MB-231 spheroids. Dosimetry 
checks were conducted once a year by Alan Doig and Sanker Andiappa of the NHS 
Medical Physics Department, Western General Hospital. The dose-rate [mGy/s] was 
measured using an Innovision Dosimeter 35050A and 150cc Ion chamber 96020C. 
The Faxitron RX-650 used had no extra filtration, with x-rays passing through a 1.6 
mm beryllium window. The spheroids used in these experiments had been cultured 
in a spinner flask for 1 week before use. The warm-up procedure was carried out for 
the Faxitron. Once completed, the spheroids were transferred from the spinner flask 
into petri dishes. The petri dish was placed onto the glass on the centre of the shelf, 
which turned at 2 RPM (revolutions per minute) to ensure uniform dosing. The 
distance from the focal spot of the x-ray tube to the cells (FSD) was 40.6 cm. The 0.5 
Gy dose was given with the voltage set to 130 kV (kilovolts) for 30 seconds. Directly 
after irradiation, the spheroids were collected and placed into a universal, and a 
single cell suspension was made by syringing the media + spheroids through a fine 
bore needle. The suspension was centrifuged and the media discarded. The cell pellet 
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was re-suspended in 1 ml of DMEM, and the number of cells was counted twice to 
ensure an accurate cell count. 1,000 cells were placed into a new plate, with or 
without the drug. The cells were cultured at 20% O2 for 1 week to allow colony 
formation. After 1 week, the media was removed and the cells were stained with 1,9-
dimethyl-methylene blue zinc chloride double salt (Sigma, 341088). The plates were 
placed on a rocker and left for 45 mins to ensure all of the colonies were stained. The 
plates were then washed 3 times with H2O and left to dry. Only colonies of 50 cells 
or over were counted.  
 
2.11 Xenograft studies 
 
These experiments were carried out in collaboration with Simon Langdon and 
Edward Jarman. Simon Langdon carried out the mice work, while myself and 
Edward Jarman performed the IHC staining and analysis. MDA-MB-231 tumour 
fragments were inserted subcutaneously into the flanks of adult nude mice. The 
tumours were grown to a diameter of 4-6 mm. A 90% tumour uptake efficiency was 
recorded. The mice were treated after 1 month of growth. There were 3 groups 
overall; control, FC9398A-treated and DTP348-treated, with 10 mice per group. 25 
mg/kg/day of FC9398A and 10 mg/kg/day of DTP348 were given in saline via the 
intraperitoneal route from day 0 until day 4. Callipers were used to quantify tumour 
size, with measurements carried out 3 times a week. The volume of each of the 
tumours was calculated using the formula  π/6 x width2 x length. Relative tumour 
volume was worked out by dividing the volume of the tumour on day t (Vt) by the 
volume of the tumour on day 0 (V0), and then multiplying by 100. 10 days after the 
completion of treatment, the tumour tissue was taken out and fixed in formalin, 
embedded in paraffin, and sections cut. CAIX and Ki67 expression levels were 
analysed after immunohistochemistry was performed (section 2.7.3). For the Ki67 
analysis, the percentage of Ki67 positive cells was measured in ten fields of 
xenograft section. For CAIX expression level analysis, the percentage area of CAIX 
positive cells was analysed using Image J. 
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3  Chapter 3: Expression analysis and pharmacological targeting 
of the tumour-associated carbonic anhydrases, NHE1 and V-
ATPase 
 
3.1  Introduction 
 
The tumour-associated carbonic anhydrases CAIX and CAXII, NHE1 and V-ATPase 
have each been strongly linked to cancer cell survival and tumour progression 
(section 1.14). The reversed pH gradient of cancer cells, formed in part from these 
pH regulating proteins, has a large effect on cancer cell biology, influencing both the 
proliferation (section 1.13.2) and invasive potential (section 1.13.1) of cancer cells. 
While previous studies have exhibited the inhibitory effects of targeting these pH 
regulating proteins on cancer cell proliferation [310, 355, 393-397] and invasion 
[260, 310, 335, 355, 373, 398-400], a comparison of the effects of targeting these 
proteins within one study has not previously been performed.  
 
The first stage of this project sought to investigate inhibitors targeting these pH 
regulatory molecules, assessing and comparing their inhibitory effects on cancer cell 
number and invasion in both aerobic and hypoxic conditions, evaluating their effects 
in differing O2 conditions and identifying the most promising agent for further 
analysis. DMA and bafilomycin A1 were the inhibitors chosen to target NHE1 and 
V-ATPase respectively, with previous studies showing that both of these drugs have 
high selectivity for their target molecules [401, 402]. The carbonic anhydrase 
inhibitors used within this chapter were novel small molecule inhibitors of the 
sulphamate class (see section 1.14.1), developed by Fabrizio Carta of the University 
of Florence. These inhibitors have been shown to target the tumour-associated 
carbonic anhydrases IX and XII at low nM concentrations, while having much less 
activity against the other carbonic anhydrase isoforms not linked with cancer [310, 
393].  
 
As well as influencing cancer cell proliferation and invasion, pH has also been 
shown to affect the responsiveness of cells to irradiation (section 1.13.3). Previous 
studies have exhibited the radio-sensitisation potential of targeting CAIX [320, 403, 
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404] and V-ATPase [405]. While little has been published to date on the effects of 
combining irradiation with the inhibition of NHE1, the targeting of this pH regulator 
has been hypothesised as a possible mechanism to increase the effectiveness of 
radiotherapy [328]. The exact mechanism through which irradiation and drugs that 
target the pH regulation proteins of cancer cells might combine is not known. One 
way through which radiotherapy achieves its therapeutic effect is through the 
induction of apoptosis [406]. Acidic pHi is thought to have a permissive role in the 
apoptotic cascade (section 1.13.2); it is believed that pH regulating proteins such as 
the tumour-associated carbonic anhydrases may be protecting cancer cells through 
their capacity to maintain an alkaline pHi [404], and that the combination of 
irradiation with drugs targeting the pH regulation mechanisms of cancer cells may 
increase the extent of radiation-induced apoptosis occurring in the cells [403]. With 
this in mind, we hypothesised that the treatment of cancer cells post-irradiation with 
drugs that target the pH regulation proteins would sensitise these cells to 
radiotherapy through the induction of increased levels of apoptosis, and lead to a 
lower survival fraction when compared against either treatment alone. 3D clonogenic 
assays, comparing the effects of inhibitors targeting the tumour-associated carbonic 
anhydrases, NHE1 and V-ATPase in combination with irradiation, were carried out 
to test this hypothesis.  
 
Studies have shown that the expression of the tumour-associated carbonic anhydrases 
and NHE1 are influenced by low O2 concentrations (section 1.10). Even though the 
link between V-ATPase expression and hypoxia is not as evident, there are some 
who believe that hypoxia may also have a role in the regulation of V-ATPase [261]. 
Because the expression levels of the pH regulatory proteins in differing O2 
conditions were hypothesised to affect the response of cells to drug treatment, the 
initial experiments carried out within this Chapter assessed the expression of the 3 
pH regulatory proteins in 2D, in a range of O2 concentrations that have been shown 
to occur in vivo (section 1.7.2). Further expression analysis was also carried out 
using multicellular tumour spheroids, a 3D model system that more accurately re-
creates the in vivo tumour environment (section 1.15.2), to assess whether similar 




3.2.1 2D protein and mRNA analysis shows that, of the 3 pH 
regulatory proteins analysed, the expression levels of the 
tumour-associated carbonic anhydrases are the most sensitive 
to changes in O2 concentration 
	
The preliminary experiments performed investigated the protein and mRNA 
expression levels of the pH regulatory proteins CAIX, NHE1 and V-ATPase in 
MCF-7, MDA-MB-231 and HBL-100 cancer cells cultured in a 2D environment in 
differing O2 concentrations. The expression levels of HIF-1α and HIF-2α, 
transcription factors that enable hypoxic cancer cells to survival in low O2 conditions 
[112], were also assessed.  
 
HIF-1α, HIF-2α and CAIX protein expression levels were evaluated in the initial 
experiments conducted. Protein expression was measured in acute hypoxic cancer 
cells cultured for 24h, 48h and 72h in both 2% and 0.5% O2 conditions, in addition to 
cancer cells cultured in 7% O2 at the same time points. Protein expression levels 
within these cells were compared against cells cultured in 20% O2 conditions for 24h 
(aerobic cells). To assess the effects of longer periods of hypoxia on protein 
expression, western blot analysis was also performed on lysates acquired from cells 
that had been cultured for 10 weeks in 0.5% O2 conditions (chronic hypoxia). 
Further, the effect of re-oxygenation on target protein expression was also analysed 
in chronically hypoxic cancer cells that were re-oxygenated in 20% O2 for 1 and 3 
weeks before lysate acquisition.  
 
Two bands were identified for HIF-1α (figure 20A, figure 21A and figure 22A), with 
changes in the intensity levels of these bands found to be similar in each of the cell 
lines cultured in the different O2 concentrations (figures 20B-C, figure 21B-C, figure 
22B-C). While increases in HIF-1α protein expression were seen in the 3 cell lines 
cultured in 2% and 7% O2, significant increases in HIF-1α levels were only observed 
in the HBL-100 cell line at 2% O2 (figure 22B-C). Although significantly higher 
levels of HIF-1α were observed in all 3 cell lines cultured in acute and chronic 
hypoxic conditions, the intensity of both the upper and lower bands was seen to 
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decrease by the 72h time point in 0.5% O2 conditions in MCF-7 (figure 20B-C) and 
HBL-100 (figure 22B-C) cells.  
 
HIF-2α expression was more variable between the cell lines in comparison to the 
results observed for HIF-1α. Hypoxic induction of HIF-2α was evident in two of the 
cell lines, with significant increases in HIF-2α levels detected in 0.5% O2 
concentrations in MDA-MB-231 cells (figure 21A and D), and in both 2% and 0.5% 
O2 conditions in the HBL-100 cell line (figure 22A and D). Longer incubation times 
in 0.5% O2 appeared to lead to a decrease in the levels of HIF-2α in both of these cell 
lines (figure 21D, figure 22D). There was no visible induction of HIF-2α seen in 
MCF-7 cells at any of the different O2 percentages tested (figure 20A and D).  
 
Because CAIX is a HIF-1α inducible protein [132], westerns were performed to 
analyse CAIX protein levels in the differing O2 concentrations to assess the 
relationship between HIF-1α and CAIX within the 3 breast cancer cell lines. The 
CAIX protein levels observed varied despite the presence of similar amounts of HIF-
1α in each of the cell lines. Significant increases in CAIX protein levels were 
observed in both acute and chronically hypoxic MDA-MB-231 (figure 21A and E) 
and HBL-100 (figure 22A and E) cells cultured in 0.5% O2, with significant 
increases in CAIX protein expression also detected in the HBL-100 cells cultured in 
2% O2 conditions (figure 22E). Out of the 3 cell lines, CAIX expression levels within 
MCF-7 cells were the least responsive to hypoxic induction (figure 20A and E). 
Despite the presence of significantly higher levels of HIF-1α, no significant increase 
in CAIX expression was seen within MCF-7 cells in acute hypoxic conditions (24-
72h in 0.5% O2). Only chronically hypoxic MCF-7 cells exhibited a significant 
increase in CAIX expression (figure 20A and E). In each of the cell lines studied, re-
oxygenation of the chronic hypoxic cells led to a reversion of CAIX protein 
intensities to levels that were similar to those of the aerobic cells (figure 20E, figure 
21E, figure 22E), suggesting that the changes in expression of this protein observed 
in the chronic hypoxic cells are reversible and temporary.  
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Figure 20. HIF-1α and CAIX protein expression are increased in MCF-7 cells in lower O2 percentages, while no induction of HIF-
2α is evident in this cancer cell line in hypoxic conditions.  
(A) Western blotting was performed to analyse the protein expression of HIF-1α, HIF-2α and CAIX in cells cultured in differing oxygen concentrations 
(20% O2, 7% O2, 2% O2 and 0.5% O2) for 24, 48 and 72h. Whole-cell lysates were also acquired from cells that had been present in 0.5% O2 for 10 
weeks, along with chronic hypoxic cells that were re-oxygenated for 1-3 weeks before lysate acquisition (re-ox). β-Actin used as the loading control. (B-
E) Graphs show the densitometry measurements of HIF-1α (B, upper band. C, lower band), HIF-2α (D), and CAIX (E). Data expressed as mean ± SEM 
(n = 3 for the 10 week and re-ox samples, n = 4 for the rest of the samples). * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001, **** P ≤ 0.0001 (One-way ANOVA 
followed by Dunnett’s multiple comparison test performed, comparing each sample to the 20% O2 group).  
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Figure 21. HIF-1α, HIF-2α and CAIX protein expression are increased in MDA-MB-231 cells in lower O2 conditions.   
(A) Western blotting was performed to analyse the protein expression of HIF-1α, HIF-2α and CAIX in cells cultured in differing oxygen concentrations 
(20% O2, 7% O2, 2% O2 and 0.5% O2) for 24, 48 and 72h. Whole-cell lysates were also acquired from cells that had been present in 0.5% O2 for 10 
weeks, along with chronic hypoxic cells that were re-oxygenated for 1-3 weeks before lysate acquisition (re-ox). β-Actin used as the loading control. (B-
E) Graphs show the densitometry measurements of HIF-1α (B, upper band. C, lower band), HIF-2α (D), and CAIX (E). Data expressed as mean ± SEM 
(n = 3 for the 10 week and re-ox samples, n = 4 for the rest of the samples). * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001, **** P ≤ 0.0001 (One-way ANOVA 
followed by Dunnett’s multiple comparison test performed, comparing each sample to the 20% O2 group). 
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Figure 22. HIF-1α, HIF-2α and CAIX protein expression are increased in HBL-100 cells cultured in lower O2 conditions.   
(A) Western blotting was performed to analyse the protein expression of HIF-1α, HIF-2α and CAIX in cells cultured in differing oxygen concentrations 
(20% O2, 7% O2, 2% O2 and 0.5% O2) for 24, 48 and 72h. Whole-cell lysates were also acquired from cells that had been present in 0.5% O2 for 10 
weeks, along with chronic hypoxic cells that were re-oxygenated for 1-3 weeks before lysate acquisition (re-ox). β-Actin used as the loading control. (B-
E) Graphs show the densitometry measurements of HIF-1α (B, upper band. C, lower band), HIF-2α (D), and CAIX (E). Data expressed as mean ± SEM 
(n = 3 for the 10 week and re-ox samples, n = 4 for the rest of the samples). * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001, **** P ≤ 0.0001 (One-way ANOVA 
followed by Dunnett’s multiple comparison test performed, comparing each sample to the 20% O2 group)  
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In addition to the evaluation of target protein expression through western blots, 
expression analysis was also performed assessing the levels of target mRNAs in the 
3 breast cancer cell lines by microarray analysis. mRNA levels were evaluated in 
hypoxic cells cultured in 0.5% O2 for 24h (acute hypoxic cells), along with cells 
cultured in 0.5% O2 conditions for 10 weeks (chronically hypoxic cells), with aerobic 
cells present in 20% O2 conditions for 24h acting as the controls. Initial analysis 
assessed the mRNA levels of HIF-1α, HIF-2α, CAIX and CAXII.  
 
No significant increases in either HIF-1α (figure 23A) or HIF-2α (figure 23B) 
mRNA levels were detected in the acute hypoxic or chronically hypoxic cells 
compared to the aerobic cells in any of the cell lines. The CAIX mRNA results 
largely mirrored those seen in the protein expression analysis, with CAIX mRNA 
levels significantly increased in the acute hypoxic and chronically hypoxic MDA-
MB-231 (figure 23C-D) and HBL-100 (figure 23C) cancer cells. Although there 
were similar levels of HIF-1α observed in each of the cell lines, there was no 
significant increase in CAIX mRNA levels in hypoxic MCF-7 cells (figure 23C-D). 
Overall, the CAIX protein and mRNA expression results suggested that there were 
differences in the control of CAIX expression between the 3 cell lines.  
 
The mRNA levels of CAXII, another tumour-associated carbonic anhydrase isoform 
whose expression levels have been shown to be influenced by hypoxia [242, 243], 
were also assessed, with varying results were observed between the 3 cell lines. High 
levels of CAXII mRNA were detected in MCF-7 cells cultured in 20% O2 
conditions, with a significant down-regulation in the levels of CAXII mRNA seen in 
both acute and chronic hypoxic conditions when compared against aerobic MCF-7 
cells (figure 23E). These results differed to those seen in the MDA-MB-231 and 
HBL-100 cell lines, which exhibited 20-fold and 22-fold lower levels of CAXII 
mRNA respectively in 20% O2 conditions compared to aerobic MCF-7 cells (figure 
23E). While hypoxic conditions led to significant decreases in the levels of CAXII 
mRNA in MCF-7 cells, both MDA-MB-231 and HBL-100 cell lines had 
significantly up-regulated levels of CAXII mRNA levels in acute and chronic 
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hypoxia (figure 23E-F). Both CAIX and CAXII play similar roles in pH regulation 
within cells. The relative lack of CAIX mRNA and protein in MCF-7 cells compared 
to the 2 other cell lines may be explained by the increased amount of CAXII in these 
cells.  
 
Figure 23. CAIX and CAXII mRNA levels exhibit a varying response to changes 
in O2 conditions between the 3 cell lines, while HIF-1α and HIF-2α mRNA levels 
are much more consistent.    
HIF1α (A), HIF-2α (B), CAIX (C and D [D without HBL-100 data]) and CAXII (E and F [F 
without MCF-7 data]) mRNA levels were analysed in the 3 breast cancer cell lines cultured 
in 20% O2 (aerobic, A), 0.5% O2 for 24h (AH) and 0.5% O2 for 10 weeks (CH). Data 
expressed as mean ± SEM (n=3). * P ≤ 0.05, ** P ≤ 0.01, **** P ≤ 0.0001 (One-way 
ANOVA followed by Dunnett’s multiple comparison test performed, comparing each sample 
to the 20% O2 group within each cell line). 
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Na+-H+ exchanger 1 protein and mRNA expression was also analysed in the 3 breast 
cancer cell lines cultured in differing O2 conditions. In contrast to the CAIX 
expression results, NHE1 protein and mRNA expression was relatively constant 
across the 3 cancer cell lines (figure 24). No significant changes in NHE1 expression 
levels were observed in either MDA-MB-231 (figure 24C) or HBL-100 (figure 24D) 
cells at any time point in the different O2 conditions. MCF-7 cells were the only cell 
line to show any significant change in NHE1 protein levels, with a significant 
increase in NHE1 protein quantity detected in MCF-7 cells cultured for 10 weeks in 
0.5% O2 conditions (figure 24B). NHE1 mRNA levels were quite stable between the 
differing conditions in the 3 cancer cell lines, with a small decrease in NHE1 mRNA 
levels observed in chronic hypoxic HBL-100 cancer cells the only significant change 





















Figure 24. NHE1 protein and mRNA expression levels are relatively constant in 
the 3 cell lines cultured in differing O2 concentrations. 
(A) Western blotting was performed to analyse the protein expression of NHE1 in MCF-7, 
MDA-MB-231 and HBL-100 cells cultured in differing oxygen concentrations (20% O2, 7% 
O2, 2% O2 and 0.5% O2) for 24, 48 and 72h, Whole-cell lysates were also acquired from 
cells that had been present in 0.5% O2 for 10 weeks, along with chronic hypoxic cells that 
were re-oxygenated for 1-3 weeks before lysate acquisition (re-ox). β-Actin used as the 
loading control. (B-D) Graphs show the densitometry measurements of NHE1 in MCF-7 (B), 
MDA-MB-231 (C) and HBL-100 (D) cells lines. Data expressed as mean ± SEM (n = 2) * P 
≤ 0.05 (One-way ANOVA followed by Dunnett’s multiple comparison test performed, 
comparing each sample to the 20% O2 group). (E) NHE1 mRNA levels were analysed in the 
3 breast cancer cell lines cultured in 20% O2 (aerobic, A), 0.5% O2 for 24h (AH) and 0.5% 
O2 for 10 weeks (CH). Data expressed as mean ± SEM (n=3). * P ≤ 0.05 (One-way ANOVA 
followed by Dunnett’s multiple comparison test performed, comparing each sample to the 
20% O2 group within each cell line). 
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Vacuolar H+-ATPases are made up of a peripheral domain (V1) and an integral 
domain (V0), each consisting of many different subunits (see section 1.12). To 
analyse the overall protein expression levels of V-ATPase within the 3 cancer cell 
lines in the varying O2 conditions, an antibody targeting the ATP6V1A subunit, 
present in the peripheral V1 domain of the complex, was used. Similar to the NHE1 
expression results obtained, V-ATPase protein expression was seen to be relatively 
steady in each of the 3 cancer cell lines cultured in the differing O2 conditions, with 
many of the samples present in low O2 concentrations having similar levels of V-
ATPase protein to the cells cultured in 20% O2 conditions (figure 25A-D). 
 
The mRNA levels of the ATP61VA subunit targeted in the protein expression 
analysis, in addition to the subunits ATP6V0A3 and ATP6V0A4 (both of which 
have been linked to the directing of the V-ATPase complex to the plasma membrane 
of cells [400]) were also assessed (figure 25E-G). While the mRNA quantities of the 
ATP6V1A subunit were found to decrease under hypoxic conditions in each of the 
cell lines (figure 25E), the expression levels of the ATP6V0A3 (figure 25F) and 
ATP6V0A4 (figure 25G) were much more constant across the different O2 
concentrations, with an increase in the levels of the ATP6V0A4 subunit within 
















Figure 25. V-ATPase protein and mRNA subunit expression levels are relatively 
constant in the 3 cell lines cultured in differing O2 conditions. 
(A-D) Cells were placed into differing oxygen concentrations (20% O2, 7% O2, 2% O2 and 
0.5% O2), and total protein was extracted from the cells at 24, 48 and 72h. Whole-cell 
lysates were also acquired from cells that had been present in 0.5% O2 for 10 weeks, along 
with chronic hypoxic cells that were re-oxygenated for 1-3 weeks before lysate acquisition 
(re-ox). Western blotting was performed to detect the expression of V-ATPase, with β-Actin 
used as the loading control. (B-D) Graphs show the densitometry measurements of V-
ATPase protein levels within the MCF-7 (B), MDA-MB-231 (C) and HBL-100 (D) cell lines. 
Data expressed as mean ± SEM (n = 3). ** P ≤ 0.01 (One-way ANOVA followed by 
Dunnett’s multiple comparison test performed, comparing each sample to the 20% O2 
group). (E-G) ATP6V1A (E), ATP6V0A3 (F) and ATP6V0A4 (G) subunit mRNA levels were 
analysed in cells cultured in 20% O2 (aerobic, A), 0.5% O2 for 24h (AH) and 0.5% O2 for 10 
weeks (CH). Data expressed as mean ± SEM (n=3). * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001 
and **** P ≤ 0.0001 (One-way ANOVA followed by Dunnett’s multiple comparison test 
performed, comparing each sample to the 20% O2 group within each cell line). 
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3.2.2 3D expression analysis indicates that, of the 3 pH regulatory 
proteins analysed, the tumour-associated carbonic anhydrases 
are the most sensitive changes in O2 conditions 
 
2D expression analysis showed that both CAIX protein and mRNA expression, along 
with CAXII mRNA levels, were differentially regulated between the 3 cell lines in 
various O2 concentrations, while both NHE1 and V-ATPase protein and mRNA 
expression levels were much more constant across the different O2 conditions. 
Further expression analysis was conducted to investigate whether the same pattern of 
expression occurred in 3D, studying the protein expression levels of each of these 
targets in multicellular tumour spheroids of the 3 cancer cell lines.  
 
Hypoxyprobe was used to reveal the presence of hypoxic areas within spheroids. 
Viable regions outside of the central necrotic cores showed extensive hypoxyprobe 
staining within both MCF-7 (figure 26) and HBL-100 (figure 28) spheroids, with 
hypoxic areas forming several cell diameters in from the outside edge of the 
spheroids. MDA-MB-231 spheroids also exhibited the formation of hypoxic areas 
(figure 27). However, the hypoxyprobe staining was much more restricted within 
these MDA-MB-231 spheroids in comparison to the spheroids of the other cell lines, 
with the presence of hypoxic areas evident only in certain regions (figure 27). 
 
Using the hypoxyprobe staining to delineate the normoxic and hypoxic areas within 
spheroids of each of the cell lines, quantitative evaluation of CAIX (figure 29), 
CAXII (figure 30) and NHE1 (figure 31) protein expression was carried out, 
measuring the levels of these proteins in the normoxic and hypoxic areas of 
spheroids from each of the 3 breast cancer cell lines. Of those cells recognised as 
having positive staining, the % of cells with low, medium or high intensity levels of 
staining within the normoxic and hypoxic areas was measured. This analysis was 
performed with Definiens Architect XD 64 Tissue Studio 4.1 (see section 2.7.4). 
 
Plasma membrane staining of CAIX was evident in spheroids of each of the 3 cancer 
cell lines (figures 26-28). However, as was already seen in the 2D expression 
analysis performed, the extent of CAIX expression again varied greatly between the 
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cell lines. Cells within MCF-7 spheroids had the lowest levels of CAIX (figure 29A), 
with no CAIX expressing cells detected within the normoxic areas of these 
spheroids, and only 0.1% of cells in the hypoxic regions expressing a low intensity 
level of CAIX (figure 29A). The % of cells detected as CAIX positive was higher in 
the HBL-100 spheroids in comparison to the MCF-7 spheroids (figure 29A), with 
over 60% of cells within the hypoxic regions of these spheroids exhibiting CAIX 
staining. The majority of cells within the hypoxic regions of HBL-100 spheroids 
were labelled as having high intensity levels of CAIX (figure 29A). MDA-MB-231 
spheroids exhibited the highest levels of CAIX expressing cells out of all the cell 
lines (figure 29A). Nearly 100% of the cells within the hypoxic regions were 
recognised as CAIX-positive, with only 9% of cells within the normoxic region 
labelled as negative for CAIX expression (figure 29A). Cells within the normoxic 
and hypoxic regions of the MDA-MB-231 spheroids were seen to have similar 




Figure 26. Large changes in the plasma membrane expression of CAXII and NHE1 are evident within the different regions of 
MCF-7 spheroids, while V-ATPase and CAIX expression is much more consistent.  





Figure 27. MDA-MB-231 spheroids exhibit large amounts of CAIX staining, with no plasma membrane staining of CAXII evident. 
NHE1 protein expression is also more consistent across the different regions of these spheroids.  






Figure 28. While no plasma membrane CAXII expression is present in HBL-100 spheroids, marked expression of plasma 
membrane CAIX and NHE1 is observed, with CAIX expression showing evident hypoxic induction. V-ATPase protein expression 
is seen to be much more consistent in the different regions. 
Images show hypoxyprobe (H probe), CAIX, CAXII, NHE1 and V-ATPase staining within HBL-100 spheroids that were allowed to form for a week 




Figure 29. Definiens analysis indicates that the 3D expression of CAIX differs 
between the 3 cell lines.  
(A) Graphs on the left show the % of cells within the normoxic (N) and hypoxic (H) regions 
of spheroids that expressed CAIX. Graphs on the right show the % of cells within the 
normoxic and hypoxic areas that had low, medium, and high intensity levels of CAIX 
staining. (B) Average intensity of CAIX membrane staining detected within the normoxic and 
hypoxic areas of spheroids of each cell line. Data expressed as mean ± SEM (n = at least 3 
for each cell line).  *P≤0.05, **P≤0.01, ***P≤0.001 and ****P≤0.0001 (Unpaired t-tests 
performed).  
Quantitative analysis of CAXII expression levels between spheroids of the different 
cell lines was also carried out. However, in contrast to CAIX, the localisation of 
CAXII expression differed between the cell lines. Plasma membrane CAXII staining 
was evident in cells within MCF-7 spheroids (figure 26), while intracellular CAXII 
staining was observed in spheroids of the MDA-MB-231 (figure 27) and HBL-100 
(figure 28) cell lines. This difference in CAXII localisation led to varying methods of 
analysis being carried out between the cell lines (see section 2.7.4).  
 
Similar to observations from the 2D mRNA analysis (figure 23), hypoxia led to a 
down-regulation of CAXII protein expression in MCF-7 spheroids, with a 
significantly higher % of cells exhibiting plasma membrane CAXII staining present 
in the normoxic areas (figure 30A). The majority (58.2%) of cells within the 
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normoxic regions had high intensity levels of CAXII staining, while in the hypoxic 
areas only 18% of cells were labelled as such (figure 30A). The overall intensity of 
plasma membrane CAXII expression was also higher in the MCF-7 cells within the 
normoxic regions compared to the cells within the hypoxic regions (figure 30A). 
Quantitative analysis indicated that regional differences in the expression levels of 
CAXII were present in HBL-100 spheroids, with an increased intensity of CAXII 
staining detected within the normoxic areas of HBL-100 spheroids (figure 30B). No 
such variations in intracellular CAXII staining were seen within the different regions 
of the MDA-MB-231 spheroids (figure 30B).  
 
Figure 30. Definiens analysis reveals the presence of regional differences in the 
expression of CAXII within MCF-7 and HBL-100 spheroids.   
Definiens analysis showing the levels of plasma membrane CAXII within MCF-7 spheroids 
(A) and intracellular CAXII staining within MDA-MB-231 and HBL-100 spheroids (B). The 
graphs on the left show the % of cells within the normoxic and hypoxic regions that exhibited 
CAXII staining. The graphs in the center show the % of cells within the normoxic and 
hypoxic areas that had low, medium, and high intensity levels of CAXII staining. The graphs 
on the right show the average intensity of CAXII staining detected within the normoxic and 
hypoxic areas of the spheroids. Data expressed as mean ± SEM (n = 4). *P≤0.05, **P≤0.01, 
***P≤0.001 and ****P≤0.0001 (Unpaired t-tests performed).  
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2D analysis showed that NHE1 protein expression was relatively consistent across 
the different cell lines cultured in various O2 conditions, with only chronic hypoxic 
MCF-7 cells exhibiting a significant increase in NHE1 protein levels (figure 24). 
Additional analysis carried out in 3D showed that large variations in NHE1 protein 
expression levels were evident within the different regions of the MCF-7 spheroids 
(figures 26 and 31A). Only 35.5% of cells within the normoxic regions of the MCF-7 
spheroids expressed NHE1, while 88.5% of cells within the hypoxic regions were 
labelled as having NHE1 plasma membrane staining (figure 31A). In contrast to the 
normoxic areas, the majority of cells within the hypoxic region were labelled as 
having high intensity levels of NHE1 staining (figure 31A). The NHE1 expression 
patterns within MDA-MB-231 and HBL-100 spheroids did not show as much 
evidence of hypoxic induction as was seen in the MCF-7 spheroids (figure 31A). Of 
the 3 cell lines, HBL-100 spheroids had the largest number of NHE1-expressing 
cells, with nearly 100% of cells within both normoxic and hypoxic regions labelled 
as NHE1-positive and having high intensity levels of NHE1 staining (figure 31A). 
An analysis of the average intensity staining of NHE1-positive cells within the 
normoxic and hypoxic regions of each of the spheroids indicated that HBL-100 cells 

















Figure 31. MCF-7 spheroids exhibit the largest regional changes in NHE1 
protein expression of the 3 cell lines.   
(A) Graphs on the left show the % of cells within the normoxic and hypoxic regions of 
spheroids that exhibited NHE1 staining. Graphs on the right show the % of cells within the 
normoxic and hypoxic areas that had low, medium, and high intensity levels of NHE1 
staining. (B) Average intensity of NHE1 staining detected within the normoxic and hypoxic 
areas of spheroids of each cell line. Data expressed as mean ± SEM (n = at least 3 for each 
cell line). *P≤0.05, **P≤0.01, ***P≤0.001 and ****P≤0.0001 (Unpaired t-tests performed). 
Preliminary experiments performed, testing different dilutions of V-ATPase antibody 
in IHC, showed that V-ATPase protein expression levels were similar in the different 
regions of both MCF-7 (figure 26) and HBL-100 (figure 28) spheroids. Further IHC 
was carried out, with the intention of assessing V-ATPase protein expression levels 
in spheroids that had been treated with hypoxyprobe, using the hypoxyprobe staining 
to demarcate the normoxic and hypoxic areas of the spheroids However, despite 
repeated attempts, the V-ATPase antibody failed to produce any positive staining in 
the hypoxyprobe stained spheroids. As a result, no quantitative analysis of V-ATPase 
protein expression in 3D was carried out. 
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Spheroids re-create different aspects of the in vivo tumour microenvironment, 
mimicking the heterogeneous cancer cell populations that occur within tumours, with 
proliferative cells present in the normoxic layer, and non-cycling or apoptotic cells 
present in the hypoxic regions (see section 1.15.2). The pH regulating proteins, 
through their role in the control of pH, support cancer cell survival (see sections 1.10 
- 1.12). Quantitative analysis was carried out to assess whether the differential 
expression of the pH regulating proteins observed between the cell lines in 3D had 
any effect on cell viability, comparing the expression levels of Ki67 and caspase 3 in 
the normoxic and hypoxic regions of spheroids.  
 
Hypoxic regions of MCF-7 spheroids had significantly lower percentages of cycling 
cells (as indicated by Ki67) in comparison to the normoxic areas (figures 32A and 
33), while also exhibiting significantly increased levels of apoptosis, as analysed 
through caspase 3 staining (figures 32B and 33). The proliferative and cell death 
gradients that appeared within MCF-7 spheroids were not present within MDA-MB-
231 spheroids, which exhibited no significant differences in either proliferation 
(figure 32A) or apoptosis (figure 32B) between the normoxic and hypoxic areas of 
the spheroids. Cells within the hypoxic regions of HBL-100 spheroids exhibited a 
similar proliferation index to the normoxic cells (figures 32A and 34). However, a 
small significant increase in caspase 3 staining was observed in the hypoxic areas of 
HBL-100 spheroids (figure 32B). 
 
Figure 32. The presence of proliferative and cell death gradients are observed 
within spheroids of the MCF-7 cell line.    
Analysis of the % of Ki67 positive cells (A) and the % area of caspase 3 staining (B) within 
the normoxic and hypoxic regions of spheroids of the 3 cancer cell lines. Data expressed as 




Figure 33. Ki67 and caspase 3 staining show evidence of the proliferative and cell death gradients present within spheroids of the 
MCF-7 cell line.  




Figure 34. Extensive Ki67 staining observed in all regions of the HBL-100 
spheroids, with caspase 3 staining present within the hypoxic areas of these 
spheroids.   
Images show hypoxyprobe (H probe), Ki67 and caspase 3 staining within HBL-100 




3.2.3 Changes in O2 concentration alters the effects of inhibitors 
targeting the tumour-associated carbonic anhydrases and 
NHE1 on cancer cell number  
	
SRB assays were performed to investigate the effects of inhibitors targeting the 
tumour-associated carbonic anhydrases, NHE1 and V-ATPase on cancer cell 
number, comparing the sensitivity of aerobic, acute hypoxic and chronic hypoxic 
cells to drug treatment. Cells in each of these conditions were treated with the 
inhibitors for 24-120h. The acute hypoxic cells were cultured at 0.5% O2 for 24h 
prior to drug-treatment to allow them to adapt to the low O2 conditions, while the 
chronic hypoxic cells had been cultured for over 21 weeks in 0.5% O2 conditions 
before the assay. Both acute and chronic hypoxic cancer cells were kept in 0.5% O2 
conditions throughout the experiment. The intensity readings procured from the SRB 
assays (figures 35 – 43 left column) were used to produce graphs showing the effect 
of pH inhibition on cancer cell number, with the control cell intensity readings 
representing 100% cell number (figures 35 – 43 middle column). The data from these 
graphs were then used to produce IC50 values (half maximal inhibitory 
concentration) for reduction in cell number in response to drug treatment (figures 35 
– 43 right column).  
 
Treatment with the carbonic anhydrase inhibitor led to a reduction in cell number in 
all 3 of the cell lines cultured in aerobic conditions (figure 35). 30 and 100 µM 
concentrations of S4 had large effects on intensity readings in the MCF-7 and MDA-
MB-231 cell lines (figure 35 left column), leading to sizeable reductions in cell 
number in comparison to the un-treated cells (figure 35 middle column). HBL-100 
cells were more resistant to the effects of S4 treatment in comparison to both the 
MCF-7 and MDA-MB-231 cells, as reflected in the IC50 values obtained for each of 
the cell lines (figure 35 right column). While concentrations of S4 were able to 
reduce MCF-7 and MDA-MB-231 cell number by 50%, no concentration of inhibitor 
used had the same effect on the HBL-100 cell line in aerobic conditions.  
 
Acute hypoxic cells were more resistant to the effects of S4 compared to aerobic 
cells (figure 36). The 30 µM and 100 µM drug concentrations, which were leading to 
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significant reductions in cell number in aerobic MCF-7 and MDA-MB-231 cells, had 
less influence on intensity readings in the acute hypoxic cells (figure 36 left column), 
with acute hypoxic HBL-100 cells displaying a near complete resistance to S4 
treatment (figure 36 left column). The augmented resistance of the acute hypoxic 
cells in comparison to the aerobic cells was supported by the IC50 values obtained. 
While drug treatment was able to reduce cell number by 50% in the aerobic MCF-7 
and MDA-MB-231 cells (figure 35 right column), most of the drug concentrations 
used did not lead to the same effect in acute hypoxic conditions (figure 36 right 
column).  
 
The results for the chronically hypoxic cells were more similar to the results obtained 
with the aerobic cells (figure 37). Higher concentrations of S4 had a sizeable effect 
on the intensity readings of both MCF-7 and MDA-MB-231 cells (figure 37 left 
column), leading to large reductions in cell number when compared against the un-
treated cells (figure 37 middle column). Comparable IC50 values were obtained for 




Figure 35: Reductions in cell number indicate that aerobic MCF-7 and MDA-MB-231 cells are sensitive to S4.   
Left column: The effects of S4 on the intensity readings of aerobic cancer cells, in comparison to un-treated cells. Data expressed as mean ± SEM 
(n=6). *P≤0.05, **P≤0.01, ***P≤0.001 and ****P≤0.0001 (One-way ANOVA followed by Dunnett’s multiple comparison test performed, comparing 
only the values within each time point). Middle column: The effects of S4 on aerobic cancer cell number, with each drug-treated intensity reading given 
as a percentage of the control intensity readings at that time point. Right column: The IC50 values (µM) for S4 in each of the aerobic cell lines. These 
values were produced using the data from the middle column.  
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Figure 36: Acute hypoxic cells are more resistant to the effects of S4 on cancer cell number.    
Left column: The effects of S4 on the intensity readings of acute hypoxic cancer cells, compared to un-treated cells. Data expressed as mean ± SEM 
(n=6). *P≤0.05, **P≤0.01, ***P≤0.001 and ****P≤0.0001 (One-way ANOVA followed by Dunnett’s multiple comparison test performed, comparing 
only the values within each time point). Middle column: The effects of S4 on acute hypoxic cancer cell number, with each drug-treated intensity reading 
given as a percentage of the control intensity readings at that time point. Right column: The IC50 values (µM) for S4 in each of the acute hypoxic cell 
lines. These values were produced using the data from the middle column.  
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Figure 37: Chronic hypoxic cells appear to be re-sensitised to the effects of S4 on cancer cell number.    
Left column: The effects of S4 on the intensity readings of chronic hypoxic cancer cells. Data expressed as mean ± SEM (n=6). *P≤0.05, **P≤0.01, 
***P≤0.001 and ****P≤0.0001 (One-way ANOVA followed by Dunnett’s multiple comparison test performed, comparing only the values within each 
time point). Middle column: The effects of S4 on chronic hypoxic cancer cell number, with each drug-treated intensity reading given as a percentage of 
the control intensity readings at that time point. Right column: The IC50 values (µM) for S4 in each of the chronic hypoxic cell lines produced using the 
data in the middle column. 
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In contrast to the carbonic anhydrase inhibitor S4, DMA treatment had a large effect 
on the cell number of all 3 cancer cell lines cultured in aerobic conditions (figure 38). 
DMA concentrations over 10 µM had the largest influence on cell number in 20% O2 
conditions, with higher concentrations causing a significant reduction in the intensity 
values obtained after only 24h of treatment (figure 38 left column). MCF-7 cells 
seemed to be the most sensitive to the effects of NHE1 inhibition in aerobic 
conditions out of all the cell lines, with MCF-7 cells requiring the lowest 
concentration of drug to reduce cell number by 50% at the later time points (figure 
38 right column).  
	
DMA also influenced acute hypoxic cancer cell number (figure 39). However, while 
30 µM DMA had a large effect on intensity values in the experiments conducted in 
20% O2 conditions (figure 38 left column), each of the acute hypoxic cell lines were 
more resistant to the effects of 30 µM treatment (figure 39 left column). This 
observation, in addition to the increased IC50 values observed with the acute hypoxic 
cells (figure 39 right column) compared to the aerobic cells (figure 38 right column), 
suggested that acute hypoxic cells were more resistant to the effects of NHE1 
inhibition.  
 
Overall, lower IC50 values were obtained in the chronic hypoxic MCF-7 and HBL-
100 cells (figure 40 right column) compared to the acute hypoxic cells (figure 39 
right column), suggesting these chronic hypoxic cell lines may have re-sensitised to 
DMA treatment. The chronically hypoxic MDA-MB-231 cells, however, seemed to 
be more resistant to drug treatment than the 2 other cell lines, exhibiting similar IC50 
values (figure 40 right column) to the acute hypoxic MDA-MB-231 cancer cells 




Figure 38. Each of the cancer cell lines exhibit sensitivity to the effects of DMA on cell number in aerobic conditions.   
Left column: The effects of DMA on the intensity readings of aerobic cancer cells, in comparison to un-treated cells. Data expressed as mean ± SEM 
(n=6). *P≤0.05, **P≤0.01 and ****P≤0.0001 (One-way ANOVA followed by Dunnett’s multiple comparison test performed, comparing only the values 
within each time point). Middle column: The effects of DMA on aerobic cancer cell number, with each drug-treated intensity reading given as a 
percentage of the control intensity reading at that time point. Right column: The IC50 values (µM) for DMA in each of the aerobic cell lines. These 
values were produced using the data from the middle column. 
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Figure 39. Acute hypoxic cancer cells show a slightly increased resistance to the effects of DMA on cancer cell number.   
Left column: The effects of DMA on the intensity readings of acute hypoxic cancer cells, compared to un-treated cells. Data expressed as mean ± SEM 
(n=6). *P≤0.05, **P≤0.01, ***P≤0.001 and ****P≤0.0001 (One-way ANOVA followed by Dunnett’s multiple comparison test performed, comparing 
only the values within each time point). Middle column: The effects of DMA on acute hypoxic cancer cell number, with each drug-treated intensity 
reading given as a percentage of the control intensity reading at that time point. Right column: The IC50 values (µM) for DMA in each of the acute 
hypoxic cell lines. These values were produced using the data from the middle column. 
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Figure 40. Chronic hypoxic MCF-7 and HBL-100 cells are re-sensitised to DMA treatment.   
Left column: The effects of DMA on the intensity readings of chronic hypoxic cancer cells, in comparison to un-treated cells. Data expressed as mean ± 
SEM (n=6). **P≤0.01, ***P≤0.001 and ****P≤0.0001 (One-way ANOVA followed by Dunnett’s multiple comparison test performed, comparing only 
the values within each time point). Middle column: The effects of DMA on chronic hypoxic cancer cell number, with each drug-treated intensity reading 
given as a percentage of the control intensity reading at that time point. Right column: The IC50 values (µM) for DMA in each of the chronic hypoxic 
cell lines produced using the data in the middle column. 
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Of the 3 drugs tested, the V-ATPase inhibitor bafilomycin A1 was the most potent, 
with nM concentrations of this drug causing significant reductions in cancer cell 
number in each of the conditions tested (figures 41 – 43). However, while the highest 
concentrations of the NHE1 inhibitor DMA tested exerted large effects on cancer cell 
number after only 24h of treatment (figures 38 – 40), the effect of bafilomycin A1 on 
cancer cell number was more delayed. 24h treatment with the concentrations of 
bafilomycin A1 tested had no large effect on cancer cell number in aerobic 
conditions (figure 41). By 48h treatment, higher concentrations of bafilomycin A1 
had reduced cell number by around 25% in each of the cancer cell lines, with 72h of 
treatment with the V-ATPase inhibitor required to reduce cell number by over 50% 
(figure 41 middle and right columns). MCF-7 and MDA-MB-231 cells treated with 3 
nM of inhibitor between the 24-120h time points had intensity values similar to that 
of the un-treated cells at 24h (figure 41 left column), indicating that cells treated with 
this concentration of drug were not exhibiting any increase in cell number compared 
to the control cells at 24h, possibly as a result of bafilomycin A1 treatment inhibiting 
the proliferation of these cells. In contrast, concentrations of bafilomycin A1 over 3 
nM were leading to decreased intensity values compared to the 24h control cells as 
treatment time increased (figure 41 left column), indicating that these higher 
concentrations of bafilomycin A1 were leading to reduced cell numbers within the 
wells, possibly through the induction of cell death.  
 
The results observed in the acute (figure 42) and chronic (figure 43) hypoxic cancer 
cells were comparable to those seen in the aerobic cells, with similar IC50 values 
obtained in these cells and the aerobic cells, suggesting that the culturing conditions 









Figure 41. Nanomolar concentrations of bafilomycin A1 are required to reduce aerobic cancer cell number.   
Left column: The effects of bafilomycin A1 on the intensity readings of aerobic cancer cells, in comparison to un-treated cells. Data expressed as mean 
± SEM (n=6). *P≤0.05, **P≤0.01, ***P≤0.001 and ****P≤0.0001 (One-way ANOVA followed by Dunnett’s multiple comparison test performed, 
comparing only the values within each time point). Middle column: The effects of bafilomycin A1 on aerobic cancer cell number, with each drug-treated 
intensity reading given as a percentage of the control intensity readings at that time point. Right column: The IC50 values (nM) for bafilomycin A1 in 
each of the aerobic cell lines. These values were produced using the data from the middle column. 
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Figure 42. Acute hypoxic cancer cells show a similar sensitivity to the effects of bafilomycin A1 on cell number compared to aerobic 
cancer cells.   
Left column: The effects of bafilomycin A1 on the intensity readings of acute hypoxic cancer cells, compared to un-treated cells. Data expressed as 
mean ± SEM (n=6). *P≤0.05, ***P≤0.001 and ****P≤0.0001 (One-way ANOVA followed by Dunnett’s multiple comparison test performed, 
comparing only the values within each time point). Middle column: The effects of bafilomycin A1 on acute hypoxic cancer cell number, with each drug-
treated intensity reading given as a percentage of the control intensity readings at that time point. Right column: The IC50 values (nM) for bafilomycin 
A1 in each of the acute hypoxic cell lines. These values were produced using the data from the middle column. 
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Figure 43. Chronic hypoxic cancer cells show a similar sensitivity to the effects of bafilomycin A1 on cell number compared to cells 
cultured in both aerobic and acute hypoxic conditions.    
Left column: The effects of bafilomycin A1 on the intensity readings of chronic hypoxic cancer cells, in comparison to un-treated cells. Data expressed 
as mean ± SEM (n=6). *P≤0.05, **P≤0.01, and ****P≤0.0001 (One-way ANOVA followed by Dunnett’s multiple comparison test performed, 
comparing only the values within each time point). Middle column: The effects of bafilomycin A1 on chronic hypoxic cancer cell number, with each 
drug-treated intensity reading given as a percentage of the control intensity readings at that time point. Right column: The IC50 values (nM) for 
bafilomycin A1 in each of the chronic hypoxic cell lines produced using the data in the middle column. 
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3.2.4 Preliminary experiments indicate that inhibitors targeting the 
tumour-associated carbonic anhydrases reduce the invasion of 
cells from MDA-MB-231 spheroids 
 
3D invasion assays were carried out to compare the effects of inhibitors targeting the 
tumour-associated carbonic anhydrases, NHE1 and V-ATPase on cancer cell 
invasion (figure 44). For these experiments, spheroids were placed into collagen type 
1, the major component of breast stroma within the body [366]. Spheroids produced 
from both MDA-MB-231 and HBL-100 cells were used in this analysis, as cells from 
spheroids of these cell lines exhibited the capacity to invade into collagen (figure 
19). MCF-7 spheroids, however, were not used, as they were non-invasive. For these 
experiments, the MDA-MB-231 and HBL-100 spheroids were left to invade for 48h 
and 72h respectively in either aerobic or hypoxic (0.5% O2) conditions.  
 
100 µM concentrations of S4 significantly reduced the % of cells invading into 
collagen from MDA-MB-231 spheroids cultured in both 20% O2 and 0.5% O2 
conditions (figure 44). However, while S4 also seemed to have an effect on the 
invasion of cancer cells from HBL-100 spheroids, reducing the % of invading cells 
in hypoxic conditions at higher concentrations, carbonic anhydrase inhibition did not 
lead to any significant reduction in invasion from HBL-100 spheroids cultured in 
either aerobic or hypoxic conditions. 
 
NHE1 and V-ATPase inhibition had little impact on invasion, with no significant 
decrease in the % of invading cells observed in drug-treated MDA-MB-231 and 
HBL-100 spheroids cultured in either aerobic or hypoxic conditions (figure 44). In 
fact, certain concentrations of both of the NHE1 and V-ATPase inhibitors were seen 





Figure 44. Preliminary invasion assays conducted with inhibitors targeting the 3 pH regulating proteins indicate that S4 reduces 
the invasion of cells from MDA-MB-231 spheroids cultured in both 20% and 0.5% O2 conditions.  
See next page for figure legend.  
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Figure 44. Preliminary invasion assays conducted with inhibitors targeting the 3 
pH regulating proteins indicate that S4 reduces the invasion of cells from MDA-
MB-231 spheroids cultured in both 20% and 0.5% O2 conditions.  
 
The effect of S4, DMA and bafilomycin A1 on cancer cell invasion from MDA-MB-231 and 
HBL-100 spheroids cultured in 20% O2 (grey bars) and 0.5% O2 (white bars) conditions was 
analysed in 3D invasion assays. Data expressed as mean ± SD (at least 4 technical 
replicates were present for each drug concentration). * P ≤ 0.05, ** P ≤ 0.01, **** P ≤ 
0.0001 (One-way ANOVA followed by Dunnett’s multiple comparison test performed). 
 
IHC was carried out in order to assess CAIX and NHE1 expression levels within 
invading spheroids present in collagen. This experiment was performed with un-
treated HBL-100 spheroids placed into collagen type 1 and left to invade for 24h 
(figure 45A) and 48h (figure 45B) in 20% O2 conditions. While the pattern of NHE1 
protein expression was similar to that already shown (figure 28), the expression of 
CAIX within these collagen embedded spheroids differed from that previously 
observed. Whereas the preceding analysis of CAIX expression in HBL-100 
spheroids showed CAIX expression to be strongest in the central hypoxic regions of 
the spheroid (figure 28), invading HBL-100 spheroids embedded in collagen for 24h 
(figure 45A) and 48h (figure 45B) exhibited strong CAIX expression in cells at the 
outer rim of the spheroids, in addition to the high levels of CAIX present in the more 
central cells. The isolation of MDA-MB-231 spheroids for IHC proved more 
problematic than that of the HBL-100 spheroids. As a result, no IHC was performed 





Figure 45. CAIX and NHE1 expression within HBL-100 spheroids present in 
collagen type 1. The CAIX expression results indicate that the spheroids 
cultured in 20% O2 conditions may be hypoxic.  
IHC assessing CAIX and NHE1 expression was performed on HBL-100 spheroids that were 
placed into collagen and left to invade for 24h (A) and 48h (B) without the addition of any 
S4. Images of the spheroids present in collagen before fixation are also shown. 
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3.2.5 Preliminary clonogenic assays suggest that inhibitors targeting 
the tumour-associated carbonic anhydrases and NHE1 have 
potential to combine with irradiation. 
 
3D clonogenic assays were carried out with MDA-MB-231 spheroids to compare the 
effects of inhibitors targeting the tumour associated carbonic anhydrases, NHE1 and 
V-ATPase on their ability to combine effectively with irradiation, and lead to 
significantly reduced colony numbers when compared to either irradiation or drug 
treatment alone.  
 
S4 and FC9403A (another carbonic anhydrase inhibitor previously shown to have 
potency in experiments carried out within the laboratory [355]) were the 2 carbonic 
anhydrase inhibitors tested in these clonogenic assays, along with the NHE1 inhibitor 
DMA and the V-ATPase inhibitor bafilomycin A1 (figure 46). Concentrations of 
these inhibitors that were previously shown to not have large effects on cancer cell 
number (section 3.2.3) were chosen for these assays.  
 
The results from these experiments suggested that both FC9403A (figure 46A) and 
DMA (figure 46C) may have the ability to combine with irradiation, with the 
combination of drug and 0.5 Gy leading to a significant reduction in the survival 
fraction of MDA-MB-231 cells when compared against either treatment alone. 
However, while positive results were observed with both of these inhibitors, no 
significant reduction in survival fraction was observed in the MDA-MB-231 cells 
treated with a combination of S4/bafilomycin A1 and 0.5 Gy compared to either 






Figure 46. 3D clonogenic assays performed with MDA-MB-231 spheroids 
suggest that inhibitors targeting the tumour-associated carbonic anhydrases 
and NHE1 have potential to combine with irradiation.  
3D clonogenic assay assessing the effect of the carbonic anhydrase inhibitors FC9403A (A) 
and S4 (B), the NHE1 inhibitor DMA (C), and the V-ATPase inhibitor bafilomycin A1 (D) on 
MDA-MB-231 surviving fraction, either alone or in combination with 0.5 Gy irradiation. 
Plating efficiencies calculated for each of the experiments were 0.083 (FC9403A), 0.115 (S4 
and DMA), and 0.112 (bafilomycin A1). Data expressed as mean ± SD (n=8-11)* P ≤ 0.05, 
*** P ≤ 0.001, **** P ≤ 0.0001 [Kruskal-Wallis test (A) and one-way ANOVA followed by 






The abnormal regulation of H+ ions within cancer cells is thought to be one of the 
most distinctive characteristics of cancer [269]. The carbonic anhydrases CAIX and 
CAXII, NHE1 and V-ATPase are pH regulating proteins that have been linked with 
cancer (see section 1.14). In addition to an assessment of the expression levels of 
these proteins in differing O2 concentrations, the work described in this chapter 
compared the effects of inhibitors targeting these molecules on cancer cell number 
and invasion in 2D and 3D culture models in both aerobic and hypoxic conditions, in 
addition to the effects of combining these inhibitors with irradiation in clonogenic 
assays. These assays were carried out in order to distinguish the most promising 
agent for further analysis.  
 
Initial experiments assessed the expression of the pH regulatory proteins in differing 
O2 conditions in both 2D and 3D culture systems. The expression levels of the 
hypoxia inducible factors, crucial mediators of the response of hypoxic tumour cells 
to low O2 concentrations [122], were also analysed to indicate the extent of hypoxia 
within the cells cultured in 2D. Hypoxyprobe, a compound that is reduced in cells 
when O2 concentration is 1.3% or less [407], forming a covalent bond with the thiol 
groups of proteins, was used to detect the presence of hypoxic areas within the 
spheroids. Hypoxyprobe has been used before for the detection of hypoxic areas 
within multicellular tumour spheroids [408, 409].  
 
The 2D expression analysis results observed with HIF-1α were consistent with 
expectation, with significantly increased levels of HIF-1α protein present in each of 
the cell lines cultured in the lower percentage O2 conditions (figures 20 – 22). Two 
bands were identified for HIF-1α in each of the cell lines. Numerous published 
studies have reported the presence of two bands in western blots when analysing 
HIF-1α protein levels [410-415], with some suggesting that the presence of the two 
bands results from HIF-1α phosphorylation [410, 412, 413, 415]. Previous work has 
indicated that HIF-1α and HIF-2α are stabilised at different O2 concentrations and 
have varying temporal responses to hypoxia, with HIF-1α reported to respond 
preferentially to acute hypoxic conditions in neuroblastoma cells [416], while HIF-
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2α has been shown to accumulate gradually over time in less severe O2 
concentrations in both neuroblastoma and cervical cancer cell lines [416, 417]. 
However, a differential response in HIF-1α and HIF-2α stabilisation in hypoxic 
conditions was not observed in the western blots performed here, with significant 
increases in the levels of HIF-2α detected within MDA-MB-231 cells cultured in 
0.5% O2 conditions, and HBL-100 cells exposed to both 2% and 0.5% O2 
concentrations, mirroring the results observed with HIF-1α in these cell lines (figures 
21 and 22). Both HIF-1α and HIF-2α mRNA levels were much more consistent 
across the different O2 conditions in the 3 cell lines compared to the protein levels 
(figure 23). These results were expected, as the O2-dependent regulation of the HIF 
pathway is known to be controlled primarily at the post-transcriptional level [112].  
 
The expected hypoxyprobe staining was observed in the multicellular tumour 
spheroids produced from the MCF-7 (figure 26) and HBL-100 (figure 28) cell lines. 
Hypoxic areas were evident in the more central areas of the spheroids from these cell 
lines, with the cells present in the outer rim lacking any positive staining. However, 
the staining of the MDA-MB-231 spheroids (figure 27) differed to that of the other 
two cell lines, with only certain areas of the spheroid surrounding the necrotic core 
exhibiting hypoxyprobe staining. The reason for the observation of such selective 
staining is unknown. Some positive staining was also seen in areas near the outer 
edge of the spheroids. A previous study has shown the detection of hypoxyprobe 
staining within normoxic MDA-MB-231 cells overexpressing cytochrome p450 
reductase [418]. The positive staining in some of the MDA-MB-231 cells near the 
outer edges of the MDA-MB-231 spheroids may be evidence of the presence of cells 
with increased levels of this enzyme.   
 
Of the pH regulatory proteins analysed, the expression levels of tumour-associated 
carbonic anhydrases were the most sensitive to changes in O2 concentrations. CAIX 
expression is induced by hypoxia and HIF-1 [132, 242]. However, CAIX protein 
expression in the 2D and 3D cell culture models differed considerably between the 3 
cancer cell lines, despite the observation of similar levels of HIF-1α and 
hypoxyprobe staining in each of the cell lines in the lower O2 concentrations. CAIX 
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mRNA (figure 23) and protein (figures 20 and 26) expression within the MCF-7 cell 
line was the least responsive to low O2 conditions, while significant increases in 
CAIX expression were evident within the MDA-MB-231 and HBL-100 cell lines in 
hypoxia in both 2D (figures 21–23) and 3D (figures 27–29). Further work, presented 
in Chapter 4, investigated the possible mechanisms leading to the varying expression 
of CAIX protein observed between the 3 cell lines.  
 
CAXII expression was also shown to be modulated by changes in O2 concentrations. 
Similar to the CAIX expression, differing results were observed between the 3 cell 
lines. Comparable levels of CAXII mRNA were detected in the MDA-MB-231 and 
HBL-100 cells, with a small significant increase in the levels of CAXII mRNA 
detected in hypoxic conditions in both cell lines. Aerobic MCF-7 cells exhibited the 
highest levels of CAXII mRNA out of all the samples analysed, with a significant 
decrease in the levels of CAXII mRNA observed in hypoxic conditions with the 
MCF-7 cells (figure 23). CAXII protein expression within the MCF-7 spheroids 
produced similar results, with a significant decrease in the levels of CAXII protein 
detected in the hypoxic regions (figure 30A). Other studies have demonstrated the 
presence of an inverse relationship between the expression of the different carbonic 
anhydrase isoforms, with the reduction of CAIX protein levels through shRNA 
previously shown to lead to increased CAXII mRNA [419, 420] and protein [420] 
expression. These observations have led some investigators to hypothesise that the 
different carbonic anhydrase isoforms might communicate in a network which has 
yet to be fully resolved [419]. Although no significant induction of CAIX protein 
was observed within acute hypoxic MCF-7 cells in 2D, or within the hypoxic areas 
of MCF-7 spheroids, the up-regulation of other carbonic anhydrase isoforms not 
assessed in the 2D or 3D analysis performed may help explain why CAXII protein 
and mRNA levels were reduced in low O2 conditions in this cell line.  
 
While plasma membrane expression of CAXII was detected within the cells of the 
MCF-7 spheroids, intracellular CAXII staining was observed within the spheroids of 
the MDA-MB-231 and HBL-100 cell lines (figures 27 and 28). Both plasma 
membrane and intracellular localisation of CAXII staining has been shown before in 
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IHC performed on human breast cancer tissue [421], with intracellular CAXII also 
seen within MDA-MB-231 cells in other studies as well [231]. The lack of plasma 
membrane CAXII in the MDA-MB-231 and HBL-100 spheroids suggests that, at 
least in 3D, this isoform is unlikely to be involved in the control of pHi within cells 
of these cell lines.  
 
NHE1 mRNA and protein expression levels were observed to be quite constant in the 
different O2 concentrations tested in 2D cell culture (figure 24). 3D expression 
analysis indicated that the hypoxic areas within MCF-7 spheroids displayed a 
significantly higher percentage of NHE1-positive cells compared to the normoxic 
regions, with the intensity of NHE1 staining also increased in the hypoxic areas 
(figure 31). While previous work conducted in other cell lines has shown NHE1 
expression to be regulated by hypoxia and HIF-1 (see section 1.11), other studies 
assessing NHE1 protein expression in MCF-7 spheroids did not observe any regional 
variation in NHE1 expression levels [422, 423]. However, within those studies 
protein expression was analysed in spheroids that were allowed to form for 1, 15 and 
30 days [422], or for 9 days [423], whereas the spheroids used in this study were 
only allowed to form for 1 week before fixation. The differing times at which NHE1 
expression was assessed within the spheroids may have contributed to the variation 
in the results observed. With reports indicating that NHE1 expression within certain 
cell types is controlled by HIF-1 [254], it is interesting that the NHE1 protein within 
the MCF-7 cell line was the most responsive to low O2 concentrations, as this cell 
line exhibited the lowest level of CAIX (another protein reported to be controlled by 
HIF-1 signalling [132, 242]) mRNA and protein expression out of the 3 cell lines. As 
such, it is probable that mechanisms other than hypoxia and HIF-1α stabilisation also 
control NHE1 expression within this cell line. pH has been shown to lead to changes 
in the expression levels of NHE1 in some cell types [424]. However, acidic pH was 
found to lead to decreased NHE1 expression levels in this study. Therefore, acidosis 
in the hypoxic areas of the MCF-7 spheroids is unlikely to be the cause of the 
increased NHE1 protein expression observed.  
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[425]Of the 3 different pH regulatory proteins analysed, the 2D protein expression 
analysis showed that V-ATPase expression was the most stable across the different 
O2 concentrations analysed (figure 25A–D). An analysis of V-ATPase expression in 
3D was also attempted, however, quantification of V-ATPase expression levels was 
not possible due to problems encountered with the antibody. Nonetheless, the 
preliminary experiments presented similar results to the 2D expression analysis, with 
no obvious difference in V-ATPase protein expression observed in the different areas 
of the spheroids analysed (figures 26 and 28). The observations were in line with the 
expected results, as little work has been published to date associating hypoxia or HIF 
to changes in V-ATPase expression levels.  
 
Studies suggest that V-ATPase subunit composition controls the targeting of V-
ATPase to different cellular compartments, with both the ATP6V0A3 and 
ATP6V0A4 subunits connected to the targeting of V-ATPase to the plasma 
membrane of breast cancer cells [400]. mRNA analysis indicated that there was no 
change in the expression levels of the ATP6V0A3 subunit in hypoxia in any of the 
cell lines (figure 25F). However, significantly increased levels of the ATP6V0A4 
subunit were detected in the chronically hypoxic MDA-MB-231 cells (figure 25G). 
These results suggest that hypoxia may increase the levels of V-ATPase targeted to 
the cell surface within the MDA-MB-231 cell line, where it could contribute to the 
invasion of cells through the increased acidification of the extracellular 
microenvironment. This would help account for the increased capacity this cell line 
exhibits to migrate and invade in hypoxic conditions [426, 427]. Therefore, while no 
large changes in V-ATPase protein expression levels were observed in the differing 
O2 conditions, hypoxia may instead influence the localisation of V-ATPase 
complexes within the cell. Further work assessing the effects of hypoxia on 
ATP6V0A3 and ATP6V0A4 subunit expression and V-ATPase localisation is 
merited. 
 
Both CAIX and CAXII support cancer cell survival as a result of their function in 
controlling pH levels within the cells (section 1.15.2). Studies have revealed the 
contribution of CAIX to the control of pH within multicellular tumour spheroids, 
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with spheroids lacking CAIX protein shown to have increased levels of acidity at 
their core [428]. Knockdown of CAIX within a colon cancer cell line was also 
demonstrated to reduce Ki67 staining within the hypoxic areas of spheroids formed 
from this cell line [429]. IHC was performed assessing Ki67 and cleaved caspase 3 
staining within spheroids (figures 33–34) to investigate whether there was any 
association between the different expression patterns of both CAIX and CAXII 
observed between the cell lines, and proliferation and apoptosis. The normoxic and 
hypoxic areas of both MDA-MB-231 and HBL-100 spheroids exhibited similar 
levels of Ki67 (figure 32A). However, large differences were detected between cells 
present in the normoxic and hypoxic regions of MCF-7 spheroids, with significantly 
lower levels of proliferative cells present in the hypoxic areas of MCF-7 spheroids 
(figure 32A). The lower levels of CAIX protein present in the hypoxic areas of 
MCF-7 spheroids, combined with the down-regulation in CAXII protein observed, 
may have contributed to these results, as the hypoxic MCF-7 cells may have been 
less able to control their pH compared to the cells present within the hypoxic areas of 
the MDA-MB-231 and HBL-100 spheroids, which exhibited high expression levels 
of CAIX.  
 
IHC staining assessing cleaved caspase 3 staining indicated that cells within the 
hypoxic areas of both the MCF-7 and HBL-100 spheroids were undergoing 
significantly increased levels of apoptosis compared to the normoxic cells (figure 
32B). However, the observation of cleaved caspase 3 staining within MCF-7 
spheroids was abnormal, as it has previously been reported that the MCF-7 cell line 
does not express caspase 3 [430-432]. With these studies in mind, tests should have 
been performed prior to the IHC experiments to ensure the specificity of the 
antibodies used. Additionally, to prevent any potential inaccuracies with the 
thresholding of staining, and to improve the validity of the IHC analysis performed, 
the image analysis conducted should have also been carried out by a second 
investigator blinded to the initial work.  
 
SRB assays were performed to compare the effects of inhibitors targeting the 
tumour-associated carbonic anhydrases (figures 35–37), NHE1 (figures 38–40) and 
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V-ATPase (figures 41–43) on aerobic, acute hypoxic and chronic hypoxic cancer cell 
number. Targeting each of the pH regulating proteins led to a reduction in cancer cell 
number, in agreement with previous studies [310, 355, 393-397]. However, culturing 
conditions had an unexpected effect on the response of the cancer cells to DMA and 
S4, with the acute hypoxic cells exhibiting increased resistance to drug treatment. 
While no increase in NHE1 protein expression levels were observed in any of the 
cell lines cultured in acute hypoxic conditions in 2D, the higher CAIX expression 
levels observed in low O2 conditions were expected to lead to an increased 
sensitivity to S4 treatment, as the raised expression levels might have meant an 
increased dependency on this protein for the control of pH within the cell. In addition 
to stimulating CAIX expression, hypoxia has also been shown to lead to the 
increased activity of both CAIX and NHE1 (section 1.16). Therefore, it is possible 
that increased CAIX protein expression, in addition to the increased activity of CAIX 
and NHE1, may actually contribute to the increased resistance of the acute hypoxic 
cells to drug treatment, meaning that higher concentrations of inhibitors are required 
to exert an effect on these cells.  
 
Both MCF-7 and MDA-MB-231 cell lines were sensitive to S4 treatment in aerobic 
conditions. The observation of high levels of CAXII mRNA in the aerobic MCF-7 
cells in 2D cell culture, in addition to the plasma membrane CAXII observed in cells 
within the normoxic regions of MCF-7 spheroids, may help explain the sensitivity of 
these cells to S4 in high O2 conditions. However, this pattern of CAXII expression 
was not observed within the MDA-MB-231 cell line present in 20% O2 conditions. 
Previous studies have shown that over-confluence can lead to CAIX expression in 
cells [242, 433]. Therefore, it is possible that the effects of S4 observed on MDA-
MB-231 cancer cell number were due to the over-confluence of cells within the 
wells. As a result of the observation of similar levels of NHE1 protein expression in 
each of the cell lines in aerobic conditions in 2D cell culture, the reduction in cancer 
cell number observed with DMA in 20% O2 was not surprising.  
 
In contrast to the acute hypoxic cancer cells, the response of chronic hypoxic cancer 
cells to S4 and DMA treatment was more similar to that seen in the aerobic cells, 
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suggesting that the chronic hypoxic cells had re-sensitised to drug treatment. The S4 
results were again unexpected, taking into account the response of acute hypoxic 
cells to this agent, as the chronic hypoxic cells also had much increased levels of 
CAIX compared to the aerobic cells. The chronic hypoxic cells had been cultured in 
0.5% O2 conditions for 20 weeks before treatment. The presence of the cells in such 
harsh culturing conditions for an extended period of time may have meant that the 
cells were more sensitive to both carbonic anhydrase and NHE1 inhibition.  
 
In comparison to the results presented with the carbonic anhydrase and NHE1 
inhibitors, the response observed with the V-ATPase inhibitor bafilomycin A1 was 
similar between each of the cell lines, with no noticeable change in the SRB results 
in either the acute or chronic hypoxic cells. V-ATPase inhibition was seen to have 
more potent effects on cancer cell number compared to the other inhibitors, with low 
nM concentrations required to reduce cell number by over 50% in each of the cell 
lines. The low IC50 values obtained for V-ATPase possibly reflect the diverse roles 
played by V-ATPase in the cell that are critical for cell function [239]. While the 
effects of the carbonic anhydrase and NHE1 inhibitors on cancer cell number were 
observed after only 24h treatment, the effects of bafilomycin A1 were delayed, with 
reductions in cell number only seen after 48 and 72h of treatment. One mechanism 
through which V-ATPase inhibition is thought to affect cancer cells is through the 
induction of apoptosis [395, 396, 434, 435], with the damage of cellular 
mitochondria [395, 396], or the increases in lysosomal pH leading to lysosomal 
dysfunction [435], possibly contributing to cell death. The induction of apoptosis 
within these studies was only detected 48 or 72h after Bafilomycin A1 addition [396, 
434], perhaps explaining why a reduction in cell number was only observed after 48h 
treatment in each of the cell lines used in this study.  
 
Many of the processes underlying tumour cell migration and invasion are dependent 
on pH (see section 1.13.1), with each of the pH regulating proteins analysed within 
this study linked to invasion. 3D collagen invasion assays were conducted with both 
MDA-MB-231 and HBL-100 spheroids to compare the abilities of S4, DMA and 
bafilomycin A1 to affect cancer cell invasion. To test the hypothesis that cells 
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present in hypoxic conditions would be more sensitive to the effects of drug 
treatment, due to increased target protein expression/activity, these experiments were 
carried out with spheroids cultured in either 20% O2 or 0.5% O2 conditions. 
However, IHC analysis of the collagen-embedded HBL-100 spheroids cultured in 
20% O2 conditions showed CAIX staining in the cells at the outer rim of the 
spheroids (figure 45), rather than in the central hypoxic regions alone, as observed in 
the previous expression analysis conducted with spheroids of this cell line (figure 
28). The collagen used in the experiments may have inhibited O2 from reaching the 
cells at the edges of the spheroid. Therefore, while these experiments were carried 
out with spheroids cultured in 20% and 0.5% O2 conditions, it is possible that all of 
the cells within the spheroids cultured in the differing O2 concentrations were 
hypoxic. 
 
S4 was shown to reduce the % of invading cells from MDA-MB-231 spheroids 
present in both aerobic and hypoxic conditions (figure 44). Other studies, testing the 
effects of S4 on the MDA-MB-231 cell line, have also produced similar results, 
displaying the inhibitory effects of S4 treatment on the 2D migration [310] and 3D 
invasion [355], with S4 shown to retain its anti-metastatic effects in vivo [310]. In 
contrast, the spheroids treated with DMA and bafilomycin A1 did not exhibit any 
reduction in cancer cell invasion (figure 44). In fact, an increase in invasion was 
observed at certain concentrations for both of these inhibitors. Previous studies have 
already exhibited the anti-invasive effects resulting from the inhibition of both NHE1 
[373, 398, 399] and V-ATPase [260, 335, 400]; therefore, the increases in invasion 
observed were surprising. However, because these results are only from one 
independent experiment with a number of technical replicates, repeat experiments 
are required testing the effects of these inhibitors on cancer cell invasion.   
 
In retrospect, the presence of additional experimental controls in both the SRB and 
3D invasion assays were required. Positive controls that are known to reduce cancer 
cell number, as well as the use of inhibitors that have been proven to reduce the 
invasion of cancer cells, would have increased confidence in the accuracy and 
validity of the results obtained from these experiments. Additionally, the passage 
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window of the cells used in some of the experiments was beyond that which is 
recommended [436]. New stocks of cells should have been obtained after 10 
passages to prevent any changes that can result from the subculturing of cells [437]. 
 
The induction of apoptosis is one mechanism through which radiotherapy achieves 
its therapeutic effect [406]. Because acidic pHi is thought to have a permissive role 
in the induction of apoptosis [280], we hypothesised that the treatment of cancer cells 
post-irradiation with agents that target the pH regulating proteins of cancer cells 
would lead to increased levels of apoptosis within these cells, thereby sensitising 
them to irradiation. 3D clonogenic assays were conducted with MDA-MB-231 
spheroids to directly compare the effects of S4, DMA and bafilomycin A1, and their 
potential to combine effectively with irradiation (figure 46). FC9403A, another novel 
carbonic anhydrase inhibitor synthesised by Fabrizio Carta of the University of 
Florence, was also used in these studies (figure 46). The spheroids in these 
experiments were irradiated with 0.5 Gy, dissociated, and then plated with or without 
the presence of drug. The results of these experiments suggested that both FC9403A 
and DMA have the potential to combine with irradiation, with a combination of drug 
and 0.5 Gy leading to a significant reduction in the survival fraction of MDA-MB-
231 cells when compared against either treatment alone. There are different methods 
available to analyse and study the effects of combining therapies, assessing whether 
the combinatorial effects are additive, synergistic, or antagonistic (reviewed in [438] 
and [439]). Further work is required to investigate which combinatorial effects were 
observed.  
 
While these experiments did present some positive results with two of the inhibitors 
tested, there were a number of issues with the experimental design. The plating 
efficiency of the control cells used in these experiments was much lower than that 
reported for other cancer cell lines [440]. The method of spheroid dissociation used 
(through repeated syringing) likely contributed to this, and any repeat experiments 
should use other methods, apart from mechanical dissociation, that have previously 
been employed in other studies [441-443]. Additionally, the cells were left for 7 days 
after irradiation before fixation. Even though this amount of time was sufficient for 
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colonies of 50 cells to form, longer periods of incubation before fixation would have 
been more appropriate [444], to ensure all cells who had the potential to form 
colonies were counted. Furthermore, while 0.5 Gy was used in the experiments 
conducted here, supplementary experiments should also test the effects of combining 
more clinically relevant doses of irradiation (such as 2 Gy) with each of the 
inhibitors. Lastly, experiments assessing a different sequence of treatments would 
also be beneficial. For the clonogenic assays conducted, the spheroids were first 
irradiated, and then treated with the different inhibitors after the cells were plated. 
While this sequence of treatments has been performed before, and shown the 
radiosensitisation effects of inhibiting V-ATPase [405], additional experiments 
performing drug treatment before irradiation, such as that carried out in other studies 
[320, 403], would also be beneficial.  
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4 Chapter 4: Further investigation of CAIX expression in 2D 




CAIX expression is induced by HIF-1α [132, 242]. However, despite the presence of 
similar levels of HIF-1α in each of the cancer cell lines cultured in the lower O2 
concentrations, CAIX protein expression levels were higher in the hypoxic MDA-
MB-231 and HBL-100 cell lines compared to the MCF-7 cell line, which only 
exhibited a significant increase in CAIX protein expression levels under more severe 
hypoxic conditions (section 3.2.1). The 2D mRNA (figure 23) and 3D protein 
(section 3.2.2) expression analysis illustrated similar results.   
 
This chapter details further expression analysis carried out in the 3 cancer cell lines 
that was performed to investigate why, despite the presence of similar levels of HIF-
1α, CAIX expression differed between the cell lines. For HIF-1α to have an effect on 
gene expression, it must be present in the nucleus of the cells, where it can bind to 
HREs and induce the expression of target genes. Experiments conducted in Chapter 
3 analysed HIF-1α levels in whole-cell lysates produced from the 3 breast cancer cell 
lines. While these experiments measured total cellular HIF-1α expression, they did 
not give an indication of the levels of transcriptionally active HIF-1α present within 
the nucleus of the cells. Therefore, to assess nuclear levels of HIF-1α, and to relate 
these levels to the quantities of CAIX, expression analysis was conducted in 2D 
using nuclear and cytoplasmic lysates acquired from each of the cancer cell lines 
cultured in either aerobic or hypoxic conditions. To further examine the relationship 
between HIF-1α and CAIX expression, additional work was also carried out 
evaluating the levels of both HIF-1α and CAIX in aerobic cancer cells treated with 
cobalt chloride (CoCl2), a chemical that prevents the proteasomal degradation of the 
HIF-α subunits in high O2 concentrations by occupying the VHL-binding domain 
[445].  
 
While PHD proteins have a major role to play in the regulation of HIF-1α signalling, 
through controlling the degradation of HIF-1α (see section 1.8.2), FIH-1 is another 
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protein present in cells that inhibits HIF-1α signalling by hydroxylating the C-TAD 
of HIF-1α, thus impeding the binding of the transcriptional co-activators p300/CBP 
[130, 133]. Although PHD proteins are inactivated in low O2 concentrations, studies 
have shown that FIH-1 retains it’s activity in hypoxia [132], with more severe 
hypoxic conditions leading to the inactivation of FIH-1 [131]. Further work shown in 
this chapter presents the results from experiments conducted with siRNA targeting 
FIH-1, which was used to investigate whether increased levels or activity of FIH-1 
were responsible for the low CAIX expression levels observed in acute hypoxic 
MCF-7 cells.  
 
Other methods of FIH-1 inactivation, apart from inhibition due to more severe 
hypoxic conditions, have also been demonstrated. Mint3 has been shown to bind 
FIH-1, preventing FIH-1 from hydroxylating the C-TAD of HIF-1α, thus enhancing 
HIF-1α activity [446]. Membrane type-1 matrix metalloproteinase (MMP14), a 
protease present in the plasma membrane of cells which promotes invasion [447], 
has been linked to this inhibition of FIH-1, as studies have shown that MMP14 
mediates the binding of FIH-1 to Mint3 [448] (figure 47). MMP14 is produced in 
cells in a latent form (60 kDa) that requires activation (reviewed in [449]). Cleavage 
of the latent form takes place in the Golgi network through the action of a protease 
called Furin, a protein that has the ability to also bind Mint3 [450]. Furin cleaves 
latent MMP14, leading to the production of active MMP14 (57 kDa), which is 
transported to the plasma membrane (reviewed in [449]). It is during the process of 
latent MMP14 cleavage by Furin that MMP14 is thought to bring FIH-1 and Mint3 
together, leading to the suppression of FIH-1 activity [448]. Further processing of 
MMP14 can also occur. Auto-catalytic cleavage of active MMP14 present on the 
plasma membrane of cells can take place, leading to the generation of an inactive 
membrane tethered 44 kDa protein and a soluble 18 kDa inactive fragment (reviewed 






Figure 47. The proposed role of MMP14 in the inactivation of FIH-1.  
Latent MMP14 is cleaved by Furin, leading to the binding of FIH-1 and Mint3, and the 
suppression of FIH-1 activity. Image adapted from [448].  
 
 
Various studies have shown that both MDA-MB-231 [451, 452] and HBL-100 [453] 
cells express MMP14, while MCF-7 cells do not [451-453], with MMP14 expression 
shown to be modulated by HIF-2α [454]. To investigate whether the differential 
expression of MMP14 may also be contributing to the CAIX expression results 
observed in Chapter 3, analysis of MMP14 expression within the 3 cancer cell lines 

















4.2  Results 
 
4.2.1 Analysis of nuclear and cytoplasmic lysate samples indicates 
that CAIX expression differs between the 3 cell lines despite 
the presence of similar levels of nuclear HIF-1α in aerobic and 
hypoxic conditions 
 
Nuclear and cytoplasmic lysates were acquired to assess the levels of HIF-1α and 
HIF-2α within the nuclei of MCF-7, MDA-MB-231 and HBL-100 cell lines, in 
addition to the protein levels of CAIX. These lysates were obtained from cells 
cultured in aerobic (24h in 20% O2), acute hypoxic (24-72h 0.5% O2) and chronic 
hypoxic (16 weeks in 0.5% O2) conditions.  
 
The results from the western blots assessing nuclear HIF-1α and HIF-2α levels were 
comparable to those seen in section 3.2.1. As in the whole-cell lysates, two bands 
were present for HIF-1α in each of the cancer cell lines cultured in both acute 
hypoxic and chronic hypoxic conditions, with increased band intensities observed in 
the lower O2 conditions (figure 48A). Large increases in HIF-2α proteins levels were 
again evident within the MDA-MB-231 and HBL-100 cell lines cultured in hypoxic 
conditions (figure 48A). Similar to the whole-cell lysates analysed in section 3.2.1, 
CAIX expression within both the MDA-MB-231 and HBL-100 cell lines was more 
responsive to hypoxic induction compared to the MCF-7 cells, which exhibited the 
lowest levels of CAIX out of the 3 cell lines (figure 48A and B). Chronic hypoxic 
MCF-7 cells again displayed an increase in CAIX levels compared to the aerobic 
cells. However, in this experiment there were also significantly increased levels of 
CAIX protein evident within 48h and 72h acute hypoxic MCF-7 cells, in addition to 
the chronic hypoxic MCF-7 cells (figure 48A and B).  
 
While quantification of CAIX protein levels was performed in the cytoplasmic 
lysates obtained from the 3 cell lines, this same analysis was not possible for either 
HIF-1α or HIF-2α due to problems encountered with expression of the loading 
controls. As the duration of hypoxic incubation increased, the levels of the nuclear 
loading control proteins Lamin B1 and TATA seemed to decrease, a problem that 
was not observed with the cytoplasmic loading control β-Actin (figure 48A). This 
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was especially noticeable within the HBL-100 cell line (figure 48C). This reduction 
in loading control levels at the later time points meant that the protein levels of HIF-
1α and HIF-2α could not be accurately quantified.  
 
Experiments were conducted to investigate why the levels of the nuclear loading 
controls were reduced in the hypoxic conditions (figure 48D). It was reasoned that 
there were two likely explanations for the drop in loading control levels; (i) either the 
slower proliferation rate of the hypoxic cells was leading to less cells being present at 
the time of lysate acquisition, and this was affecting the nuclear loading levels, or (ii) 
the expression levels of both Lamin B1 and TATA were being affected by the 
incubation of the cells in hypoxic conditions. To investigate this, additional nuclear 
lysates of HBL-100 cells cultured in 20% O2 and 0.5% O2 were obtained. The HBL-
100 cell line was chosen for this analysis, as the presence of reduced levels of 
loading control in hypoxic conditions was the most obvious within this cell line. Two 
of the samples were produced as before, without counting of either the aerobic or 
hypoxic cells before lysate acquisition. In the other two samples cultured in the same 
conditions, the cells were counted before lysate acquisition to ensure the same 
number of cells were present. As can be seen in figure 48D, equal cell number at the 
time of lysate acquisition led to nuclear loading control levels of similar intensity in 
cells cultured in both 20% O2 and 0.5% O2 conditions. However, when the same 
numbers of cells were not present at the time of lysate acquisition, the levels of 
loading control were reduced in the cells cultured in hypoxic conditions. As a 
consequence of these results, cell numbers were counted prior to lysates acquisition 
in future experiments involving nuclear lysates in an effort to produce samples with 







Figure 48. CAIX protein expression differs between the 3 cell lines cultured in 
hypoxic conditions, despite the presence of similar levels of HIF-1α within the 
nuclei of the cells.  
(A) Nuclear and cytoplasmic proteins were extracted from aerobic cells and acute hypoxic 
cells that had been cultured in 0.5% O2 conditions for 24, 48 and 72h, in addition to cells 
that had spent 16 weeks in 0.5% O2 conditions (Chr). Western blotting was performed to 
detect the nuclear levels of HIF-1α and HIF-2α, along with the cytoplasmic levels of CAIX. 
Lamin B1, TATA and β-Actin were used as the loading controls. (B) Densitometry 
measurements of CAIX levels. Data expressed as mean ± SEM (n = 3). * P ≤ 0.05, ** P ≤ 
0.01, *** P ≤ 0.001, **** P ≤ 0.0001 (One-way ANOVA followed by Dunnett’s multiple 
comparison test performed, comparing each sample to the 20% O2 group). (C) Western 
blotting performed to detect the levels of Lamin B1 and TATA in nuclear lysates acquired 
from HBL-100 cells cultured in differing O2 conditions. (D) Nuclear lysates acquired from 
HBL-100 cells cultured for 72h in either 20% or 0.5% O2 conditions. Samples in which the 
cells were counted to ensure equal cell numbers were present prior to lysate acquisition are 
labelled.  
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To further analyse the relationship between HIF-1α and CAIX in the 3 cell lines, 
additional experiments were carried out assessing their protein and mRNA levels in 
aerobic cells treated with CoCl2, a chemical that prevents the proteasomal 
degradation of HIF-1α in high O2 concentrations. Untreated cells present in 20% O2 
conditions were used as controls. An analysis of HIF-2α levels within CoCl2-treated 
cells was also carried out.   
 
Two bands were again identified for HIF-1α in each of the aerobic cancer cell lines 
treated with CoCl2 (figure 49A-C). Out of all the time points analysed, the largest 
amount of stabilised HIF-1α was detected in the 5h CoCl2-treated cells (figure 49A-
C). A large significant increase in the levels of both HIF-1α bands was seen at this 
time point in each of the cell lines, with decreased HIF-1α protein levels observed at 
the later time points. The stabilisation of HIF-2α due to CoCl2 treatment was not as 
apparent as that observed for HIF-1α, with only small increases in the levels of HIF-
2α detected in the CoCl2-treated MDA-MB-231 and HBL-100 cells (figure 49A). 
Differing results were observed in the mRNA analysis performed. While no 
significant changes were detected in the mRNA levels of HIF-1α after CoCl2 
addition in any of the cell lines (figure 49E), CoCl2 treatment led to significantly 
increased levels of HIF-2α in the MDA-MB-231 and HBL-100 cell lines (figure 
49F).  
 
Induction of CAIX protein expression was evident in both MDA-MB-231 and HBL-
100 cells treated with CoCl2 (figure 49A and D). HBL-100 cells exhibited higher 
CAIX protein expression levels out of the two cell lines, and were the only cell line 
to show an induction of CAIX mRNA levels after CoCl2 treatment (figure 49G). 
Despite the presence of similar levels of HIF-1α in the CoCl2-treated MCF-7 cells 
compared to the other cell lines, no CAIX band was visible in the CoCl2-treated 





Figure 49. HIF-1α stabilisation due to CoCl2 treatment leads to differing CAIX 
expression between the cell lines.  
The protein (A-D) and mRNA (E-G) expression levels of HIF-1α, HIF-2α and CAIX in 
aerobic cancer cells treated with 400 µM CoCl2 for the indicated time points, with un-treated 
aerobic cells cultured in 20% O2 conditions acting as the controls. (A) Western blots 
performed assessing the protein expression levels of HIF-1α, HIF-2α and CAIX. (B-D) 
Densitometry measurements of the upper (B) and lower (C) HIF-1α bands, in addition to 
CAIX (D). Data expressed as mean ± SEM (n = 5 for the nuclear control, 24/48/72h MCF-7 
and MDA-MB-231 lysates. n = 4 for the nuclear control, 24/48/72h HBL-100 lysates. n = 2 
for the 5h CoCl2 nuclear lysates. n = 3 for the 5h CoCl2 cytoplasmic lysates). * P ≤ 0.05, ** 
P ≤ 0.01, *** P ≤ 0.001, **** P ≤ 0.0001 (One-way ANOVA followed by Dunnett’s multiple 
comparison test performed, comparing each sample to control group). (E-G) mRNA levels of 
HIF-1α (E), HIF-2α (F) and CAIX (G). Data expressed as mean ± SEM (n=3). ** P ≤ 0.01, 
**** P ≤ 0.0001 (Unpaired t-test, comparing each CoCl2 sample to the 20% O2 group within 
each cell line). 
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4.2.2 2D expression analysis indicates that the protein expression of 
FIH-1 and MMP14 varies between the 3 cell lines 
 
The protein and mRNA expression analysis conducted so far has shown that CAIX 
expression differs between the 3 cell lines, with hypoxic and CoCl2-treated MCF-7 
cells expressing much lower levels of CAIX in comparison to the two other cell 
lines. The observation of similar levels of nuclear HIF-1α in each of the 3 cancer cell 
lines indicated that this variation in CAIX expression was not due to any disparity in 
HIF-1α levels. Further analysis was conducted, assessing the protein expression 
levels of FIH-1 and MMP14 in each of the cancer cell lines, to investigate whether 
the differential expression of these proteins might explain the variation in CAIX 
expression observed (figure 50). Protein expression levels were analysed in cells 
cultured in aerobic (24h in 20% O2), acute hypoxic (24-72h in 0.5% O2) and chronic 
hypoxic (16 weeks in 0.5% O2) conditions. An antibody targeting the extracellular 
domain of MMP14, which is released after autocatalysis of the active plasma 
membrane MMP14 as a soluble 18 kDa protein, was used to identify the presence of 
MMP14 in the western blots performed.  
 
FIH-1 protein was detected in each of the 3 cancer cell lines (figure 50A). The 
culturing of cells in hypoxic conditions did not lead to any changes in the levels of 
FIH-1 (figure 50C). Out of the 3 cell lines, MCF-7 cells exhibited the highest 
expression levels of FIH-1 (figure 50C). Greater variation in MMP14 protein 
expression was observed between the 3 cancer cell lines (figure 50B). Both latent (60 
kDa) and active (57 kDa) MMP14 were observed in MDA-MB-231 and HBL-100 
cells cultured in aerobic and hypoxic conditions (figure 50B). Culture conditions had 
no significant effect on MMP14 expression within these two cell lines, although 
HBL-100 cells were seen to have increased amounts of the active 57 kDa MMP14 
compared to MDA-MB-231 cells (figure 50D). Neither the latent (60 kDa) nor the 
active form (57 kDa) of MMP14 protein was detected within the MCF-7 cells (figure 
50B). The mRNA analysis showed small significant changes in FIH-1 mRNA levels 
within the different culture conditions in both MCF-7 and MDA-MB-231 cells 
(figure 50E). MMP14 mRNA expression levels were constant in all 3 cell lines in the 
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differing conditions, with MCF-7 cells exhibiting comparable levels of MMP14 
mRNA to the other two cell lines (figure 50F). 
 
The mRNA analysis (figure 50F) showed that the absence of MMP14 protein (figure 
50B) in MCF-7 cells was not due to a lack of gene transcription within these cells. A 
possible explanation for the lack of MMP14 protein detection within the western blot 
analysis, despite the presence of MMP14 mRNA within the cells, could be that the 
MMP14 mRNA present within MCF-7 cells is not translated into protein. However, 
the antibody used in the western blots binds to the extracellular portion of the 
MMP14 protein. This part of the protein is released after autocatalysis of MMP14, 
and would not be collected in the lysates used in this analysis. Therefore, the 
possibility that MCF-7 cells were expressing MMP14, but that this MMP14 was not 
detected with the antibody used, cannot be excluded.  
 
The results presented thus far suggest a possible hypothesis to explain the lower 
CAIX expression levels observed within the acute hypoxic and CoCl2-treated MCF-7 
cells in comparison to the 2 other cell lines cultured in the same conditions. A 
combination of high FIH-1 protein levels in the MCF-7 cell line, combined with the 
lack of any MMP14 protein detected in the westerns performed, could be leading to 
higher levels of active FIH-1 in the MCF-7 cells. The greater levels of active FIH-1 
in the MCF-7 cell line could be causing the increased hydroxylation of the HIF-1α 
C-TAD in these cells, thus inhibiting the binding of the co-activator p300/CBP to 
HIF-1α. Only partial HIF signalling would occur in these cells, thereby giving rise to 
lower levels of CAIX expression in the CoCl2-treated and acute hypoxic MCF-7 
cells. In contrast, MDA-MB-231 and HBL-100 cells displayed lower levels of FIH-1 
protein in comparison to the MCF-7 cells, with the existence of MMP14 protein also 
detected in the western blots performed. The presence of MMP14 may be leading to 
the inhibition the FIH-1 within these 2 cell lines, enabling the binding of p300/CBP 
to the stabilised HIF-1α in the acute hypoxic and CoCl2-treated cells, resulting in full 






Figure 50. Western Blots indicate that MMP14 protein expression differs 
between the 3 cell lines despite the presence of similar levels of MMP14 mRNA. 
FIH-1 protein expression is unchanged across the different O2 conditions.  
(A-D) Cytoplasmic proteins were extracted from the 3 cell lines cultured in in either aerobic 
or acute hypoxic conditions at the indicated time points, with cytoplasmic lysates also 
acquired from cells that had spent 16 weeks in 0.5% O2 conditions (Chr). Western blotting 
was performed to detect FIH-1 (A, lower band) and MMP14 (B), with α-Tubulin acting as a 
loading control. Densitometry measurements of FIH-1 (C) and MMP14 (D) protein 
expression levels are also shown. (E-F) FIH-1 (E) and MMP14 (F) mRNA levels in cells 
cultured in 20% O2 (cont), 0.5% O2 for 24h (AH) and 0.5% O2 for 10 weeks (CH). mRNA 
levels were also analysed in aerobic cells treated with 400 µM CoCl2 for 24h. Data 
expressed as mean ± SEM (n = 3). * P ≤ 0.05, ** P ≤ 0.01 (One-way ANOVA followed by 
Dunnett’s multiple comparison test, comparing each sample to the 20% O2 group within the 




4.2.3 FIH-1 contributes to the low levels of CAIX observed within 
the MCF-7 cell line 
 
Experiments conducted in section 4.2.2 suggested that increased levels of active 
FIH-1 might have been the cause of the low CAIX expression levels seen within the 
acute hypoxic MCF-7 cells (see sections 3.2.1 and 4.2.1). siRNA targeting FIH-1 
was used to investigate whether this was the case. MCF-7 cells were cultured in 
0.5% O2 conditions for 24h prior to siRNA addition, and were treated with either 
single siRNAs targeting FIH-1 (19-22), or a mixture of 4 siRNAs (pool). MCF-7 
cells cultured in 0.5% O2 conditions and treated with transfection reagent alone 
(mock) acted as the control in these initial experiments.  
 
Each concentration of the pool of siRNAs tested led to a reduction in the levels of 
FIH-1 protein (bottom band) within the acute hypoxic MCF-7 cells compared to the 
mock control sample (figure 51A). The single siRNA 21 caused the largest reduction 
in FIH-1 protein levels of the 4 single siRNAs tested. A corresponding increase in 
CAIX protein levels was observed within the samples that exhibited the largest 
decrease in FIH-1 protein levels, with increased CAIX protein expression observed 
in the cells treated with the pool of siRNA and siRNA 21 (figure 51A). 
 
Repeat experiments were performed to confirm these results (figure 51B). MCF-7 
cells were again cultured in 0.5% O2 conditions for 24h prior to treatment with either 
a pool of siRNAs at a concentration of 50 nM, or a single siRNA (21) at the same 
concentration. Hypoxic MCF-7 cells treated with scrambled siRNA (scrambled) and 
cells treated with transfection reagent alone (mock) acted as the controls, in addition 
to acute hypoxic MCF-7 cells that received no treatment (control). Both the pool and 
the single siRNA targeting FIH-1 reduced FIH-1 protein expression levels within the 
acute hypoxic MCF-7 cells compared to each of the controls (figures 51B and C). 
The CAIX protein expression levels within the pool and single siRNA-treated 






Previous work showed that HIF-1α stabilisation as a result of CoCl2 treatment did 
not lead to CAIX expression within MCF-7 cells, whereas CAIX protein expression 
was observed in both the MDA-MB-231 and HBL-100 cell lines (figure 49). siRNA 
targeting FIH-1 was used to investigate whether reducing the levels of FIH-1 in 
CoCl2-treated MCF-7 cells led to CAIX expression within this cell line (figure 51E-
G). MCF-7 cells cultured in 20% O2 conditions were treated with a pool of siRNAs, 
with CoCl2 added 48h after the initial siRNA treatment. The duration of CoCl2 
treatment ranged from 24-72h. Aerobic MCF-7 cells that received siRNA alone, in 
addition to un-treated MCF-7 cells cultured in 20% O2 conditions, acted as the 
controls. 
 
Both the aerobic MCF-7 cells that received siRNA alone, and the cells that were 
given a combination of siRNA and CoCl2, exhibited decreased FIH-1 protein levels 
in comparison to the control cells (figure 51E and F). While no increase in CAIX 
protein levels was observed within the cells that were treated with siRNA alone, a 
strong induction of CAIX protein expression was observed within MCF-7 cells that 
received a combination of both siRNA and CoCl2, with the highest intensity CAIX 
protein bands observed after 48h and 72h CoCl2 treatment (figure 51E and G).  
 
Weak CAIX expression was also observed within the un-treated cells (figure 51E 
and G). Transfection of siRNA into cells causes a small amount of cell death. To 
counteract this effect, and to ensure that an adequate number of cells were present at 
the time of lysate acquisition, high numbers of cells were seeded per well. The same 
numbers of cells were seeded per well for each of the different treatments within this 
experiment. While this cell seeding number led to sufficient cell numbers in the wells 
that received siRNA, the control wells, which did not receive any transfection 
reagent, had too many cells at the time of lysate acquisition and were over-confluent. 
Previous studies have shown that over-confluence can lead to CAIX expression in 
cells [242, 455]. The presence of too many cells within the control wells may explain 






Figure 51. siRNA targeting FIH-1 leads to increased CAIX expression in 
hypoxic and CoCl2-treated MCF-7 cells. 
(A) MCF-7 cells cultured in 0.5% O2 conditions for 24h were treated with either a mixture of 
4 siRNAs targeting FIH-1 (pool), or individual siRNAs targeting FIH-1 (19, 20, 20 and 22. 
50nM concentration used). Cells treated with transfection reagent alone (mock) acted as the 
control. Cytoplasmic lysates were acquired 120h after the initial siRNA treatment, and 
western blots were performed to assess the protein expression of FIH-1 (lower band) and 
CAIX. α-Tubulin and β-Actin acted as the loading controls. (B) Repeat of the experiment 
conducted in (A), with the addition of hypoxic MCF-7 cells that received scrambled siRNA 
(50 nM), along with the presence of an un-treated hypoxic control. (C-D) Densitometry 
measurements of the FIH-1 (C) and CAIX (D) bands shown in (B). (E) MCF-7 cells cultured 
in 20% O2 conditions were treated with a mixture of 4 siRNAs targeting FIH-1 (pool, 50nM 
concentration used) and 400 µM CoCl2. Aerobic MCF-7 cells that did not receive either 
siRNA or CoCl2 (cont), and cells that were treated with siRNA alone (pool), acted as the 
controls. Western blots assessed the expression of FIH-1 and CAIX in cytoplasmic lysates 
acquired. α-Tubulin and β-Actin acted as the loading controls. (F-G) Densitometry 
measurements of the FIH-1 (F) and CAIX (G) bands shown in (E).  
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4.2.4 3D expression analysis indicates that each of the cancer cell 
lines may produce MMP14, but that the processing of this 
protein may differ between the cell lines 
 
The 2D expression analysis presented above showed that the 3 cancer cell lines 
expressed comparable levels of FIH-1, with both FIH-1 protein and mRNA detected 
within each of the cancer cell lines. However, MMP14 expression differed. While 
similar levels of MMP14 mRNA were seen in each of the cell lines, no MMP14 
protein was observed within the MCF-7 cells cultured in 2D (see section 4.2.2). 
Further analysis was conducted in 3D, investigating MMP14 and FIH-1 protein 
expression within spheroids of each of the cancer cell lines (figure 52). The same 
MMP14 antibody used in the 2D analysis, which binds to the extracellular portion of 
the MMP14 protein that is released after autocatalysis, was used to analyse MMP14 
expression in 3D. Quantitative analysis of protein expression was carried out using 
Definiens Architect XD 64 Tissue Studio 4.1 (figure 53A and B). 
 
As in the 2D analysis, MMP14 protein expression again differed between the 3 
cancer cell lines. Plasma membrane expression of MMP14 was detected within both 
MDA-MB-231 and HBL-100 spheroids (figure 52). The pattern of expression 
differed slightly between the two cell lines, with a lower % of MDA-MB-231 cells 
exhibiting plasma membrane staining compared to the HBL-100 cells, which also 
exhibited an increased intensity of staining (figure 53B). The analysis with the 
Definiens software indicated that hypoxia may have caused a slight induction in 
MMP14 expression within the HBL-100 spheroids, with a greater percentage of cells 
within the hypoxic areas of these spheroids labelled as having a high intensity of 
MMP14 staining (figure 53B). 
 
MMP14 protein expression was also detected within the MCF-7 spheroids. However, 
in contrast to both the MDA-MB-231 and HBL-100 spheroids, no plasma membrane 
MMP14 staining was detected within the MCF-7 spheroids (figure 52). The 
Definiens analysis indicated that the MCF-7 protein expression differed in the 
various regions of the MCF-7 spheroids, with significant increases in the intensity of 
staining observed in the hypoxic areas (figure 53A). These results show that, at least 
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when cultured in 3D, MCF-7 cells do express MMP14 protein. However, in contrast 
to MDA-MB-231 and HBL-100 spheroids, the MMP14 protein in cells within MCF-
7 spheroids may autocatalyse. This may have led to the formation of an inactive 
membrane-tethered protein, in addition to an 18 kDa soluble protein, which is 
perhaps the form being detected with the antibody used.  
 
Tissue inhibitor of metalloproteinases-2 (TIMP-2) is a protein that has been shown to 
regulate the autocatalysis of plasma membrane MMP14, with lower levels of TIMP-
2 linked to the increased degradation of MMP14 [456]. Analysis of the levels of 
TIMP-2 mRNA in each of the cell lines was carried out to see if the decreased 
expression of TIMP-2 within the MCF-7 cell line might explain the positive, non-
membranous staining detected within the MCF-7 spheroids, possibly present due to 
the autocatalysis of plasma membrane MMP14 within this cell line. However, 
similar levels of TIMP-2 mRNA were present in both the MCF-7 and HBL-100 cell 
lines (figure 53C). 
 
IHC assessing FIH-1 protein expression was also carried out in spheroids of each of 
the 3 cancer cell lines. As in the 2D expression analysis, FIH-1 protein was detected 
in all of the cell lines, with both nuclear and cytoplasmic localisation of FIH-1 
evident in each of the spheroids (figure 52). While an increased proportion of nuclear 
staining may have been present within the cells of MCF-7 and MDA-MB-231 
spheroids, the nuclear and cytoplasmic FIH-1 staining within HBL-100 spheroids 
appeared to be very similar. Attempts were made to quantify the nuclear and 
cytoplasmic staining of FIH-1 within the spheroids; however, this analysis was 













Figure 52. MMP14 and FIH-1 protein expression differ within spheroids of the 3 cancer cell lines. 
Hypoxyprobe, MMP14 and FIH-1 staining within spheroids of the 3 cell lines that were allowed to form for a week before fixation.  
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Figure 53. Definiens analysis indicates that MMP14 expression is induced in the 
hypoxic areas of MCF-7 and HBL-100 spheroids, while mRNA analysis shows 
the presence of similar levels of TIMP-2 mRNA in the 3 cell lines.   
Definiens analysis showing the levels of intracellular MMP14 within MCF-7 spheroids (A)  
and plasma membrane MMP14 staining within MDA-MB-231 and HBL-100 spheroids (B). 
The graphs on the left show the % of cells within the normoxic and hypoxic regions that 
exhibited MMP14 staining. The graphs in the centre show the % of cells within the normoxic 
and hypoxic areas that had low, medium, and high intensity levels of MMP14 staining. The 
graphs on the right show the average intensity of MMP14 staining detected within the 
normoxic and hypoxic areas of the spheroids. Data expressed as mean ± SEM (n = 3). 
*P≤0.05, **P≤0.01, ***P≤0.001 and ****P≤0.0001 (Unpaired t-tests performed). (C) 
TIMP-2 mRNA levels in cells cultured in 20% O2 (cont), 0.5% O2 for 24h (AH) and 0.5% O2 
for 10 weeks (CH). mRNA levels were also analysed in aerobic cells treated with 400 µM 
CoCl2 for 24h. Data expressed as mean ± SEM (n = 3). * P ≤ 0.05 (One-way ANOVA 
followed by Dunnett’s multiple comparison test, comparing each sample to the 20% O2 
group within the same cell line). 
 150 
The initial 2D expression analysis conducted on the whole-cell lysates showed that 
CAIX protein expression levels were increased in the chronic hypoxic MCF-7 cells 
in comparison to the acute hypoxic cancer cells (see section 3.2.1). More severe 
hypoxic conditions have been shown to inhibit FIH-1 activity [131], with the work 
presented in section 4.2.3 displaying the inhibitory role FIH-1 has on CAIX 
expression in hypoxic MCF-7 cells. Only small amounts of CAIX expression were 
observed within the hypoxic areas of MCF-7 spheroids that were allowed to form for 
1 week (figure 26). Further IHC was performed on MCF-7 spheroids cultured for 2 
and 3 weeks before fixation, to investigate whether longer periods of hypoxia might 
lead to higher CAIX expression levels within the hypoxic areas of these spheroids 
due to FIH-1 inhibition (figure 54). IHC analysis did not reveal any positive 
hypoxyprobe staining in the MCF-7 spheroids left for 2 or 3 weeks in spinner flasks 
before fixation, indicating that no hypoxic cells were present in these spheroids. No 
CAIX-positive cells were detected within these spheroids.  
 
Figure 54. MCF-7 spheroids cultured for 2 and 3 weeks do not exhibit 
hypoxyprobe or CAIX staining.   
Hypoxyprobe (H probe) and CAIX staining within MCF-7 spheroids that were allowed to 




The results from Chapter 3 showed that the level of CAIX expression varied 
markedly between the 3 cancer cell lines in differing O2 conditions, with MCF-7 
cells exhibiting the lowest induction of CAIX in hypoxia. The work presented in this 
chapter was performed to investigate why CAIX expression levels differed between 
the 3 cell lines.  
 
The control of the transport of transcription factors into the nucleus of cells is one 
mechanism through which cells can regulate transcriptional activity (reviewed in 
[457]). Studies have shown that both the HIF-1α and HIF-2α subunits interact with 
nuclear transport receptors [458], with the extent of nuclear localisation of HIF-1α 
after hypoxia demonstrated to be cell line dependent [459]. Therefore, a difference in 
the nucleocytoplasmic shuttling of HIF-1α between the cell lines was one possible 
mechanism to explain the differences in CAIX expression observed in Chapter 3. 
However, while this prior expression analysis displayed the levels of the total HIF-1α 
protein levels, it did not give an indication of the levels of HIF-1α present in the 
nucleus, which may have differed between the 3 cell lines, and possibly explained 
the differential CAIX expression observed. Initial experiments conducted in this 
Chapter assessed the nuclear levels of HIF-1α in cells cultured in 0.5% O2 
conditions, relating the levels of nuclear HIF-1α to CAIX expression (figure 48). 
This analysis was also performed with CoCl2-treated cells (figure 49). Comparable 
HIF-1α levels were observed in each of the nuclear lysates produced from the 3 cell 
lines when cultured in 0.5% O2 conditions. CoCl2 treatment also led to the detection 
of similar levels of nuclear HIF-1α in each of the cell lines. However, a pattern of 
CAIX expression similar to that already observed in Chapter 3 was seen here, with 
MCF-7 cells again exhibiting the lowest levels of CAIX out of the 3 cell lines. The 
results from these experiments indicated that the variation in CAIX expression 
observed between the cell lines was not due to differences in the nucleocytoplasmic 




Further analysis was conducted, assessing whether the expression of FIH-1 (a 
negative regulator of HIF-1α transcriptional activity [129, 130]) and MMP14 
(reported to inhibit FIH-1 activity [section 4.1.1]) were contributing to the varying 
CAIX expression between the 3 cell lines. The initial analysis conducted in 2D 
suggested that the differing CAIX expression may have been due to a lack of 
MMP14 protein in the MCF-7 cells (figure 50B), possibly contributing to increased 
levels of active FIH-1 in this cell line compared to the MDA-MB-231 and HBL-100 
cells, with the addition of siRNA to both hypoxic and CoCl2-treated MCF-7 cells 
leading to increased CAIX protein expression levels (figure 51). While the 2D 
expression analysis indicated that a lack of MMP14 protein in MCF-7 cells may have 
been contributing to increased levels of active FIH-1 in this cell line, the 3D 
expression analysis showed the presence of positive staining within the MCF-7 
spheroids, with non-plasma membrane staining detected within the MCF-7 spheroids 
(figure 52). In contrast to the 2D protein expression analysis conducted here (figure 
50B), and the results from other studies assessing MMP14 protein expression 
through Western Blots [451, 452], this positive staining detected in the 3D analysis 
indicated that MCF-7 cells may actually be producing MMP14 protein, but that the 
active 57 kDa MMP14 produced may autocatalyse, leading to the formation of a 
soluble form released from the MCF-7 cells that was detected in the spheroids, but 
not in the 2D analysis. Further experiments are required to investigate if soluble 
MMP14 is present in conditioned media, to confirm the expression of the MMP14 
protein in the MCF-7 cell line in 2D  
 
Sakamoto et al reported that MMP14 contributes to FIH-1 inhibition through 
mediating the binding of Mint3 to FIH-1, hypothesising that this inhibition occurs 
during the cleavage of latent MMP14 (60 kDa) into active MMP14 (57 kDa) [448] 
(figure 47). The detection of similar levels of MMP14 mRNA in MCF-7 cells 
compared to the other cell lines, in addition to the MMP14 staining detected within 
MCF-7 spheroids, indicates that MCF-7 cells may actually express MMP14 protein, 
and that this cleavage may occur in these cells too. If this is the case, and the 
mechanism of FIH-1 inhibition by MMP14 put forward by Sakamoto et al is correct, 
then MMP14 should contribute to the inhibition of FIH-1 in MCF-7 cells. Therefore, 
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MMP14 may not be the cause of the differing CAIX expression results observed 
between the 3 cell lines. Further experiments, possibly involving the reduction in 
MMP14 protein translation through the use of siRNA in each of the cell lines, are 
required to investigate what role MMP14 has in the expression of CAIX within these 
3 cell lines.  
 
If the staining within the MCF-7 spheroids is from detection of the soluble form of 
MMP14, released through autocatalysis of the plasma membrane form, then what 
processes are leading to higher rates of MMP14 autocatalysis within the MCF-7 cells 
compared to the other cell lines? Tissue inhibitor of metalloproteinases-2 (TIMP-2) 
is a protein that has been shown to regulate the degradation of active 57 kDa MMP14 
present on the plasma membranes of cells, with lower levels of TIMP-2 
demonstrated to lead to increased autocatalysis of the active MMP14 [456]. A prior 
study indicated that MCF-7 cells have low levels of TIMP-2 mRNA [460]. To 
investigate if low levels of TIMP-2 within MCF-7 cells may be the cause of the 
differential MMP14 expression results observed, mRNA analysis of the levels of 
TIMP-2 in each of the cell lines was performed. Similar levels of TIMP-2 were 
found within both the MCF-7 and HBL-100 cell lines (figure 53C), indicating that 
differences in the levels of TIMP-2 are unlikely to explain the variation in MMP14 
processing between the cell lines. Further experiments, assessing the protein 
expression levels of TIMP-2 in each of the cell lines, are required.  
 
Definiens analysis of MMP14 expression indicated that the staining intensity of the 
MMP14 antibody was significantly higher in the hypoxic areas of the MCF-7 and 
HBL-100 spheroids (figure 53A and B). Studies have indicated that MMP14 
expression can be regulated by hypoxia. A functional HIF-binding site has been 
identified in the proximal promoter of MMP14, with MMP14 gene expression 
controlled by HIF-2α [454], possibly explaining the increased levels of MMP14 
present detected in the hypoxic regions with the setting used.  
 
Varying localization of FIH-1 protein was evident between the spheroids of the cell 
lines. While high amounts of FIH-1 staining were observed within both the 
cytoplasm and nuclei of HBL-100 spheroids, an increased nuclear localization was 
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evident within the MCF-7 and MDA-MB-231 spheroids (figure 52). Previous studies 
have shown FIH-1 to have distinct subcellular localization patterns within breast 
cancer tissue, with FIH-1 expression found to be either exclusively nuclear, 
exclusively cytoplasmic, or both nuclear and cytoplasmic [461, 462]. The 3D CAIX 
expression analysis conducted in Chapter 3 showed MDA-MB-231 spheroids to have 
the highest CAIX expression levels out of the 3 cell lines. However, this increased 
CAIX expression in 3D may not be explained by the FIH-1 localisation staining 
presented here, as the study by Tan et al found nuclear FIH-1 expression to be 
inversely correlated with CAIX expression levels, with exclusive cytoplasmic FIH-1 
expression associated with CAIX expression [462].  
 
There are other negative regulators of HIF-1α transcriptional activity, apart from 
FIH-1, present within the cell that may be contributing to the CAIX expression 
results observed. CBP/p300 Interacting Transactivator With Glu/Asp Rich Carboxy-
Terminal Domain 2 (CITED2) is one such protein that has been shown to compete 
with HIF-1α for binding to p300/CBP, thereby inhibiting HIF-1 signalling [463-465]. 
Additional experiments investigating the expression levels of CITED2 are required 
to examine whether the varying levels of this protein may be contributing to the 




5 Chapter 5: Further testing of the novel carbonic anhydrase 




The experiments presented in section 3.2.3 showed that carbonic anhydrase 
inhibition had a significant effect on cancer cell number. Inhibition of carbonic 
anhydrase protein function, or a decline in carbonic anhydrase protein levels as a 
result of drug treatment, resulting in the loss of pH regulating capabilities within the 
cancer cells and thus affecting cell survival, might help explain how S4 treatment 
produced this effect. Cytosolic acidification is thought to have a permissive role in 
the apoptotic cascade, with caspase activation shown to be more efficient in acidic 
pHi conditions (see section 1.13.2). Poly (ADP-ribose) polymerase (PARP) is a 
protein involved in DNA damage repair [466], with PARP cleavage seen in cells 
undergoing apoptosis [467]. Initial work presented in this chapter investigated the 
effect of S4 treatment on both CAIX and cleaved PARP expression, examining 
whether drug treatment was affecting the levels of either of these protein in hypoxic 
cancer cells. NHE1 and V-ATPase protein expression levels were also assessed, to 
ascertain whether drug-treated cancer cells expressed higher levels of these pH 
regulating proteins in an attempt to adapt to inhibition of the carbonic anhydrases.   
 
The 3D invasion assays conducted in section 3.2.4 showed that S4 significantly 
inhibited the invasion of cells from MDA-MB-231 spheroids into collagen type 1. 
However, as already discussed in section 1.15.4, there are disadvantages to the use of 
spheroids in such assays. 3D invasion assays conducted with explant tissue derived 
from treatment naive biopsy specimens from human patients represents an 
improvement over this spheroid model, enabling the testing of pharmacological 
compounds on heterogeneous tumour material containing cells usually found within 
the cancer stroma (see section 1.15.4). Further work presented in this chapter 
examined the effects of carbonic anhydrase inhibition on the invasion of cells from 




Lastly, MDA-MB-231 xenografts were used to assess whether the carbonic 
anhydrase inhibitors retained their effects in vivo. Pharmacokinetic data (personal 
communication - Simon Langdon) indicated that two carbonic anhydrase inhibitors 
previously used within the laboratory, FC9398A and DTP348, had better in vivo 
stability than the other compounds, with positive results already reported in HT-29 
colorectal xenografts [320, 468]. Therefore, these compounds were used in in vivo 
experiments to characterise (i) the influence of carbonic anhydrase inhibition on the 
growth of MDA-MB-231 xenografts in a murine model, and (ii) the effects of these 




























5.2.1 S4 treatment leads to the reduction of CAIX protein levels and 
induces apoptosis within acute hypoxic cancer cells 
 
Whole-cell lysates of MCF-7, MDA-MB-231 and HBL-100 cell lines treated with S4 
were acquired to investigate the effects of carbonic anhydrase inhibition on the 
protein expression levels of CAIX and PARP. Cells were cultured in 0.5% O2 
conditions for 24h to allow them to adapt to hypoxic conditions, after which they 
were treated with 10, 30 and 100 µM concentrations of S4 for 24, 48 and 72h. Un-
treated cells present in 0.5% O2 conditions acted as controls.  
 
Initial experiments showed that S4 treatment led to a reduction in CAIX protein 
levels within hypoxic MCF-7 cells (figure 55A). The highest concentration of S4 
tested (100 µM) caused a reduction in the expression of CAIX at 24 and 48h, with 
each of the concentrations used producing this effect in the 72h-treated cells (figure 
55A). Repeat experiments were performed with the MCF-7 cells without the 
inclusion of 100 µM S4 at 48 and 72h (figure 55B), as S4 treatment at this 
concentration was affecting loading control values at these time points, possibly due 
to the reduction of cell number at this drug concentration. These experiments showed 
that S4 significantly reduced the levels of CAIX protein in hypoxic MCF-7 cells 
(figure 55B). Hypoxic MDA-MB-231 cells were less responsive to S4 treatment in 
comparison to the MCF-7 cell line, with only 100 µM concentrations of S4 causing a 
reduction in CAIX protein levels within this cell line (figure 55A). As with the MCF-
7 cells, repeat experiments were again performed. However, because higher 
concentrations of S4 were having effects on loading control levels at the later time 
points, repeat experiments were only conducted with the 24h treated cells (figure 
55C). While 100 µM concentrations of S4 were again shown to reduce CAIX 
intensity values within hypoxic MDA-MB-231 cells, this reduction in CAIX protein 
levels was not found to be significant when compared to the control cells (figure 
55C). Out of the 3 cell lines, hypoxic HBL-100 cells exhibited the greatest resistance 
to S4 treatment (figure 55A). No concentration of drug used had any effect on CAIX 
expression levels within this cell line at any of the time points analysed. 
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Using an antibody that identifies the presence of both full length and cleaved PARP, 
westerns were performed to investigate if cleaved PARP could be detected in any of 
the drug-treated hypoxic cells, thereby showing that carbonic anhydrase inhibition 
could induce apoptosis (figure 55D). PARP expression was observed in the MCF-7 
cell line at each time point analysed. Bands corresponding to both full length and 
cleaved PARP were seen in each of the MCF-7 samples at the 72h time point, with 
stronger cleaved-PARP bands observed in the 10 and 30 µM-treated cells in 
comparison to the control cells, indicating that S4 treatment was leading to increased 
levels of apoptosis in hypoxic MCF-7 cells (figure 55D). While full length PARP 
expression was observed in both MDA-MB-231 and HBL-100 cells at each of the 





Figure 55. While S4 leads to reduced CAIX protein levels and increased levels of 
cleaved PARP in MCF-7 cells, the other cell lines were more resistant to 
treatment. 
MCF-7, MDA-MB-231 and HBL-100 cells were cultured in 0.5% O2 conditions for 24h, 
after which they were treated with 10, 30 and 100 µM concentrations of S4 for 24, 48 and 
72h. Untreated cells cultured in 0.5% O2 conditions acted as the controls. Western blotting 
was performed to detect CAIX (A), PARP (D) and cleaved PARP (D), with β-Actin used as 
the loading control. (B/C) Densitometry measurements of CAIX protein levels in S4-treated 
MCF-7 (B) and MDA-MB-231 cells (C). Data expressed as mean ± SEM (n = 3). *P≤0.05, 
**P≤0.01 (One-way ANOVA followed by Dunnett’s multiple comparison test performed, 




2D expression analysis was also conducted assessing the levels of the pH regulating 
proteins NHE1 (figure 56A) and V-ATPase (figure 56B) in hypoxic cancer cells 
treated with S4, to investigate whether the drug-treated cells were up-regulating the 
levels of other pH regulating proteins to help them adapt to the inhibition of the 
carbonic anhydrases. No consistent differences in the expression levels of either 
NHE1 (figure 56A) or V-ATPase (figure 56B) were observed in the drug-treated 
cells in comparison to the control cells at any time point, indicating that S4 treatment 
was not leading to an up-regulation of either NHE1 or V-ATPase protein.  
 
 
Figure 56. S4 treatment does not induce either NHE1 or V-ATPase expression 
in hypoxic cancer cells.  
MCF-7, MDA-MB-231 and HBL-100 cells were cultured in 0.5% O2 conditions for 24h, after 
which they were treated with the 10, 30 and 100 µM concentrations of S4 for 24, 48, and 
72h. Untreated cells cultured in 0.5% O2 conditions acted as the controls. Western blotting 




5.2.2 Tumour-associated carbonic anhydrase inhibition reduces the 
invasion of cells from explant tissue derived from human 
patients 
 
The experimental work presented in this section was performed in collaboration with 
Dr Carol Ward, with both Dr Carol Ward and myself carrying out the experimental 
work and performing the image analysis.  
 
3D invasion assays were carried out with 3 carbonic anhydrase inhibitors (S4, 
FC9403A and FC9398A), testing their effects on the invasion of cells from explant 
tissue derived from human patients into collagen type 1. Briefly, tumour tissue was 
cut into 1 mm3 pieces, placed into collagen, and left to invade for 15 days overall, 
with photos of the explants taken every 5 days. Representative images from an 
experiment carried out with FC9403A are shown in figure 57, where higher 
concentrations of the carbonic anhydrase inhibitor can be seen reducing the number 
of cells invading into the collagen.  
 
Figure 57. Representative images from a 3D invasion assay conducted with 
explant tissue derived from human patients treated with FC9403A.   
Representative images taken from an invasion assay conducted with explant tissue placed 
into collagen type 1 and treated with FC9403A. These images were acquired after 5 days of 
treatment.  
 162 
In the initial analysis performed, the influence of drug treatment on invasion was 
examined by the effects of the compounds on the areas of the explant tissue, as 
measured through ImageJ. Explant areas were measured at 0, 5, 10 and 15 days. The 
areas of the explants at 5, 10 and 15 days were compared to the area at day 0, with 
the % increase in area giving an indication of the amount of invasion that had 
occurred. Figure 58 displays pooled data from 26 different biopsy specimens, with 
the % invasion of un-treated samples shown. Ten days after being placed into 
collagen, un-treated explants exhibited a significantly increased area in comparison 
to the tissues at day 0.  
 
Figure 58. Control explant invasion analysed through the measurement of 
explant area.  
Invasion measured by increased area compared to day 0 explant size. Data pooled from 26 
separate biopsy samples. Data expressed as mean ± SEM. *** P ≤ 0.001 (One-way ANOVA 
followed by Tukey’s multiple comparison test).  
 
Figure 59 presents the data from each of the carbonic anhydrase inhibitors tested. 
Higher concentrations of S4 had an effect on explant invasion, with 30 and 100 µM 
concentrations causing a significant reduction in the % area of the explants after 10 
and 15 days of treatment compared to the un-treated explants at the same time points 
(figure 59A). Similar results were seen with the 2 other carbonic anhydrase inhibitors 
tested, FC9403A (figure 59B) and FC9398A (figure 59C). FC9403A was the most 
potent of the 3 drugs, with 3 and 10 µM, in addition to 30 and 100 µM 
concentrations, leading to a significant reduction in the % area of the explants 
compared to the controls (figure 59B).  
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Figure 59. The carbonic anhydrase inhibitors S4, FC9398A and FC9403A 
significantly reduce the invasion of cells from explant tissue.  
% invasion of collagen-embedded explants treated with S4 (A), FC9403A (B) and FC9398A 
(C). Explants were cultured for 15 days overall with images taken every 5 days. The areas of 
the explants at 5, 10 and 15 days were compared against the area at day 0, with the % 
increase in area giving an indication of the amount of invasion that had occurred. Data 
expressed as mean ± SEM (n=8). * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001 (One-way ANOVA 
followed by Tukey’s multiple comparison test).  
 
Even though the explants showed invasive capabilities, some also exhibited 
regression in size after drug treatment. If explant area were the only criteria used to 
measure the effects of carbonic anhydrase inhibition on invasion, then many of the 
explants would have been considered non-invasive. Therefore, to ensure that the 
effects of the carbonic anhydrase inhibitors on explant invasion were analysed 
accurately, another method was also used. This involved recording only whether an 
explant was invasive or non-invasive, without taking explant area into account. With 
this method, it was observed that after 5 days there was a significant increase in the 
percentage of invasive explants (figure 60A). Using this method of analysis, the 
effects of drug treatment after 15 days of explant invasion was analysed. Similar 
results were observed to those presented in figure 59. Significant reductions in the % 
of explants that had invaded after 15 days were seen with higher concentrations of 
each of S4 (figure 60B), FC9403A (figure 60C) and FC9398A (figure 60D). Again, 
FC9403A was shown to be the more potent of the 3 carbonic anhydrase inhibitors, 
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with 30 and 100 µM concentrations of this drug completely preventing the invasion 
of cells from the explant tissue (figure 60C).  
 
Figure 60. Carbonic anhydrase inhibitors significantly reduce the invasion of 
cells from explant tissue.   
(A) Percentage of un-treated explants invading over 15 days. Data expressed as mean ± 
SEM (n=230). (B-D) The % of explants showing invasive morphology in explant tissue after 
15 days of S4 (B), FC9403A (C) and FC9398A (D) treatment. Data expressed as mean ± 
SEM (n=8). *** P ≤ 0.001 (One-way ANOVA followed by Tukey’s multiple comparison test)  
 
Lastly, experiments were conducted to assess whether the 3 carbonic anhydrase 
inhibitors had any effect on established invasion (figure 61), with drug addition 
carried out after the explants had been left to invade for 15 days. 30 µM drug 
concentrations were chosen for these experiments, as this concentration had 
previously been shown to significantly reduce the invasion of cells from explant 
tissues. Initial measurements of the areas of the explants were conducted after 15 
days of invasion (day 0 control measurements), with further measurements taken 5 
and 10 days after the start of treatment. The areas of the drug-treated explants after 5 
and 10 days of treatment were compared against the day 0 control explants to assess 
whether any reversal of invasion, identified through a significant reduction in area, 
had occurred. Explant areas after 5 and 10 days of drug treatment were also 
compared to the control explants at the same time points, to examine whether the 
drugs were affecting any continued explant invasion.  
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No reversal of invasion was observed in the S4-treated explants over the treatment 
period (figure 61A). However, after 10 days the S4-treated explants had significantly 
different areas to both the day 0 and day 10 controls, indicating that even though 
invasive growth was continuing in these treated explants, it was continuing at a 
reduced rate in comparison to the un-treated explants (figure 61A). FC9398A-treated 
explants also did not exhibit any reversal of invasion (figure 61C). However, 
addition of this compound prevented any further invasion from occurring, as no 
significant differences were observed in the areas of the day 5 and day 10 treated 
explants in comparison to the day 0 explants (figure 61C). The results observed with 
FC9403A indicated that treatment with this compound reversed the invasion that had 
occurred over the 15 days prior to treatment, with the day 5 and day 10 treated 
explants having significantly reduced areas in comparison to the day 0 controls 
(figure 61B). Day 5 and day 10 FC9403A-treated explants also had significantly 
decreased areas compared to the day 5 and day 10 controls (figure 61B).   
 
For the reversal of invasion experiments presented in figure 61A-C, separate biopsy 
tissue had been used for each of the 3 carbonic anhydrase inhibitors. Due to the 
heterogeneous nature of the biopsy tissue, an additional experiment was carried out 
testing the 3 compounds using explant tissue from the same biopsy tissue, employing 
the same treatment schedule as was used before (figure 61D). Treatment with both 
S4 and FC9398A for 5 and 10 days led to significantly reduced areas in comparison 
to the controls at the same time points, indicating that these compounds had 
prevented any further invasion from occurring (figure 61D). However, no reversal of 
invasion was seen with these compounds. As was the case in figure 61B, FC9403A 
treatment again led to a significant decrease in area of the explants after 5 and 10 
days treatment compared to the day 0 controls (figure 61D), indicating that this 




Figure 61. Of the 3 inhibitors tested, FC9403A is the only one to lead to the 
reversal of established invasion.   
(A-C) The effects of S4 (A), FC9403A (B) and FC9398A (C) on the reversal of invasion. 
Explant were left to invade into collagen for 15 days, after which they were treated with 30 
µM of the carbonic anhydrase inhibitors. (A) Data shown as mean ± SEM (n=10-13). * P ≤ 
0.05, ** P ≤ 0.01 compared to day 0 control. + P ≤ 0.05 compared to day 10 control. (B) 
Data shown as mean ± SEM (n=10-13). ** P ≤ 0.01, *** P ≤ 0.001 compared to day 0 
control. §§§ P ≤ 0.001 compared to day 5 control. +++ P ≤ 0.001 compared to day 10 
control. (C) Data shown as mean ± SEM (n=10). *** P ≤ 0.001 compared to day 0 control. 
§§§ P ≤ 0.001 compared to day 10 control. (D) Comparing the effects of S4, FC9403A and 
FC9398A on the reversal of invasion using the same biopsy tissue. Explants were left to 
invade for 15 days before treatment with 30 µM of the carbonic anhydrase inhibitors. Data 
expressed as mean ± SEM (n=3).  * P ≤ 0.05, *** P ≤ 0.001 compared to day 0 control. ++ 
P ≤ 0.01, +++ P ≤ 0.001 compared to day 5 control. §§§ P ≤ 0.001 compared to day 10 














5.2.3 In vivo experiments with MDA-MB-231 xenografts suggest 
that tumour-associated carbonic anhydrase inhibitors may 
lead to diminished tumour growth through reducing the 
proliferation rate of cancer cells 
 
The work performed in this section, investigating whether the carbonic anhydrase 
inhibitors could retain their effects in vivo by analysing their effects on MDA-MB-
231 xenografts, was carried out in collaboration with Dr Simon Langdon and Edward 
Jarman. Dr Simon Langdon performed the in vivo work, while myself and Ed Jarman 
performed the IHC staining and analysis.  
 
The influence of 2 carbonic anhydrase inhibitors, FC9398A and DTP348, on the 
growth of MDA-MB-231 tumours within mice was examined. Briefly, mice were 
given the carbonic anhydrase inhibitors via the intraperitoneal route from days 0 to 
day 4. Tumour size was measured 3 times a week, and the relative tumour volume 
was calculated for each individual tumour. Differences in the growth of the drug-
treated tumours were observed, with both FC9398A and DTP348-treated mice 
exhibiting significantly lower tumour volumes compared to the controls (figure 
63A). These significant differences in tumour volume were observed in the 
measurements taken during the treatment period at days 2 and 4, and also at day 7.  
 
The tumours were removed and fixed 14 days after the initial treatment. IHC was 
performed to investigate whether drug treatment was having any effect on either 
proliferation or CAIX expression levels within the tumours, with proliferation 
measured by analysing Ki67 staining (representative images of the IHC performed 
shown in figure 62). Even though both compounds significantly reduced the growth 
of tumours within mice, only DTP348 treatment led to a significant reduction in the 
percentage of Ki67 expressing cells in comparison to the controls (figure 63B). 
Neither DTP348 nor FC9398A had any significant effect on the % area of CAIX 






Figure 62. Representative images showing Ki67 and CAIX IHC in MDA-MB-
231 xenografts.  
Representative images of Ki67 and CAIX staining within control and DTP348-treated 
xenografts.  
 
Figure 63. DTP348 and FC9398A-treated xenografts exhibit significantly 
reduced volumes compared to control explants, with DTP348 also leading to 
lower Ki67 expression, while CAIX expression is unaffected by treatment. 
(A) The effects of DTP348 and FC9398A on the relative mean tumour volume of MDA-MB-
231 tumours was analysed. 25 mg/kg/day of FC9398A and 10 mg/kg/day of DTP348 were 
given in saline via the intraperitoneal route from day 0 until day 4. Relative tumour volume 
was calculated, with measurements taken 3 times a week. Data expressed as mean ± SD 
(n=10). * P ≤ 0.05 (Related t-tests comparing against the control on each day). (B/C) The % 
of Ki67-positive cells (B) and the % area of CAIX-positive cells (C) were analysed in both 
drug-treated and control xenografts that had been fixed 14 days after the initial treatment. 
Data expressed as mean ± SD (n=10). * P ≤ 0.05 (Mann-Whitney test, comparing the 




Of the 3 different pH inhibitory compounds tested within Chapter 3, the carbonic 
anhydrase inhibitor S4 produced the most promising results. This Chapter focused on 
additional experiments carried out with novel inhibitors targeting the tumour-
associated carbonic anhydrases. 
 
The initial work presented assessed the effects of the carbonic anhydrase inhibitor S4 
on the protein expression levels of CAIX and cleaved PARP, an indicator of 
apoptotic cell death [467], within the 3 cell lines cultured in acute hypoxic 
conditions. MCF-7 cells were the only cell line to show a significant reduction in 
CAIX protein levels due to drug treatment, with increased PARP cleavage also 
detected within this cell line (figure 55). Studies have indicated that plasma 
membrane CAIX can undergo shedding, wherein the extracellular domain of the 
protein is released from the plasma membrane through proteolytic cleavage [469]. 
CAIX shedding is thought to regulate the distribution, abundance and function of 
CAIX, and is believed to be a regulated process that responds to differing stimuli 
(reviewed in [470]). CAIX ectodomain shedding has been shown to be induced in 
cells treated with cytotoxic drugs, and is thought to be a consequence of apoptosis 
[471]. The observation of increased cleaved PARP expression in MCF-7 cells, in 
combination with the significant decrease in CAIX protein expression levels 
detected, possibly as a result of the increased shedding of CAIX, may signify the 
occurrence of higher levels of apoptosis in the acute hypoxic MCF-7 cells treated 
with S4.  
 
Previous studies have shown that carbonic anhydrase inhibition can impede the pH 
regulating capabilities of cancer cells in vitro [320, 468]. Because cytosolic 
acidification is believed to have a permissive role in apoptosis (see section 1.13.2), 
the reduced CAIX expression levels after S4 treatment may be hindering the 
capability of MCF-7 cells to control pH, possibly contributing to increased apoptosis 
in the acute hypoxic MCF-7 cells. In contrast, no significant changes in CAIX 
expression were observed within the MDA-MB-231 or HBL-100 cell lines, with no 
cleaved PARP detected within these cell lines either. The higher protein expression 
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levels of CAIX within these two cell lines compared to the MCF-7 cell line in acute 
hypoxic conditions might have contributed to the results observed. Higher 
concentrations of S4 may therefore be required to observe the same effect in these 
two cell lines. Further work is required to assess the mechanism through which S4 is 
leading to reduced CAIX protein levels in the MCF-7 cell line. 
 
Prior studies, performed with colorectal carcinoma cell lines [472] and a mouse 
laryngeal tumour model [473], have also shown that S4 treatment can affect CAIX 
protein levels. However, S4 treatment was found to produce varying effects on CAIX 
protein levels in these investigations. In the study by Hektoen et al, the effect of S4 
treatment on CAIX expression was cell line dependent, with the decreased CAIX 
protein levels observed in one cell line attributed to the increased shedding of the 
CAIX ectodomain from the surface of the cell, while higher CAIX protein 
expression levels were observed in another cell line after S4 addition [472]. In the 
study by Meijer et al, CAIX ectodomain shedding was demonstrated to decrease 
after S4 treatment [473]. Metalloproteinases have been shown to be involved in the 
process of CAIX shedding [469]. Because prior studies indicated that sulphonamide-
based inhibitors can inhibit metalloproteinases in addition to the carbonic anhydrases 
[474], some hypothesise that treatment with carbonic anhydrase inhibitors may lead 
to decreased rates of shedding due to the inhibition of the metalloproteinases [472]. 
However, while this may help explain the increased levels of CAIX protein observed 
after S4 treatment in some studies, it does not explain why S4 addition is leading to 
the lower CAIX levels observed here.  
 
Tests performed in Chapter 3 indicated that S4 had the ability to affect the invasion 
of cells from MDA-MB-231 spheroids. Additional experiments were carried out in 
this Chapter, assessing the effect of carbonic anhydrase inhibition on the invasion of 
cells from explant tissue derived from treatment naïve biopsy specimens. The novel 
carbonic anhydrase inhibitors S4, FC9403A and FC9398A were tested in these 
experiments, and were all shown to significantly reduce the invasion of cells from 
explant tissue into collagen type 1 (figure 59 and 60), whilst also having a significant 
effect on established invasion (figure 61). Because experiments indicated that S4 
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treatment may be causing cell death (figure 55), it was recognised that the effects of 
the carbonic anhydrase inhibitors on the invasion of cancer cells may have been 
partly down to the induction of cell death, especially at the higher concentrations 
used. Because of this, each piece of explant tissue utilised in the invasion assays was 
fixed for IHC analysis, in order to assess the expression of markers for cell death. 
However, this analysis was prevented due to the small size of the sections obtained, 
which detached from the slides during the antigen retrieval process. 
 
Studies have shown that tumour grafts from patients suffering from breast cancer that 
are cultured in mice re-create the metastatic potential and pathology of the different 
breast cancer classifications [475]. Others have also reported the use of explant tissue 
derived from human patients, showing that the explants retain the different 
histological markers of the original tumour, such as ER and HER2 positivity, in 
addition to the proliferation indices [476]. These explants were also shown to inform 
the outcomes of therapeutic response to a cyclin dependent kinase 4 (CDK4) 
inhibitor [476], exhibiting the value of this preclinical model in the testing of 
pharmacological compounds. The tumour explant tissue used within this study also 
preserves different aspects of the original cancer pathophysiology, while also 
enabling the effect of stromal elements [which have a role to play in cancer cell 
invasion (reviewed in [477])] on drug response to be investigated. Biopsies from the 
different breast cancer subtypes were used within this study; the potency of the 
carbonic anhydrase inhibitors exhibited suggests that these compounds may be able 
to affect the invasion of cells from different types of breast cancer.  
 
The last section of this Chapter assessed the in vivo effects of 2 carbonic anhydrase 
inhibitors on MDA-MB-231 xenografts. The statistical analysis conducted indicated 
that the mean relative tumour volumes of the mice treated with the inhibitors were 
significantly lower than that of the un-treated mice, with the tumours of the DTP348-
treated mice also exhibiting significantly decreased levels of Ki67 staining compared 
to the controls (figure 63). While these results suggested that carbonic anhydrase 
inhibition may be leading to diminished tumour growth through reducing the 
proliferation rate of the cancer cells, the biological significance of the growth assay 
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results must be questioned, as the mean relative tumour volumes of the drug-treated 
mice were quite similar to those of the un-treated mice at each of the measurements 
taken. Analysis of CAIX expression was also conducted, the results of which 
indicated that drug treatment had no effect on CAIX protein expression levels. 
However, this expression analysis was performed on tissue that had been fixed ten 
days after drug treatment had ended. Different results may have produced had the 
analysis been performed on tissue that had been fixed immediately after the cessation 
of treatment.  
 
Various studies have shown the importance of CAIX in the growth of tumours within 
mice, with knock down of CAIX observed to significantly decrease tumour growth 
in xenografts produced from colon carcinoma cell lines [429] and the MDA-MB-231 
cell line [307]. Others have also reported the testing of carbonic anhydrase inhibitors 
in vivo, but with varying results. While DTP348 has been described to reduce the 
growth rate of HT-29 tumours [320], S4 did not have an effect on the growth of 
tumours derived from either a breast [310] or a transglottic laryngeal squamous cell 
carcinoma cell line [473].  
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6 Chapter 6: Conclusion 
 
6.1  Summary 
 
While previous studies have investigated the effects of targeting the tumour-
associated carbonic anhydrases, NHE1 and V-ATPase separately, a direct 
comparison of the effects of targeting these proteins within one study has not 
previously been carried out. The aim of this project was to compare the therapeutic 
effect of inhibitors targeting these 3 pH regulatory molecules on breast cancer 
proliferation and invasion, in addition to assessing the effects of combining these 
inhibitors with irradiation, with experiments conducted using both 2D and 3D cancer 
models. Low O2 conditions have been shown to lead to the increased expression of 
both the tumour-associated carbonic anhydrases and NHE1, while some believe 
hypoxia may also have a role in V-ATPase expression. Additionally, increased levels 
of activity have been reported for CAIX and NHE1 in reduced O2 concentrations. 
Due to this increased expression and/or activity in low O2 conditions, we 
hypothesised that agents targeting these pH regulators might be more effective in 
hypoxic conditions.  
 
The initial experiments performed investigated the expression of the pH regulatory 
proteins in the differing O2 concentrations that have been shown to occur in vivo, to 
assess the expression of these proteins in the cancer cell lines used within this study 
in both 2D and 3D cancer cell models. While NHE1 and V-ATPase expression was 
seen to be relatively consistent in the varying O2 concentrations, the expression of 
the HIF-1α inducible CAIX was seen to be markedly increased in the 3 breast cancer 
cell lines in low O2 conditions, in agreement with other studies. However, despite the 
presence of similar levels of HIF-1α between the 3 cell lines, the extent of CAIX 
expression varied, with MCF-7 cells exhibiting the lowest levels of CAIX mRNA 
and protein.  
 
Further experiments were performed, assessing the expression of FIH-1 (a negative 
regulator of HIF-1α [129, 130]) and MMP14 (reported to inhibit FIH-1 [448]), to 
investigate whether the expression levels of these proteins might explain the 
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variation in CAIX expression seen. The initial analysis conducted in 2D suggested 
that increased levels of active FIH-1 within the MCF-7 cells, possibly due to a lack 
of MMP14 protein in this cell line, may have been the reason for the lower levels of 
CAIX observed within these cells. However, the 3D analysis performed indicated 
that the MCF-7 cells may actually express MMP14 protein.  
 
SRB assays were carried out to investigate the effects of targeting the pH regulating 
proteins on cancer cell number, with these experiments conducted using aerobic, 
acute hypoxic and chronic hypoxic cancer cells. Due to the increased CAIX protein 
expression levels observed in cells cultured in hypoxic conditions, in addition to the 
increased activity of the pH regulatory proteins reported in low O2 conditions, we 
hypothesized that the hypoxic cancer cells might be more sensitive to treatment with 
inhibitors targeting each of these proteins. Contrary to the expected results, acute 
hypoxic cells treated with inhibitors targeting the tumour-associated carbonic 
anhydrases and NHE1 actually showed increased resistance to drug treatment.  
 
Invasion assays, conducted with spheroids cultured in both 20% O2 and 0.5% O2 
conditions, suggested that carbonic anhydrase inhibitors had the most potential of all 
the agents tested to reduce cancer cell invasion. Preliminary experiments were also 
carried out assessing the ability of drugs targeting the tumour-associated carbonic 
anhydrases, NHE1 and V-ATPase to combine with irradiation. These clonogenic 
assays indicated that inhibitors targeting both the tumour-associated carbonic 
anhydrases and NHE1 have potential to combine effectively with irradiation.  
 
The positive results observed with the novel carbonic anhydrase inhibitors led to 
additional testing with these agents. The treatment of hypoxic cancer cells with S4 
was shown to lead to a significant reduction in CAIX protein levels, in addition to 
increased cleaved PARP expression, suggesting that drug treatment was leading to 
higher levels of apoptosis within hypoxic cancer cells. Further 3D invasion assays 
demonstrated the ability of the novel carbonic anhydrase inhibitors to inhibit the 
invasion of cells from explant tissue derived from human patients, with significant 
effects observed in all of the breast cancer subtypes assessed. The carbonic 
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anhydrase inhibitors were also shown to have anti-cancer effects in an in vivo model, 
significantly reducing the growth and proliferation of tumours within mice.  
 
6.2 Future work 
 
Further experiments are required to investigate possible reasons for the differential 
CAIX expression patterns observed between the 3 cancer cell lines studied. While 
the initial 2D expression analysis performed indicated that the low levels of CAIX 
within MCF-7 cells were consistent with an increased activity of FIH-1, possibly due 
to a lack of MMP14 protein within this cell line, the 3D expression analysis 
suggested that the MCF-7 cells may produce the MMP14 protein.  
 
Further work is required to ascertain whether MCF-7 cells cultured in 2D express 
MMP14 protein, and, if so, whether the MMP14 protein auto-catalyses within this 
cell line. Additional experiments, employing siRNA targeting MMP14, are also 
required to assess the function of this protein in the control of CAIX expression. If 
the role of MMP14 in FIH-1 inhibition discussed by Sakamoto et al is correct [448], 
then the reduction of MMP14 protein expression would be expected to lead to 
decreased CAIX expression levels in each of the cancer cell lines. Additionally, 
while CAIX expression was analysed in each of the cell lines in the differing O2 
conditions, further experiments assessing the expression levels of other C-TAD 
sensitive genes that rely on FIH-1 inhibition for expression apart from CAIX, such as 
hexokinase-2 [478], would increase the confidence in the results obtained. Aside 
from FIH-1, there are other negative regulators of HIF-1α transcriptional activity, 
such as CITED2, that may be influencing the CAIX expression observed in the 3 cell 
lines (section 4.3). The expression levels of proteins such as CITED2 should also be 
analysed to assess whether differing expression levels of this protein may be 
contributing to the CAIX expression patterns observed. 
 
The treatment of cancer usually involves a combination of the different therapies 
described in section 1.5. While treatment with each of the tumour-associated 
carbonic anhydrase, NHE1 and V-ATPase inhibitors alone produced anti-cancer 
effects, the potential benefit of combining irradiation with inhibitors targeting the pH 
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regulating proteins of cancer cells was shown in the preliminary clonogenic assays 
conducted. However, there were several issues with the experimental design. Further 
work, incorporating the changes suggested in section 3.3, should be performed to 
more accurately analyse the effects of combining each of the inhibitors with 
clinically relevant doses of irradiation.  
 
In addition to combining inhibitors targeting the pH regulation mechanisms of cancer 
cells with irradiation, there are other possible combinations that were not tested. One 
possible strategy would be to combine agents that target pH regulating proteins with 
compounds currently used in the clinic [330]. The reversed pH of cancer cells has 
been shown to influence the effectiveness of chemotherapy (see section 1.13.4). 
While studies have shown the chemomodulatory properties of drugs targeting CAIX, 
leading to the improved effectiveness of certain chemotherapeutics [479], others 
have produced mixed results [480], indicating that further work is required before 
combining these pH inhibitors with more standard treatment modalities [480]. 
Therefore, further experiments with the agents used in this study in combination with 
chemotherapeutic agents are merited.  
 
We hypothesised that hypoxic cancer cells might be more sensitive to the effects of 
drugs targeting the pH regulatory molecules of cancer cells, due to the increased 
expression and/or activity of the pH regulatory proteins in low O2 conditions. 
However, acute hypoxic cells exhibited an increased resistance to drug treatment. It 
may be the case that the increased expression/activity in hypoxic conditions is 
actually leading to the enhanced resistance of cells to treatment. Another possible 
strategy for combination treatment involves the use of a ‘cocktail’ of inhibitors 
targeting the different pH regulatory proteins that are linked to pH control within 
cancer cells [330]. A recent study in melanoma cells showed that the combination of 
PPIs, which have the ability to target V-ATPases, with carbonic anhydrase inhibitors 
was more effective than treatment with either agent alone [481]. As a result of the 
increased protein expression/activity in hypoxic conditions, combinations of 
‘cocktails’ of inhibitors targeting the different pH regulatory proteins may be 
required to achieve the same effect as seen with single agent treatment in the aerobic 
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cancer cells. Therefore, future experiments assessing the effects of combining 
inhibitors targeting the different pH regulating proteins of hypoxic breast cancer cells 
are merited. In addition to assessing the effect of combining ‘cocktails’ of drugs that 
target different pH regulatory proteins, experiments evaluating the effects of 
combining compounds that target the same pH regulatory protein are also worthy of 
investigation. Experiments involving the use of multiple tumour associated carbonic 
anhydrase inhibitors, for example, would be hypothesised to have greater effects on 
cancer cells than single agent treatment alone.  
 
Many of the different processes involved in the migration and invasion of cancer 
cells are dependent on pH (section 1.13.1), with each of the pH regulating proteins 
analysed in this study connected with the invasion of breast cancer cells. The 
preliminary 3D invasion assays conducted showed that S4 was the only drug to 
negatively affect tumour cell invasion, while the NHE1 and V-ATPase inhibitors, 
which have previously been shown to reduce the invasive potential of cancer cells 
(section 3.3), were seen to lead to increased amounts of invasion at certain 
concentrations. Because these results are from one independent experiment including 
a number of technical replicates, further experimentation is needed to suitably 
compare the anti-invasive effects of the inhibitors against one another, with the use 
of an agent that has been proven to reduce the invasive capabilities of cancer cells 
also included as an additional experimental control.  
 
Studies show that MMP14 increases the invasive ability of cells, with this protein 
demonstrated to have a role in the invasion of cancer cells into collagen type 1 [482]. 
Reports also indicate that CAIX interacts with MMP14, leading to the localisation of 
these proteins in the invadopodia of invading cells, where CAIX is thought to 
promote the ability of MMP14 to break down collagen type 1 during the process of 
invasion [483]. High levels of plasma membrane MMP14 protein were observed in 
spheroids of both the MDA-MB-231 and HBL-100 cell lines (section 4.2.4). 
Experiments assessing the combination of tumour-associated carbonic anhydrase 
inhibitors with a selective MMP14 inhibitor are warranted in any future invasion 
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assays carried out, and would be hypothesised to have a greater effect on cancer cell 
invasion than single agent treatment alone.     
 
Further invasion assays exhibited the ability of the novel carbonic anhydrase 
inhibitors tested to affect the invasion of cells from explant tissue derived from 
human patients, with significant effects observed in all of the different breast cancer 
subtypes tested. However, the anti-invasive effects of the 3 inhibitors analysed were 
not shown to be equal, with FC9403A observed to be the most potent of the 
inhibitors tested. Similarly, in the preliminary 3D clonogenic assays carried out, 
FC9403A was observed to have more potential in combining with irradiation than S4 
at the dose tested. Additional work with these novel inhibitors is required to 
investigate why these differences in activity were observed, and may give an idea of 
the structural alterations in these compounds that led to these differences, which 
could be incorporated into any future inhibitors produced.  
 
The novel carbonic anhydrase inhibitors used within this study inhibit the tumour-
associated carbonic anhydrases CAIX and CAXII at nM concentrations [310, 393]. 
However, treatment with S4 had an effect on aerobic MCF-7 cancer cell number 
(section 3.2.3). These cells were shown to express elevated levels of CAXII mRNA 
and protein in high O2 concentrations in the 2D (section 3.2.1) and 3D (section 3.2.2) 
analyses performed, indicating that the carbonic anhydrase inhibitors may be 
affecting cell number by targeting CAXII within these cells. Hypoxic incubation was 
shown to lead to decreased levels of CAXII mRNA in the MCF-7 cell line (section 
3.2.1). Other studies have demonstrated the presence of an inverse relationship 
between the expression of CAIX and CAXII [419, 420], which has led some 
investigators to hypothesise that the various carbonic anhydrase isoforms present in 
the cell might communicate in a network that has yet to be resolved [419]. Further 
work investigating the expression of the different carbonic anhydrase isoforms 
within MCF-7 cells is merited to assess whether such a network exists within this 
cell line, and, if it is present, the mechanisms through which it functions. The use of 
inhibitors that target both CAIX and CAXII may be useful if such a network does 
exist, and could lead to carbonic anhydrase inhibition affecting cancer cells present 
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in both the normoxic and hypoxic areas of patient tumours, thereby increasing the 
effectiveness of drug treatment.  
 
While anti-cancer effects were observed with DMA and bafilomycin A1 in the 
experiments conducted in this study, there are other more recently developed 
inhibitors that target NHE1 and V-ATPase. Cariporide is one such NHE1 inhibitor 
that is believed to have potential in the treatment of cancer (reviewed in [328]). 
Studies conducted with PPIs such as esomeprazole and omeprazole show the 
potential of drugs such as these to inhibit the proliferation [484] and invasion [485] 
of cancer cells, while also exhibiting the ability to induce apoptosis [486-488]. A 
direct comparison of more recently developed inhibitors such as Cariporide and PPIs, 
alongside the novel tumour-associated carbonic anhydrases inhibitors, would be 
beneficial in any future work conducted.  
 
Experiments carried out with the novel carbonic anhydrase inhibitors in MDA-MB-
231 xenografts indicated that carbonic anhydrase inhibition may be reducing tumour 
growth in vivo through a reduction in the proliferation rate of cancer cells, without 
having any effect on CAIX expression levels. However, as outlined in section 5.3, 
while the growth assay results obtained were statistically significant, the biological 
significance of these must be questioned, as the mean relative tumour volumes of the 
drug-treated mice were very similar to those of the control mice. Repeat xenograft 
experiments are required to more accurately assess the effects of carbonic anhydrase 
inhibition on both tumour growth and CAIX expression, with the expression analysis 
conducted on tissue that has been fixed immediately after treatments have finished, 
rather than 10 days after treatment has concluded, as was the case in this study.  
 
6.3 Final remarks 
 
In agreement with previous studies employing drugs that target the pH regulating 
proteins of cancer cells, the results reported here show the potential of agents that 
inhibit the pH regulation mechanisms of cancer cells in the treatment of breast 
cancer. Of the different drugs analysed, the novel tumour-associated carbonic 
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